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Collagen I is a member of the Collagen superfamily of proteins, the proteins most 
abundant in mammals, and an essential component of bones, teeth, skin and connective 
tissues including ligaments and tendons. COL1A1 and COL1A2 are the genes that code 
for the collagen I alpha chains, α1 and α2 respectively. Collagen I is a heterotrimer of 
these two alpha chains, formed of two α1 and one α2 chains. Diseases resulting from 
genetic mutations in COL1A1 and COL1A2, include osteogenesis imperfecta (OI) and 
Ehlers-Danlos syndrome (EDS), however, mutations in these genes have not been 
implicated in the development of osteoarthritis (OA). 
At MRC Harwell Institute, large-scale mutagenesis screens, including the Harwell Ageing 
Screen, have been used to identify novel models of disease and establish links between 
genes and diseases. The mutagenised mouse lines MP-107 and TM44 were identified in 
such screens, exhibiting early-onset mild bone abnormalities at the pelvis and elbow. 
These animals subsequently developed late-onset phenotypes including abnormal bone 
growth at the knee and OA. 
Genetic mapping and sequencing revealed that MP-107 and TM44, contained mutations 
in Col1a2 and Col1a1 respectively, which correspond to the genes COL1A2 and COL1A1 
in humans.  The MP-107 mutation was a T to A transversion at position 4521226 of 
Chromosome 6 resulting in alternative splicing at exon 22 of Col1a2. The TM44 mutation 
was a C to T transition at position 94836670 of Chromosome 11 resulting in a premature 
stop codon in exon 31 of Col1a1. 
Extensive phenotyping analysis revealed that the bone abnormalities observed in these 
lines are a result of an OI phenotype. Evidence of an EDS phenotype was also identified 
in the line MP-107, indicating that MP-107 is likely a model of Col-1 related overlap 
syndrome, a proposed EDS subtype exhibiting aspects of OI and EDS. Collagen I related 
changes to the joint tissues is likely the cause of the OA phenotypes. The project has the 
potential to enhance understanding of both the development of Col-1 related overlap 
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1.1. Collagen I 
1.1.1. The Collagen Family 
Type I collagen is a member of the Collagen superfamily, which are the most abundant 
family of proteins in mammals, accounting for around 30% of total dry protein weight 
[1]. There are currently 28 proteins classified as collagens, numbered with Roman 
numerals (I-XXVIII). In addition to these there are many other proteins, which contain 
collagen-like domains, but are not regarded as collagens. The defining feature of  a 
collagen is the presence of 3 polypeptide chains (commonly called α chains) each of 
which forms a left handed Polyproline-II (PPII) type helix, made up of G-X-Y tripeptide 
repeats, where X is most commonly Proline, and Y is most commonly Hydroxyproline 
[2]. This open form of helix, devoid of internal hydrogen bonds, enables the 3 helices to 
twist together to form a right-handed triple helix, with a one residue stagger between 
adjacent α chains.  The number of helical domains varies in each of the members of the 
collagen family, collagen I contains a single large helical domain, while Collagen XVII 
contains 15 smaller helical domains [3]. 
The majority of collagens are homotrimers, with 3 identical α chains making up the triple 
helix, while the minority are heterotrimers, such as collagen I which is made up of 2 
different α chains, and collagen IV which can be made up of different combinations of 
up to 6 different α chains [1, 4]. 
The 28 collagens are split into 7 groups: fibril forming collagens, fibril associated 
collagens with interrupted triple helix (FACIT), beaded filament forming collagens, 
anchoring fibril collagens, network forming collagens, transmembrane collagens and 




Classification  Type Distribution/remarks 
 Fibril-forming I  Non-cartilaginous connective tissues –e.g. tendon, 
    ligament, cornea, bone, annulus fibrosis, skin 
  II  Cartilage, vitreous humour and nucleus pulposus 
  III  Co-distributes with collagen I, especially in embryonic  
   skin and hollow organs 
  V Co-distributes with collagen I, especially in embryonic  
   tissues and in cornea 
  XI Co-distributes with collagen II 
  XXIV   Shares sequence homology with the fibril-forming collagens; 
    has minor interruptions in the triple helix; selective  
    expression in developing cornea and bone 
 XXVII  Shares sequence homology with the fibril-forming collagens; 
  
 has minor interruptions in the triple helix; found in a number 
of embryonic tissues but restricted to cartilage in adults  
FACIT IX  Co-distributes with collagen II, especially in cartilage 
   and vitreous humour 
  XII  Found with collagen I 
  XIV Found with collagen I 
  XVI Integrated into collagen fibrils and fibrillin-1 microfibrils 
 XIX  Rare; localised to basement membrane zones; contributes to  
  muscle physiology and differentiation 
 XX Widespread distribution, most prevalent in corneal epithelium 
 XXI Widespread distribution 
 XXII  Localised at tissue junctions – e.g. myotendinous junction,  
   cartilage, synovial fluid, hair follicle-dermis 
Beaded-filament forming VI  Widespread, especially muscle 
  XXVI  Also known as EMI domain-containing protein 2, protein 
   Emu2, Emilin and multimerin domain-containing protein 2 
 XXVIII A component of the basement membrane around Schwann  
  cells; a von Willebrand factor A domain-containing protein 
   with numerous interruptions in the triple helical domain 
Anchoring fibrils VII Dermal-epidermal junction 
Network-forming IV Basement membranes 
  VIII  Descemet’s membrane 
  X  Hypertrophic cartilage 
Transmembrane XIII  Neuromuscular junctions, skin 
  XVII Also known as the bullous pemphigoid antigen 2/BP180; 
    localised to epithelia; an epithelial adhesion molecule;  
   ectodomain cleaved by ADAM proteinases 
  XXIII  Limited tissue distribution; exists as a transmembrane  
   and shed form 
  XXV  CLAC-P – precursor protein for CLAC 
    (collagenous Alzheimer amyloid plaque component) 
Endostatins XV Located between collagen fibrils that are close to basement 
   membranes; found in the eye, muscle and microvessels;  
   a close structural homologue of collagen XVIII 
  XVIII Associated with basement membranes; endostatin is 
    proteolytically released from the C-terminus of collagen XVIII; 
     important for retinal vasculogenesis 
 
Table 1.1.  Table showing each group within the collagen family and the members of those 
groups, as well  as distribution. Adapted from Kadler et a l.,  2007  [5].  
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1.1.2. Collagen I Structure and Synthesis 
Type I collagen is typically a heterotrimer composed of two α1 chains (encoded by the 
gene COL1A1) and one α2 chain (encoded by the gene COL1A2), however under certain 
circumstances type I collagen can exist as a homotrimer of three α1 chains, including in 
fetal tissues, fibrosis, and cancer [6]. Collagen I exists extracellularly as collagen fibres, 
made up of collagen micro fibrils, which are composed of collagen molecules (Figure 
1.1). Collagen molecules self-assemble into microfibrils in a staggered offset, which gives 
collagen fibrils a characteristic D-periodicity of 67nm, which consists of a 40nm gap 
between molecules, and a 27 nm overlap zone [7]. 
 
Figure 1.1.  Collagen Structure and organisation. Taken from Canelón  et al.,  2016 [7].  
There are a number of essential processes, which occur throughout the production of 
the collagen molecule, which allow the formation of these microfibrils and fibrils, which 
will be outlined below, and starts with the genes COL1A1 and COL1A2. 
The genes COL1A1 and COL1A2 are very similar in terms of their exon structure, resulting 
in very similar structures in the α1 and α2 chains. Both genes contain large triple helical 
domains flanked by C- and N-propeptides separated from the triple helix by C- and N- 
 
5 
telopeptides respectively. The N-propeptide region also contains a smaller additional 
triple helical domain (Figure 1.2).  
 
Figure 1.2.  A diagram showing the Exon structure of COL1A1  and COL1A2,  and the 
elements of the α chains that they code for. The N-propeptide of both COL1A1  and COL1A2  
contain a short trip le helical domain. Adapted from Rossert and de Crombrugghe, 2002 
[8] 
The similar structure of the collagen I genes, allow the formation of a pro collagen 
molecule where the 3 left-hand helices (2 pro α1 (I) and 1  pro α2 (I)) interact and form 
a right-handed triple helix (Figure 1.3). 
 
Figure 1.3. A schematic representation of the type I pro-collagen molecule. Adapted from 
Marcius et al., 2006 [9]. 
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The mechanisms by which collagen I is produced is a complicated process, including 
synthesis, post-translational modifications, and folding; the processing takes place both 
intracellularly and extracellularly [10]. 
Initially the genes for each of the alpha chains are transcribed to mRNA in the nucleus, 
before the mRNA exits the nucleus and interacts with the membrane-bound ribosomes 
of the rough endoplasmic reticulum (rER) [11, 12]. The ribosomes translate the mRNA 
into polypeptide chains, which are secreted into the lumen of the endoplasmic reticulum 
(ER) [10]. While most proteins fold from the N terminal end before the chain has finished 
synthesising, procollagens do not start folding until after the entire chain is synthesised, 
and the folding commences from the C-terminal end [13]. The polypeptide chains 
undergo a number of post-translational modifications during the folding process, 
starting with the cleavage of the N-terminal signal peptide. As mentioned previously, 
the repeating Glycine motif, of Gly-X-Y, where X is most commonly proline and Y is 
mostly commonly hydroxyproline, is essential to proper folding of the collagen I triple 
helix. The triple helix of collagens is stabilised by proline in the X position and 4-
hydroxyproline and arginine in the Y position [2, 13]. It is therefore also essential that 
approximately half of proline residues in the Y position are hydroxylated by prolyl 4-
hydroxylase, although some specific proline residues are hydroxylated by the prolyl 3-
hydroxylation complex, which involves a number of different proteins, including CRTAP, 
P3H1 and CyPB. The role in the stabilisation of the triple helix of 4-hydroxyproline is by 
providing hydrogen bonds and water bridges [14]. Additionally, lysine residues are 
hydroxylated by lysyl hydroxylases to form hydroxylysine residues which can then 
undergo further modifications such as glycosylation or covalent crosslinking [15]. The 
folded pro-collagen molecule is then ready for secretion. ER chaperone proteins such as 
BiP bind to unfolded and partially folded chains and ensure the chains remain in a 
foldable state. When these chaperones are released it signals that the molecule is ready 
for transportation [13, 16]. Due to the large, rigid structure of the pro-collagen I 
molecule, trafficking of the molecule from the endoplasmic reticulum to the Golgi 
apparatus requires specialised COPII vesicles, which are able to cope with larger 
molecules. Jin et al. showed the actions of ubiquitin ligase CUL3–KLHL12, which 
catalyses the monoubiquitylation of the COPII-component SEC31, drives the assembly 
of large COPII coats, although the precise mechanism remains elusive [17, 18].  Golgi to 
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plasma membrane transport carriers, which are a type of vesicle formed by the 
detachment of large regions of the trans golgi network, enable the pro-collagen  to leave 
the trans face of the Golgi [19]. C- and N- terminal propeptides are cleaved by their 
respective proteinases, BMP1 (Bone morphogenetic protein-1) and ADAMTS-2 (A 
Disintegrin and Metalloproteinase with Thrombospondin Motifs-2) [20]. After the 
cleavage of the propeptides the ~300nm tropocollagen is then able to self-assemble into 
microfibrils. It has previously been suggested that interaction of the C-terminal 
telopeptide with specific binding sites on other triple helical monomers may facilitate 
the self-assembly [21]. These microfibrils then bind together, forming fibrils which have 
diameters ranging from 50 to 500nm [22]. Cross-linking between the molecules in the 
fibril then provides strength and stability [23]. 
Myllyharju and Kivirikko published a schematic summarising the biosynthesis of fibril 
forming collagens, which is reproduced in Figure 1.4 [24]. 
 
Figure 1.4.  An overview of the synthesis of a fibr il-forming collagen. Taken from 
Myllyharju and Kivirikko 2004 [24].  
1.1.3. Collagen I and Connective Tissues 
Type I collagen is an important protein in tissues with mechanical functions, as it confers 
mechanical stability, strength and toughness [25]. 
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It is the major constituent of tendons and ligaments, the majority of the organic matrix 
in bone and dentine, and is also present in a number of other tissues such as skin, 
arteries, cornea and meniscus [1]. Despite collagen I being major constituents in all these 
tissues, the tissues all have unique behaviours and functions. In bone, in addition to the 
collagen I fibrils, the tissue is mineralised, which changes the mechanical properties. In 
other tissues the collagen fibrils are heterotypic, in that they can contain more than one 
type of fibrillar collagen. For example, the fibrils in skin are made up of both type I and 
type III collagen, and those in tendon are predominantly type I and type V [26, 27]. Other 
differences in tissue behaviours can relate to the orientation of the fibrils or varying 
ratios of the constituents of the extracellular matrix (ECM) [28]. 
Additionally, these tissues tend to be anisotropic, meaning the mechanical properties of 
the tissue varies depending on the direction, much like the grain of wood, the direction 
of the collagen fibres has an effect on the mechanical properties [29]. 
Examples of the function of collagen I in connective tissues are outlined in the 
subsections below. 
1.1.3.1. Tendons 
Tendon are fibrous tissues that connect muscles to bone and their main function is to 
transfer force from the muscle to the bone at joints [22]. Tendons are collagen rich 
tissues, constituting 65-85% of the dry weight of tendons, and approximately 90% of this 
collagen is collagen I [30]. The collagen fibrils in tendon are heterotypic where collagen 
V is present in the centre of the collagen I fibrils, likely acting as a template for 
fibrilogenesis [31]. Other collagens are also present including fibrillar collagens, type III 
and XI, as well as fibril associated collagens, XII and XIV [30]. 
Tendons have a hierarchical organisation where collagen molecules and collagen fibrils, 
which have previously been described, aggregate to form fibres, and fascicles, which are 
the largest subunit of tendons. The fascicles are surrounded by the interfascicular 




Figure 1.5.  Schematic diagram of tendon in cross-section showing the hierarchical 
structure.  Collagen fibri ls are bundled into fascicles containing vessels, lymphatics and 
nerves. The fascicles are grouped together, surrounded by epitenon, and form the gross 
structure of the tendon, which is further enclosed by paratenon. Taken from Parmar, 2018 
[32]. 
The structure and composition of tendons vary slightly depending on where the tendon 
is located and whether its primary purpose is as an energy-storing tendon, such as the 
Achilles tendon or as a positional tendon, such as the anterior tibial tendon. The material 
and mechanical properties of these tendons vary accordingly. Positional tendons are 
relatively inextensible under physiological loads, with high stiffness, but low strain, less 
than 3%, and stresses of 20-30MPa. Energy storing tendons have a high degree of 
extensibility, high strains and very high stresses up to around 90 MPa, which is close to 
the failure stress of tendons [33]. The differences between these two tendon types have 
been attributed to the geometric arrangement of collagen within the fascicles [34]. 
Another theory is that the presence of trivalent crosslinks within energy storing fibrils 
appears to limit molecular sliding, which may allow the higher stresses [35]. The multiple 
hierarchical levels of tendon structure, mean that local extension and sliding mechanics 
can be altered by small changes at different levels, which can impact the behaviour of 




Fratzl et al. proposed a model attributing the mechanical properties of tendons to the 
collagen I structure. As the tendon is extended initially, the macroscopic crimp of the 
fibrils is removed, followed by straightening of molecular kinks in the gaps and finally  
the linear region to a gliding of molecules [36] (Figure 1.6).  This model has been further 
built upon; Gupta et al. found that inter-fibre and inter-fibril shearing are significant 
mechanisms for dissipation of energy [37]. At the higher hierarchical scale, Thorpe et al., 
found that inter-fascicular sliding also plays a role in the ability of energy storing tendon 
to fulfil their role [38]. 
 
Figure 1.6. Typical stress–strain curve of a rat  tail tendon. (A) The removal  of the 
macroscopic crimp visual ised with polarized light. (B) Further structural changes occur at 
the fibril lar level.  Taken from Fratzl  et  al., 1998 [36].  
 
1.1.3.2. Bone 
Bone is a hierarchical tissue, which at the macroscale is made up of trabecular or cortical 
bone and at the nanoscale is composed of mineralised collagen fibrils (Figure 1.7).  
Mineralised collagen fibrils are linked by an organic phase to form fibril arrays that  are 
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overlaid in layers oriented at different angles to provide the lamellar structure of 
osteons, which make up the trabecular and cortical bone [39]. 
 
Figure 1.7.  Hierarchical structure of bone. The macroscale arrangements of bones are 
either compact/cortical (dense material found at the surface of all bones) or 
spongy/cancel lous (foam-like material whose struts are some 100 μm thick). Compact 
bone is composed of osteons that surround and protect blood vessels. Osteons have a 
lamellar structure. Each individual lamella is composed of fibres arranged in geometrical 
patterns. These fibres are the result of several collagen fibrils,  each linked by an organic 
phase to form fibri l arrays. Each array makes up a single collagen fibre. The mineralized 
collagen fibrils are the basic bui lding blocks of bone. They are composed of collagen 
protein molecules (tropocollagen) formed from three chains of amino acids. Taken from 





Bones have a variety of functions within the body, and require different structures and 
make up to fulfil their function. The bones play a major role in structural support, 
provide leverage to enable movement, and protect vital organs. Approximately 80% of 
total bone is classified as cortical, with only 20% trabecular, but the ratios in different 
bones vary according to function.  Both cortical and trabecular bone are made up of 
osteons, but the structure of the bone differs with trabecular bone  being a honeycomb 
of trabeculae with bone marrow compartments and cortical bone being a solid, dense 
mass [40]. 
The mineralised collagen fibrils are formed in the extracellular space, where osteoblasts 
secrete collagen molecules, which self-assemble into fibrils (as previously described in 
section 1.1.2). The osteoblasts also secrete hydroxyapatite crystals, which form in matrix 
vesicles before elongation into the extracellular space [41]. They then nucleate in the 
gaps, provided by the staggered offset between collagen molecules, and grow 
preferentially in their crystal-axis direction and broaden into nanoplatelets. The 
hydroxyapatite within bone grows within the collagen fibrils (intrafibrillar) and on the 
surfaces of the fibrils (extrafibrillar) [42](Figure 1.8). TEM imaging in multiple dimensions 
has led to the formation of a model that indicates that the mineral lamellae formed by 
the hydroxyapatite, surrounds the outer surface of the fibril as opposed to mainly being 
embedded in the fibril. These mineral lamellae improve the stiffness and strength of the 





Figure 1.8. Schematic of the mineralisation of collagen I  fibri ls.  (a) A single collagen 
molecule, 1.23 nm in diameter, 300 nm in length and spaced 0.24 nm apart,  is shown as 
well  as a 2D aggregate of collagen molecules, cross-l inked into a quarter-staggered array 
with characterist ic gap (40 nm) and overlap (27 nm) zones. (b) Packing of consecutive 2D 
arrays into 3D assemblages occurs with str ict  registration of all  gap and overlap zones so 
that channels are created throughout the model. Cuboids indicate these channels. (c) The 
hydroxyapatite crystals,  shown in blue, nucleate principally  in the collagen gaps and grow 
preferentially in their  crystal-axis direction. (d) Growth of the hydroxyapatite phase to 
occupy the entire 40-nm length of the gap. The channels are thought to allow lateral 
growth of the hydroxyapatite nuclei into nanoplatelets. As pictured, the hydroxyapat ite 
has extended beyond the gap zone, but  the narrow pore spaces (0.24 nm) between 
adjacent collagen molecules have unknown capacity to accommodate mineral. Taken from 
Stock, 2015 [42].  
 
The hydroxyapatite that mineralises the bone accounts for 50-70 % of the bone mass, 
with small quantities of other minerals such as carbonate and magnesium and acid 
phosphate, with 20-40% organic matrix (of which 90% is collagen I), 5-10% water and 
<3% lipids making up the remained of the tissue [44]. 
Collagen gives the bone elasticity and the ability to dissipate energy under mechanical 
deformation through molecular stretching and inter-molecular gliding, which have been 
mentioned previously. The mineral phase has an elastic modulus, which is more than 10 
times higher than collagen, and therefore mineralisation is critical to the stiffness of 
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bone [44]. Various models have been used to explore the relationships between the 
mineralised and unmineralised phases of the collagen fibrils. For example, Nair et al. 
developed a model to identify deformation mechanism. They observed that the 
mineralized fibrils showed a higher modulus compared with the non-mineralised fibril, 
which increased in samples with higher mineral densities. In addition to the higher 
modulus, the hydroxyapatite phases of the mineralised fibrils exhibited approximately 
4 times higher stress than the collagen phase of the same fibrils. This suggests that the 
load is predominantly carried by the mineral phase of the mineralised fibril [45]. 
1.2. Diseases Associated with Collagen I 
There are several diseases associated with collagen I, including osteogenesis imperfecta 
(OI), Ehlers-Danlos syndrome (EDS), osteoporosis and an overlap condition with 
elements of OI and EDS.  Additionally, there are other conditions including atypical 
Marfan syndrome and Caffrey’s disease. 
As of November 2020, 2053 individuals were reported with 1065 individual variants in 
COL1A1, and 1069 individuals were reported with 612 individual variants in COL1A2 [46-
48]. These variants result in a number of different conditions, which will be described in 
this section. 
1.2.1. Osteogenesis Imperfecta 
Osteogenesis imperfecta (OI) is characterised by an inherent susceptibility to fractures, 
though the severity ranges from a lethal phenotype to very mild. It was first described 
in a scientific manner in the thesis ‘Congenital osteomalacia’ by Olaus Jackob Ekman in 
1788. Ekman’s observations included the hereditary nature of the bone fragility [49]. 
The term osteogenesis imperfecta was reportedly first used by the Dutch professor 
Willem Vrolik, when describing a new-born that was born with numerous fractures and 
hydrocephalus, and died 3 days after birth [50]. 
The variability in the phenotypes, and their severity led to a classification system 
published by Sillence et al. in 1979, classifying the patients into four types, each 
designated a Roman numeral (I-IV). The four types were I- Dominantly inherited OI with 
blue sclerae, II- Lethal perinatal OI with radiographically crumpled femora and beaded 
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ribs, III- Progressively deforming OI with normal sclerae and IV- Dominantly inherited OI 
with normal sclerae [51].  
As more cases were studied, and understanding grew, the Sillence classification was 
modified, expanding the definitions and adding OI types V-VII in 2004 [52]. The vast 
majority of cases of OI, over 90%, have mutations in one of the collagen I genes, COL1A1 
and COL1A2, and are classified as types I-IV [53]. The new classifications (V-VII) were 
created for cases with unknown aetiology, or clinical classifications that differed from 
those in type I-IV. As more genetic causes have been identified, the classification system 
has further changed. It was found that many different genes can cause types I-IV and 
that the use of VI and VII for cases with unknown aetiology were no longer required, 
leading to the use of types I-V for clinical diagnosis, and a separate ‘molecular type’ 
pertaining to the genetics. Table 1.2. gives a breakdown of the genes involved in OI, the 
mode of inheritance and the molecular type of OI caused by mutations in these genes, 
and which of the updated Sillence classification each falls into. The autosomal dominant 
forms of the disease, making up over 90% of cases of the disease predominantly involve 
mutations in COL1A1 and COL1A2, the exceptions being IFITM5 and PSL3 [53]. The 
remaining less than 10 % of OI cases are caused by autosomal recessive mutations in a 
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Table 1.2.  Types of osteogenesis imperfecta, organised by mechanism and gene. AD, 
autosomal dominant; AR, autosomal recessive; XLD, X-linked dominant; XLR,  X-l inked 
recessive; BRKS1, Bruck syndrome-1; BRKS2 Bruck syndrome-2; BMND18, Bone Mineral 
Density Quantitative Trait Locus 18. *Seen only in a few consanguineous families. Adapted 
from Makit ie et al., 2019 and Chetty  et al., 2020 [54, 55].  
In addition to the mutations in genes coding for the collagen I alpha chain, mutations in 
seven genes known to be involved in the biosynthesis, processing and secretion of 
collagen I have also been identified as causing OI. 
The genes CRTAP [56, 57], LEPRE1 [58] and PPIB [59] encode the  proteins which form 
the collagen-3-hydroxylation complex that resides in the endoplasmic reticulum and 
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modifies the unfolded collagen I α1 and  α2 chains [60]. PLOD2, encodes Procollagen-
lysine, 2-oxoglutarate 5-dioxygenase 2 which catalyses the hydroxylation of lysyl 
residues in collagens. This enzyme is required for the hydroxylation of lysyl residues of 
collagens, including those residues that are involved in the formation of glycosylated 
hydroxylysyl residues and hydroxylysyl-derived collagen cross-links [61]. The specific 
phenotype caused by mutations in PLOD2, lead to Bruck syndrome type 2, which has 
previously been considered a type of OI, but as of 2020, has been removed from the OI 
nosology [55]. Mutations in two other genes involved in the biosynthesis of collagen I 
have also been identified in OI cases, SERPINH1 and FKBP10 [62, 63]. SERPINH1 encodes 
HSP47, and FKBP10 encodes FKBP65, which are chaperone proteins that are involved in 
procollagen transit and folding respectively. BMP1, encodes Bone morphogenetic 
protein 1 (BMP1) which is a procollagen C-endopeptidase, which as the name suggests 
cleaves the carboxyl propeptides of procollagens (specifically I, II and III) and plays a role 
in inducing bone and cartilage development. Mutations in BMP1 can block cleavage of 
the c-propeptide and lead to impaired assembly of type I collagen, mutation in COL1A1 
and COL1A2, that inhibit propeptide cleavage can have similar effects [64]. Figure 1.9 
gives an overview of the biosynthesis process and each of the stages where these 




Figure 1.9. Overview of collagen type I biosynthesis.  A number of proteins are essential 
for the biosynthesis of Collagen, mutations in the genes coding for these proteins are 
known to cause OI. These proteins and their function in the biosynthesis process are 
marked in the diagram. Taken from Van Dijk and Sillence, 2014 [65].  
In addition to abnormal collagen and collagen processing, genes affecting the 
osteoblast, and mineralisation can also lead to OI, but will not be explored further in this 







1.2.1.1. Mechanisms Behind the OI Phenotype 
The overwhelming majority of cases of OI are due to mutations in the genes coding for 
the collagen I alpha chains, but the different types of mutation can manifest in different 
ways and by different mechanisms. These mechanisms will be discussed here. 
Most cases of type I OI, the least severe form, have haploinsufficency due to a null 
COL1A1 allele.  Mutations causing a frameshift, premature stop codon, or abnormal 
splicing leading to a premature stop codon, lead to a quantitative reduction of type I 
collagen without affecting collagen structure [66]. Mutations in COL1A2 have been 
noted to cause similar phenotypes, including splice site mutation reducing levels of 
COL1A2 transcript [67]. The other three types of OI caused by mutations in collagen I 
genes, II-IV are generally caused by structural defects in one of the collagen I chains, 
which can then lead to a variety of downstream effects. The most common of these is a 
substitution of glycine, disrupting the repeating motif, and the next most common, 
causing about 20% of cases, are mutations affecting splicing, which can lead to exon 
skipping or intronic inclusion [68]. Should the structural changes prevent trimerisation, 
the protein is degraded by the proteasome in a process known as ER-associated 
degradation (ERAD) [69]. If the proteins are able to trimerise, but are unable to be 
retrotranslocated from the ER, due to over modification or defects in folding, then the 
proteins, or their aggregates, are removed by autophagy. Both of these processes can 
lead to ER stress, which in turn can lead to apoptosis of osteoblasts, as can delays in the 
collagen processing. Osteoblasts are essential for bone remodelling and therefore 
apoptosis impairs bone homeostasis [70, 71]. Structurally abnormal protein often leads 
to delayed helical folding, leading to over modification. Upon secretion, these 
modifications can cause a variety of effects downstream including, impairing the ability 
of non-collagen proteins to bind to the fibrils.  This is often the case in the lethal type II 
form [66, 72, 73]. Forlino et al. summarised these mechanisms in a figure, which is 





Figure 1.10. Mechanisms contr ibuting to osteogenesis imperfecta. (1)Mutant procollagen 
chains unable to incorporate into heterotrimer are retrotranslocated into the cytosol and 
degraded by the ER-Associated Degradation (ERAD) pathway. (2) Fully misfolded 
heterotrimers with structural defects generate supramolecular aggregates that are 
eliminated by autophagy. (3) Mutant molecules with triple helical mutations can be 
degraded through an unidentified pathway. (4) Abnormal procollagen can be secreted, 
processed and incorporated in the extracellular matrix.  The secreted mutant collagen 
affects fibril  structure and interactions of non-collagen proteins (NCPs) with matrix,  as 
well as matrix mineralization and osteoblast development and cell-cell and cell -matrix 
cross-talk. The overall  result is bone deformity and fragil ity. Taken from Forlino  et al.  
[66]. 
Matrix abnormalities including heterogeneity of collagen forms, abnormal fibril 
organization and altered modifications may increase stress in osteoblast and altered 
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cell-cell signalling, which in turn alters bone homeostasis, leading to enhanced bone 
dissolution and absorption by osteoclasts [66, 74]. 
 
1.2.1.2. Mouse Models of OI 
The majority of murine models of OI have alterations to the genes Col1a1 and Col1a2, 
however a number of genes known to be involved in collagen biosynthesis, bone 
mineralisation, and osteoblast function have been knocked out to create further 
models.  A summary of murine models of OI is shown in Table 1.3. 
As with the mechanisms of OI, only the models that involve the genes Col1a1 and Col1a2 
will be discussed further. Unsurprisingly, due to defects in Col1a1 generally being more 
deleterious than mutations in Col1a2, there are also more mouse models involving 
Col1a1 than Col1a2.  These murine models of OI replicate phenotypes seen in all four 
Sillence type that are caused by mutations in COL1A1 and COL1A2 in human. However 
due to the sheer number of different mutations detected in human OI cases, it is not 
feasible that these models will replicate all the different mechanisms by which 
mutations lead to OI, however they can help elucidate mechanisms. Examples of models 
resulting in all 4 OI types involving both Col1a1 and Col1a2 will be described briefly 
below. 
The Mov-13 mouse is essentially a Col1a1 null, as the transcription is blocked by the 
insertion of Moloney leukaemia virus [75]. The homozygous Mov-13-/- exhibits arrested 
development between day 11 and 12 of gestation [76]. This model is classed as a model 
of type II OI due to the lethal phenotype; however, it does not replicate the type II OI 
phenotypes seen in humans. The heterozygous Mov-13-/+ animals exhibit a 50% 
reduction in type I collagen production; however, the protein is structurally normal, 
heterotrimic, and indistinguishable from wild-type [77]. The heterozygous Mov-13-/+ 
animals did not exhibit an overt OI phenotype, such as spontaneous fractures, however 
the animals were shown to have reduced mechanical properties in bone (around a 25% 
reduction in bending strength, among other parameters), and hearing loss, together 








Mov-13−/− a OI II COL1A1 Perinatal mortality 
Mov-13−/+ a OI I COL1A1 Hearing loss, reduced mechanical properties in bone, 
and reduced collagen production 
oim/oim b OI III COL1A2 
Fragile bones, osteopenia, cortical thinning, bone 
deformities, joint laxity, kyphosis 
oim/+ b OI I COL1A2 Decreased material properties of bone 
G610C/G610CNeo+ c OI IV COL1A2 
Decreased body weight, bone mineral density, bone 
volume, and mechanical properties of bone 
+/G610CNeo+ c OI I/IV COL1A2 
Decreased body weight, bone mineral density, bone 
volume, and mechanical properties of bone 
+/G610CNeo− 
(Amish) c 
OI IV COL1A2 
Decreased body weight, bone mineral density, bone 
volume, and mechanical properties of bone 
G859C d OI II COL1A1 
Short and wavy ribs, poor bone mineralization, 
underdeveloped skeleton, pliable limbs, perinatal 
death 
Aga2/+ e OI II/III COL1A1 
Skeletal deformities, fragile bones, osteopenia, 
perinatal death (in some cases) 
Aga2−/− e OI II COL1A1 Embryonic mortality 
BrtlII f OI II COL1A1 Rib fractures, short vertebral bodies, poor skull 
mineralization, perinatal mortality 
BrtlIV/+ f OI IV COL1A1 
Perinatal death to long-term survival, bone deformity, 




COL1A1 Bone deformity, bone fragility, osteopenia 
Human COL1A1 
minigene d 
OI II–IV COL1A1 
Fragile bones, low bone mineral density, ~90% 
perinatal mortality rate (when high levels of minigene 
expressed) 
Ifitm5 transgenic a OI V IFITM5 
Skeletal deformities, fragile bones, poor bone 
mineralization, perinatal death 
Pedf−/− * OI VI SERPINF1 Decreased material properties of bone 
Crtap−/− c OI VII CRTAP 
High bone mineralization and mineral density in bone 
(but low bone density), progressive kyphoscoliosis, 
cartilage dysplasia, decreased material properties in 
skin 
P3h1−/− a OI VIII LEPRE1 
Small body size, low mineral density in calvarial and 
long bones, decreased material properties of bone, 
impaired hearing 
Ppib−/− * OI IX PPIB 
Decreased body size and weight, low bone mineral 
density and volume, progressive kyphosis, decreased 
material properties in skin 
Hsp47−/− a OI X SERPINH1 Embryonic mortality 
Fkbp10−/− a OI XI FKBP10 
Delayed growth beginning at E13.5, fragile tissue, 
skeletal deformities, perinatal mortality 
Sp7−/− c 
Possibly 
OI XII SP7 
Decreased trabecular bone mineralization, osteopenia, 
cortical bone thinning 
Wnt1Sw/Sw * 
(Swaying) 
OI XV WNT1 
Poor coordination, osteopenia, fragile bones, cerebellar 
deficit 
 
Table 1.3.   A table documenting murine models of OI. Backgrounds of these models are 
as fol lows a  C57BL/6J, b  B6C3Fe,  c  129/SvEv, d  FVB, e  C3HeB/FeJ, f 129/SvJ x C3H/HeJ,  *not 
specified. Adapted from Enderl i et al., 2016 [79].  
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The Aga2 mouse model was identified as part of an ENU screen, where a mutation 
caused a C-terminal frame shift, leading to a poorly secreted protein and ER-stress 
induced apoptosis [71]. The Aga2-/- animals were lethal around day 9 of gestation, and 
the heterozygous Aga2-/+ animals showed reduced viability in addition to increased bone 
fractures, fragility and deformity, and osteopenia [71]. The heterozygous Aga2-/+ models 
type II or type III OI, depending on the severity of the phenotype. The homozygous      
Aga2-/- could be viewed as modelling type II OI, however as with Mov-13-/-, aside from 
lethality it does not resemble the phenotype seen in humans. 
The BrtlII and BrtlIV mouse models were created in an attempt to induce a G349C 
substitution using the Cre/Lox system in Col1a1. An unexpected allelic expression due 
to the stop cassette created the BrtlII where heterozygous animals died within hours of 
birth and exhibited rib fractures and poor skeletal mineralisation, modelling type II OI 
[80]. The stop cassette was subsequently removed to create an F2 generation that 
possessed the desired G349C substitution, BrtlIV. The heterozygous animals showed a 
variable phenotype with a severe lethal phenotype and a moderately severe non-lethal 
phenotype, both exhibited fragile bone, deformity and osteopenia, the bones appeared 
more fragile in the lethal animals [80]. The heterozygotes that showed the lethal 
phenotype showed increased expression of transforming growth factor beta (TGF-β), 
which the non-lethal heterozygotes did not [81]. BrtlIV appears to model type II/IV of 
OI. The homozygous BrtlIV animals show a similar OI IV phenotype, but milder than the 
non-lethal heterozygotes [66]. 
The OIM mouse model is the result of a spontaneous mutation in Col1a2, resulting the  
deletion of a guanine at position 3978 causing a frameshift, leading to  a deficiency in 
the pro α2(I) chains, which in turn leads to the production of α2(I) homotrimer [82]. The 
homozygous animals exhibit phenotypes including spontaneous fractures, bone 
deformity, small body size and reduced material properties under mechanical testing 
(around a 50% reduction in maximum load, among other parameters), indicating a type 
III OI phenotype [82, 83]. The heterozygotes did not show spontaneous fractures, but 
did exhibit reduced material properties under mechanical testing (around a 20% 
reduction in maximum load) indicating a mild type I OI phenotype. 
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The G610C (Amish) mouse model is a knock-in replicating the G610C mutation in COL1A2 
first identified in Old Order Amish (OOA) kindred [84]. The initial line retained a 
neomycin-targeting vector, which caused the secretion of homotrimer in addition to 
heterotrimer containing the G610C substitution. The neomycin-targeting vector was 
subsequently removed. The homozygotes retaining the neomycin-targeting vector were 
viable, and the homozygotes, which did not, were found to die perinatally. The 
heterozygotes without the vector, which replicates the genetic mutation in the OOA, 
exhibited decreased body weight, BMD, bone volume, and mechanical properties of 
bone testing (around a 40% reduction in maximum load) [84]. 
1.2.2. Ehlers-Danlos Syndrome 
Ehlers-Danlos Syndrome (EDS) is a heterogeneous group of connective tissue disorders 
with phenotypes including joint hypermobility, skin hyperextensibility and fragility [85]. 
EDS is named for two dermatologist Edvard Ehlers and Alexandre Danlos. Ehlers 
described some of the most important clinical signs of EDS, including joint 
hypermobility, skin fragility and haemorrhages in a condition he called cutis laxa  [86]. 
Danlos also made a description of cutis laxa in which he emphasised excessively 
stretchable skin [87]. It later transpired that the case described by Danlos was more 
likely to be Pseudoxanthoma elasticum than the syndrome that bears his name [88]. 
Much like the classification of OI, the nosology of EDS has changed over time with 
different types, and subtypes being identified or re-classified. The different genetic 
causes of EDS has further diversified the classification, which started with 3 types 
described by Barabas in 1967 [89], increasing to 5 types described by Beighton in 1968 
[90], and 7 types described by Mckuisick in 1972 [91]. The 2017 international 
classification of the Ehlers-Danlos syndromes recognises 13 subtypes of EDS which 
maintains the clinical classification, as opposed to genetic classification, primarily 
because the names are widely used in the scientific and medical communities [92]. 
These 13 types are shown in Table 1.4. After the publication of the 2017 international 
classification of the Ehlers-Danlos syndromes, variants in the gene AEBP1 have been 
found to cause an EDS-like phenotype, inherited in an autosomal recessive manner. The 
phenotypes include joint hypermobility, hyperextensible skin, poor wound healing with 
atrophic scarring, and osteoporosis [93, 94]. This potential new subtype on EDS has not 
been included in Table 1.4, as it has not been given a designation yet.  
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Clinical EDS subtype Abbreviation IP Genetic basis Protein 
Classical EDS cEDS AD 






c.934C>T, p.(Arg312Cys)   
Classical-like EDS clEDS AR TNXB Tenascin XB 
Cardiac-valvular EDS cvEDS AR 
COL1A2 (leading to 
NMD and absence of  
pro α2 (I) chains) 
Type I 
collagen 




Rare: COL1A1 Type I 
collagen 





p.(Arg1093Cys)   
Hypermobile EDS hEDS AD Unknown Unknown 
Arthrochalasia EDS aEDS AD COL1A1, COL1A2 
Type I 
collagen 
Dermatosparaxis EDS dEDS AR ADAMTS2 ADAMTS-2 
Kyphoscoliotic EDS kEDS AR PLOD1 LH1 
      FKBP14 FKBP22 
Brittle Cornea 
syndrome 
BCS AR ZNF469 ZNF469 
      PRDM5 PRDM5 
Spondylodysplastic EDS spEDS AR B4GALT7 β4GalT7 
      B3GALT6 β3GalT6 
      SLC39A13 ZIP13 
Musculocontractural 
EDS mcEDS AR CHST14 D4ST1 
      DSE DSE 




COL12A1 Type XII 
collagen 
Periodontal EDS pEDS AD C1R C1r 
      C1S C1s 
 
Table 1.4.  The 2017 internat ional classification of the Ehlers-Danlos syndromes. IP, 
inheritance pattern; AD, autosomal dominant; AR, autosomal recessive, NMD, nonsense-
mediated mRNA decay. Adapted from Malfait et al., 2017 [92]. 
There is considerable overlap in phenotypes of these different forms of EDS, and many 
include some of the hallmarks of EDS, joint hypermobility, skin fragility and 
hyperextensibility. As such the new classification includes major and minor criterion for 
diagnosis, however, definite diagnosis relies on molecular confirmation of a causative 
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variant with the exception of hypermobile EDS, where the causative gene is unknown 
[92]. 
There are 4 acknowledged types of EDS which can be caused by mutations in COL1A1 
and COL1A2: classical EDS, cardiac-valvular, vascular EDS and arthrochalasia EDS. Due to 
the high degree of overlap of the 13 types of EDS, this brief overview will only specifically 
cover these 4 forms of EDS. 
1.2.2.1. Classical EDS 
Classical EDS is inherited in an autosomal dominant  manner, and is caused by mutations 
in COL5A1 or COL5A2 in over 90% of cases [95], however a specific amino acid 
substitution (Arg134Cys) in COL1A1  has been observed to cause a classical EDS 
phenotype [96]. Where there was a causal involvement of Collagen V, the majority of 
mutations affect COL5A1, with less than 20% affecting COL5A2.  The majority of COL5A1 
mutations lead to a COL5A1 null allele, with the remainder, structural mutations 
including missense mutation and in-frame splicing or deletions. To date no COL5A2 
mutations have been found to lead to a COL5A2 null allele, mutations tend to be 
structural mutations including missense mutations and in-frame splicing or deletions 
[95]. The arginine to cysteine mutation in COL1A1 occurs at the X position of the 
previously mentioned G-X-Y repeating motif. It has been suggested that the cysteine 
could lead to intermolecular di-sulphide bridges, which could impair efficient secretion 
[96]. 
Diagnosis of most forms of EDS is made on the basis of major and minor criteria.  The 
major criteria for classical EDS are skin hyperextensibility and atrophic scarring, and 
generalised joint hypermobility (GJH). A minimal criteria for diagnosis is either both 
major criteria, or skin hyperextensibility and atrophic scarring with at least 3 of the 
minor criteria. Minor criteria include easy bruising, doughy skin, skin fragility, molluscoid 
pseudotumors, subcutaneous spheroids, hernias, epicanthal folds, complications of 
joint hypermobility, and a family history of a first degree relative who meets clinical 
criteria [92]. 
GJH is defined as having a Beighton score of 5 or more out of a possible total of 9. The 
Beighton score for assessment of generalized joint hypermobility was first published in 
1973 [97] (Table 1.5). 
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 Right Left 
Passively dorsiflex the fifth finger to 90° 1 1 
Bend the thumb to the volar aspect of the 
forearm 1 1 
Hyperextend the elbow to 10° 1 1 
Hyperextend the knee to 10° 1 1 
Place hands flat on floor without bending the 
knees 1 
Total possible score 9 
 
Table 1.5.  A table showing the Beighton score for assessment of generalized joint 
hypermobility [97].  
 
1.2.2.2. Cardiac-valvular EDS 
Cardiac-valvular EDS is inherited in an autosomal recessive manner and is caused by 
mutations in COL1A2, leading to a complete deficiency of pro α2 (I) collagen. A number 
of causes have been identified including splice mutations that lead to mRNA instability 
and nonsense mutations creating premature termination codons. Both the aberrant 
splicing and nonsense mutations alters mRNA processing, leading to nonsense mediated 
decay, and an absence of the pro α2 (I) collagen chain [98, 99]. 
The major criteria for cardiac-valvular EDS are more diverse than classical EDS, in 
addition to joint hypermobility (which can be generalised as in classical, or restricted to 
smaller joints) and skin involvement including hyperextensibility and atrophic scarring 
(as in classical EDS), as well as easily bruised or thin skin, the key major criterion is severe 
progressive cardiac-valvular problems.  The minimal criteria for diagnosis is the cardiac-
valvular problems with a family history compatible with recessively inherited disease 
and one other major criterion, or two minor criteria. Minor criteria include inguinal 
hernias, pectus deformity, joint dislocations and foot deformities [92]. 
1.2.2.3. Vascular EDS 
Vascular EDS is inherited in an autosomal dominant manner and is caused by mutations 
in COL3A1 in the vast majority of cases, although a number of different arginine to 
cysteine substitution in COL1A1 have been observed to cause a vascular EDS phenotype. 
A large number of different mutations in COL3A1 have been identified, and the majority 
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are missense or splice mutations, with a few nonsense mutations. The majority of these 
missense mutations alter the repeating glycine motif, and the splice variants introduce 
premature termination codons that lead to mRNA instability through nonsense-
mediated decay and a null allele [100]. The mechanism by which mutations in COL1A1 
lead to  vascular EDS is not known, however delayed procollagen processing by N-
proteinases has been noted in some patients [101]. Another possibility that has been 
suggested is that the introduction of the cysteine residue could lead to intermolecular 
di-sulphide bridges, which could impair efficient secretion [96]. 
Vascular EDS is unique among the EDS subtypes, in that the major criteria do not include 
joint hypermobility or skin involvement, but include ruptures of tissues such as arteries 
and uterus, colon perforation and the formation of carotid-cavernous sinus fistulas. 
Minor criteria include easy bruising, thin translucent skin, acrogeria (skin ageing), and 
characteristic facial appearance, spontaneous pneumothorax, talipes equinovarus (club 
foot), hypermobility of small joints, congenital hip dislocation, tendon and muscle 
rupture, keratoconus (corneal defect), gingival recession or fragility, early onset varicose 
veins.  There are not minimal criteria for diagnosis, only criteria suggestive of vascular 
EDS, and generally, diagnosis is made by molecular testing.  The criteria are a family 
history of the disorder and one other major criteria; however, combinations of major 
and minor criteria should be tested [92]. 
1.2.2.4. Arthrochalasia EDS 
Arthrochalasia EDS is the type of EDS most commonly associated with collagen I defects. 
Mutations causing arthrochalasia EDS occur in either COL1A1 or COL1A2, but in either 
gene, the mutations cause either complete or partial deletion of Exon 6, most commonly 
due to exon skipping caused by a splice variant. The downstream effect of this is that 
the N-propeptide is retained due to the loss of the cleavage site [102, 103]. 
The major criteria for arthrochalasia EDS include congenital bilateral hip dislocation, 
severe GJH with dislocations and subluxations and skin hyperextensibility. Minor criteria 
include muscle hypertonia, kyphoscoliosis, radiologically mild osteopenia, tissue fragility 
and easily bruised skin.  A minimal criteria for diagnosis is congenital bilateral hip 
dislocation and skin hyperextensibility, or congenital bilateral hip dislocation, severe 
GJH dislocations and subluxations and two of the minor criteria [92]. 
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1.2.2.5. Mouse Models of EDS 
There are a number of mouse models of EDS, including classical EDS and vascular EDS, 
however a literature search revealed no mouse models of arthrochalasia EDS or cardiac-
valvular EDS. The models of classical EDS involve Col5a1, either Col5a1 
haploinsufficency, or a tissue specific homozygous Col5a1 deletion due to the 
homozygous Col5a1 null allele being lethal [104, 105]. Models of vascular EDS all involve 
Col3a1, including Col3a1 haploinsufficency and glycine substitutions [106-108]. As none 
of these mouse models involves either Col1a1 or Col1a2, they will not be explored 
further here. 
1.2.3. Osteogenesis Imperfecta/Ehlers-Danlos Syndrome Overlap 
A number of publications have reported patients as having mixed features of both EDS 
and OI [109-112]. These cases were termed osteogenesis imperfecta/Ehlers-Danlos 
syndrome overlap (OI/EDS overlap).  
Cabral et al. identified 7 children with type III or IV OI which also showed a joint laxity, 
and found that each child had a mutation in the first 90 residues of the helical region of 
COL1A1, leading to a delay in, or a prevention of, cleavage of the N-propeptide. In 6 of 
the 7 cases, the mutation was a glycine substitution and in one case a skipping of Exon 
7 [113]. 
Malfait et al. reported 7 cases of OI/EDS overlap, where the patients predominantly 
presented with an EDS phenotype that resembled, but was distinct from, the 
acknowledged EDS subtypes, with elements of OI phenotypes. Two patients had 
mutations in COL1A1, both glycine substitutions in exons 7 or 8, however the remaining 
5 patients had mutations in COL1A2, two with glycine substitutions in exons 8 or 12, and 
3 mutations leading to exon skipping of exons 7, 9 and 14.  The conclusions were similar 
to those of Cabal et al., that the phenotypes arise from mutations in the most N-terminal 
region of the helical domain, causing delayed, or impaired N-propeptide processing, and 
disturbing collagen fibrillogenesis [114]. 
More recently, it has been suggested, by Morlino et al., that the OI/EDS overlap should 
be renamed Col1-related overlap disorder and that is should be included as part of the 
EDS nosology [115]. To aid with diagnosis, and to prevent confusion with either EDS or 
OI, new diagnostic criteria were suggested, which included exclusion criteria.  Major 
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criteria include, blue sclera, flat feet with valgus deformity, generalized joint 
hypermobility according to age and soft, doughy, or hyperextensible skin. Minor criteria 
include dolichostenomelia, hearing loss, short stature, two or more atrophic scars, two 
or more fractures in pre-pubertal age, two or more joint dislocations and two or more 
injuries or ruptures of ligaments/tendons/muscles. The exclusion criteria include, 
congenital fractures, dentinogenesis imperfecta, molluscoid pseudotumors, 
papyraceous scars, progressive/severe heart valve disease, platspondyly, and stable or 
progressive long bone deformities. The diagnosis criteria for Col-1 related overlap 
disorder is three major criteria; or two major criteria and two or more minor criteria, or 
one major criterion and 5 or more minor criteria [115]. 
Whilst the majority of OI/EDS overlap cases are caused by mutations at the N-terminal 
end of the helical region, this is not always the case.  Nicholls et al. reported an OI/EDS 
case caused by homozygous splice mutation in COL1A2 yielding a non-functional proα2 
(I) chain [110]. A number of other examples of this are shown in Figure 1.11. 
 
Figure 1.11.  A diagram showing mutations in COL1A1  and COL1A2  reported in patients 
fitt ing the diagnostic criteria of Col-1 related overlap disorder.   Notat ions in red are 
novel mutations reported in Morlino  et al., notations in blue are previously reported 
mutat ions but  also included the Morlino  et al.  study, notations in  black are previously 
reported mutations, which were not included the Morlino  et al.  study. Figure adapted 
from Morl ino  et al., 2019 [115].  
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The phenotypes of this syndrome are variable and cases with the identical mutations 
often have different combinations of phenotypes, this is the case in several of the 
families reported by Morlino et al. In one such family, one patient would have been 
diagnosed with non-deforming OI (type I) if assessed separately from the other family 
members with identical mutations, due to the lack of generalised joint hypermobility, 
however the other family members did show generalised joint hypermobility [115]. 
 
1.2.3.1. Mouse models OI/EDS Overlap 
There is only one acknowledged mouse model of OI/EDS overlap disorder, however it is 
possible that mouse models with mutations in Col1a1 or Col1a2 currently categorised 
as OI models, could also model this disorder.  An example of this is the oim mouse (see 
section 1.2.1.3), where the phenotype includes joint laxity and altered skin and tendon 
physiology of OI, in addition to the OI phenotype, although it should be noted that skin 
fragility has not been reported [116]. None of the currently known EDS mouse models 
are attributed to mutations in Col1a1 or Col1a2, and therefore cannot be models for 
OI/EDS. 
The mouse model of OI/EDS is known as Jrt, and was published by Chen et al., an ENU 
induced splice variant led to skipping of Exon 9 in Col1a1. The homozygous animals were 
not viable, and phenotypes observed in the heterozygotes included small body size, a 
number of bone related phenotypes including reduced BMD, bone volume/tissue 
volume ratio, trabecular number, and fragile, fracture prone bones, in addition to fragile 
skin [117]. 
1.2.4. Other Conditions Related to Collagen I 
1.2.4.1. Osteoporosis 
Osteoporosis is a disease characterised by low bone mass and deterioration of the bone 
microarchitecture, leading to an increase in bone fragility, and an increased 
susceptibility to facture [118]. Fractures occurring at the hip and vertebrae are the 
“classic” osteoporotic fractures [119]. The diagnostic criterion for osteoporosis is having 
a bone mineral density (BMD) T score of -2.5 or less (2.5 standard deviations below an 
established baseline calculated from a mean BMD from young adults of the appropriate 
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sex) at the femoral neck [120]. Incidences of osteoporosis increase with age, and affects 
women far more frequently than men,  affecting 21% and 6% respectively in the 50-84 
year age bracket in the EU in 2010 [121]. 
Osteoporosis has a strong genetic component as shown by both familial studies and twin 
studies on the heritability of BMD [122-124]. Generally, osteoporosis is viewed as a 
complex polygenic disease where multiple genes each have a modest individual effect 
on BMD, and combine with environmental factors to have an effect greater than their 
individual parts [125]. Several possible monogenic causes of osteoporosis have been 
identified including WNT1 [126] and PLS3 mutations [127, 128]. 
There is some overlap is the clinical manifestation of mild OI and osteoporosis, with both 
disease having similar bone fragility and low BMD [129]. Patients have been identified 
with mutations in COL1A2, where the clinical criteria for OI were not met, resulting in a 
diagnosis of osteoporosis [130]. Additionally, a polymorphism in the SP1 binding site of 
COL1A1 has been found to predispose patients to osteoporotic fractures in multiple 
clinical studies [131-133]. 
1.2.4.2. Atypical Marfan Syndrome 
Marfan syndrome (MFS) is typically caused by mutations in the fibrillin-1 gene (FBN1).  
MFS is associated with abnormalities of the skeleton, cardiac and ocular systems  [134]. 
Abnormalities of the skeleton can include disproportionate overgrowth of the long 
bones, chest deformity (caused by over growth of the ribs), arachnodactyly, scoliosis and 
joint laxity  [135]. Abnormalities of the ocular system can include dislocation of the lens, 
flat cornea and hypoplastic iris [136]. Cardiac abnormalities can include thickening 
and/or prolapse of the atrioventricular valves, dilated cardiomyopathy, aortic dissection 
and aneurysm, and congestive heart failure [137, 138]. The mechanism by which 
mutations in FBN1 lead to MFS is not fully realised, however, there is evidence that it 
may lead to dysregulation of TGFβ activity and signalling [139, 140].  
A case of atypical Marfan syndrome has been identified by Phillips et al., where the 
patient  presented with skeletal and cardiovascular abnormalities consistent with MFS, 
including progressive lumbar scoliosis, and aortic dilation, resulting in congestive heart 
failure, arachnodactyly and a decreased upper to lower segment ratio. A mutation in 
COL1A2 causing an arginine to glutamine substitution (R618Q) was detected and found 
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to cause abnormal migration of the Pro α2(I) chain in SDS gels. It should be noted that 
this mutation does not affect the repeating glycine motif as it occurs at the Y position of 
the G-X-Y repeat, and the mechanism by which this mutation causes the phenotypes is 
unknown [141]. 
1.2.4.3. Caffrey’s Disease 
Caffrey’s disease was first described in 1945 by Caffrey and Silverman, but the first case 
identified as a distinct entity was in 1930 [142, 143]. Caffrey’s disease is an autosomal 
dominant disorder the “classical” disease presents in the first 5 months after birth, with 
periosteal hyperostosis in bones including mandible, ulna, ribs, clavicle and scapulae, 
which normally resolves by 2 years of age [144, 145]. Patients also exhibit joint 
hyperlaxity, soft, hyperextensible skin, similar to Ehlers-Danlos syndrome type III, which 
does not resolve. Approximately 50 % of cases in the Gensure et al. study had 
experienced peripheral fractures indicating an OI/EDS like phenotype [146].  If the 
disease presents prior to birth, it is usually lethal, and presents as OI type II, with 
periosteal hyperostosis [147].  
A mutation in COL1A1 resulting in an arginine to cysteine substitution in exon 41 (R836C) 
has been identified in both the non-lethal “classical” [146] and the lethal Caffrey’s 
disease [147]. Gensure et al. observed some lethal cases did not contain this mutation, 
and Kamoun-Goldrat et al., also state “it is likely that the mutation of an unknown gene 
is responsible for some cases of cortical hyperostosis, either classical (infantile) or 
prenatal forms” [147]. 
 
1.3. Osteoarthritis 
Osteoarthritis (OA) is a metabolically active, progressive degenerative arthropathy, 
which affects the synovial joints and is characterized by degradation of the articular 
cartilage [148]. OA is a complex syndrome, a group of overlapping disorders with similar 
biological and clinical outcomes [149, 150]. OA has previously been regarded as a 
disease of the cartilage, a disease of ‘wear and tear’, however this idea has evolved and 
OA is now viewed as a disease of the whole joint [151].  
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There are many risk factors for OA including systemic risk factors such as age, gender 
and hormones, and genetics; as well as local risk factors such as obesity and injury [152]. 
Epidemiologically OA can be defined pathologically, radiographically or clinically, and 
these classifications are not necessarily synonymous [152]. Clinically, OA is characterised 
by pain and impairment of joint function [153]. Radiographic OA is most commonly 
defined using the Kellgren-Lawrence classification (K&L) [154, 155] with a 0 grade 
indicating no OA, 2 or higher indicating definite OA, with 4 indicating severe OA. The 
radiographic evidence of OA includes osteophytes (new bone growth at the periphery 
of the joint), joint space narrowing and sclerosis of the sub-chondral bone [156]. There 
is often a discordance between clinical and radiographic OA, which is likely to be because 
patients tend not to experience symptoms during the early stages of OA, due to articular 
cartilage being aneural [157]. 
 
1.3.1. The Synovial Joint 
There are three main classifications of joint in the body; cartilaginous joints, fibrous 
joints and synovial joints. Synovial joints are freely movable joints and are identified by 
articulating bones capped with articular cartilage, enclosed within a flexible articular 
capsule.  Within this joint class there are three main sub-classes, uniaxial (such as the 
knee), biaxial (such as the metacarpophalangeal joints) and multiaxial (such as the hip) 
[158]. OA can affect any synovial joint, but is most common in the hips, knees, spine and 
specific joints in the hands (including first carpometacarpal joints, proximal 
interphalangeal joints and distal interphalangeal joints) [159]. Interestingly, these 
examples of the most commonly affected joints include all three sub-classes of synovial 
joints; uniaxial, biaxial and multiaxial, and are also the joints which are most commonly 
subjected to excessive and repeated loading [160]. 
As mentioned previously, OA is a disease of the whole joint, and whilst cartilage 
degradation is a hallmark, OA phenotypes in other tissues include synovial 
inflammation, new bone formation (sclerosis and osteophyte formation), degeneration 
of ligaments and tendons, hypertrophy of the joint capsule and where present, 




Figure 1.12. A diagram comparing a normal knee and an osteoarthritic knee. Taken from 
Wieland  et  al., 2005 [162].  
 
1.3.1.1. Articular Cartilage 
Articular cartilage is a low-friction, wear-resistant tissue, which is ideal to bear and 
distribute loads [163]. The articular cartilage is normally between 2 and 4mm thick, and 
is avascular, aneural and alymphatic [164]. Cartilage contains a single cell type, 
chondrocytes, surrounded by an extracellular matrix (ECM), which is primarily 
composed of water, collagens, proteoglycans, with a smaller fraction of non-collagenous 
proteins [165]. 
Water is by far the most abundant component of articular cartilage comprising 
approximately 65-80% of its ‘wet weight’, with collagen II then next most abundant 
component at approximately 10-20%.  Chondrocytes, make up less than 5% of the total 
articular cartilage volume, but are essential for maintenance of the homeostasis of the 
cartilage [163, 166]. The chondrocytes respond to stimuli such as chemical factors, and 
mechanical factors such as, hydrostatic pressure and mechanical forces, and modifies 
the ECM metabolism. The most important of these factors are the growth factors and 
pro-inflammatory cytokines that have catabolic and anabolic effects, which in turn 
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modulate the synthesis and degradation of the matric molecules [167]. Imbalances in 
the metabolic processes can lead to a ‘vicious cycle’ of degeneration [162, 166].  
The ECM can be viewed as a biphasic structure, of a solid and fluid phase, the solid being 
collagens and proteoglycans, and the fluid, being water and ions.  The biphasic nature is 
due to the low permeability of the solid phase, creating a high interstitial fluid pressure, 
which contributes greatly to the load transmission of cartilage [163, 168]. The fluid 
phase also plays an important role in nutrient transport, as the chondrocytes are 
avascular and therefore acquire nutrients through osmosis from the synovial fluid via 
the water in the ECM.  
The structure of the ECM is created by a three-dimensional mesh of collagen fibrils, 
predominantly type II, interacting with proteoglycans (including aggrecan, decorin, 
biglycan and fibromodulin).  The majority of the intrafibrillar space is filled with large 
proteoglycan aggregates formed by the interaction of aggrecan monomers, and 
hyaluronan by way of link proteins.  Aggrecan monomers themselves are formed when 
glycosaminoglycan (GAGs) chains, such as keratan sulphate or chondroitin sulphate, are 
bound to an aggrecan core[169]. These proteoglycan aggregates provide compressive 
and tensile strength due to the highly negatively charged nature of the GAGs, which 




Figure 1.13.   The extracellular matrix (ECM) of cartilage. The ECM features a network of 
proteins including collagens (predominantly type II ),  proteoglycans (predominantly 
aggrecan); and other non-collagenous proteins (including l ink protein, fibronect in, 
cartilage oligomeric matrix protein (COMP)) and the smaller proteoglycans (biglycan, 
decorin and f ibromodulin). The interact ion between highly negatively charged carti lage 
proteoglycans and type I I collagen f ibri ls is responsible for the compressive and tensile 
strength of the tissue, which resists load in vivo. Taken from Chen  et al.,  2006 [170].  
The articular cartilage is divided into 3 identifiable zones; the superficial zone, the 
middle zone and the deep zone. The superficial zone, which makes up 10-20% of the 
ECM, is the zone closest to the articular surface. The chondrocytes in this zone are 
flattened, and the collagen fibrils, are aligned parallel with the articular surface. The 
middle zone, which as the name suggests is sandwiched between the other zones, 
makes up 40-60% of the ECM volume. The chondrocytes are not flattened, and are more 
spherical in shape, and less densely packed than the superficial zone. The collagen fibrils 
in this zone are thicker and are arranged more obliquely. Figure 1.14 shows the shape 




Figure 1.14.  Cross-sectional diagram of healthy articular carti lage: A- cellular 
organization in the zones of articular cart ilage; B- collagen f ibre architecture. Taken from 
Buckwater,1994 [171] 
In terms of resisting mechanical forces, the deep zone provides the greatest resistance 
to compressive forces due to the collagen fibrils being positioned at right angles to the 
subchondral bone and running through the calcified cartilage. The middle zone is 
responsible for resistance to compressive forces, but to a lesser extent. The superficial 
zone is responsible for resisting the tensile and shear forces [171]. 
Aside from the difference in the organisation of chondrocytes and the orientation of 
collagen fibres within the different zones of the cartilage, the ECM also has a different 
make up depending on proximity to chondrocytes. The regions with differing 
constituents are referred to as the pericellular matrix (PCM), the territorial region and 
the interterritorial region (the latter two regions are sometimes referred to collectively 
as the further removed matrix). The PCM surrounds the chondrocyte and contains 
mostly proteoglycans with some loose collagen fibres (Collagen VI and IX, but not II) 
[172]. It has been suggested that the PCM plays a role in mechanotransduction [173]. 
The PCM is thought to amplify mechanical signals transmitted through the ECM and 
release growth factors and other regulatory molecules in response to these signals 
[174]. The territorial region surrounds the PCM, and contains abundant collagen fibrils 
(mainly collagen II) arranged in a web-like manner as well as proteoglycans [175]. The 
interterritorial region is the largest of the three regions, and fills the spaces between the 
territorial zones, and contains similar components to the territorial regions, but with a 
far higher concentration of proteoglycan aggregates [176]. 
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Cartilage requires a balance between catabolic and anabolic factors in the ECM, some 
of which are secreted by the chondrocytes and others that are provided through the 
synovial fluid. Catabolic factors include cytokines, such as interleukin-1 (IL-1), tumor 
necrosis factor α (TNFα) and leukemia-inhibitory factor (LIF), and proteinases, such as 
the metalloproteinases, and factors such as cathepsin K and Dickkopf-related protein. 
Anabolic factors include cytokine regulators such as interleukin-1 receptor agonist (IL-
1RA); growth factors, such as fibroblast growth factor (FGF), epidermal growth factor 
(EGF) and transforming growth factor-β (TGFβ); and proteinase inhibitors [177-179]. 
Mueller et al. provide a good summary of the various catabolic and anabolic factors 
[177]. 
1.3.1.2. Subchondral Bone 
Below the deep zone of the articular cartilage, the cartilage becomes calcified at a 
point called the tidemark, and is known as the zone of calcified cartilage (ZCC). The ZCC 
attaches the cartilage to the subchondral bone and is an important interface for the 
transmission of force [180]. The subchondral bone is generally defined as the bony 
tissue that lies distal to the calcified cartilage, separated by the cement line, and 
comprises the subchondral bone plate and the subchondral trabecular bone [181]. The 
subchondral bone plate consists of relatively nonporous cortical bone, which is poorly 
vascularised [182], however channels do provide a direct link between articular 
cartilage and trabecular bone, with blood vessels and nerves penetrating into the 
calcified cartilage [183]. The trabeculae of the subchondral trabecular bone connect to 
the subchondral bone plate and plays an important role in shock absorbing and 
supportive functions in the normal joint [181, 184]. The subchondral bone and articular 
cartilage, and the layers between them can be viewed as a single functional unit, the 
osteochondral junction, where there is intensive biomechanical and biochemical cross 
talk, and alteration of one tissue in the unit can modify the function of others [185]. 
1.3.1.3. Other Joint Components 
The capsule is a triple layered structure that surrounds the joint, the outer layer is made 
of fibrous connective tissue and the middle and inner layer, which together are called 
the synovium or synovial membrane, are the subintima and the intima respectively 
[186]. The outer capsule is thickened in places by the blending of ligaments and helps to 
 
40 
stabilise the joint [187]. Two types of synoviocytes reside in the intima, Type A, or 
synovial macrophages and Type B, or synovial fibroblasts. Type A cells remove waste 
and debris from the joint cavity and Type B cells produce specialized matrix constituents 
including hyaluronan, collagens and fibronectin for the synovial fluid [188]. 
The synovial fluid is an ultrafiltrate of blood plasma that lubricates the joint, provides 
nutrients to the articular cartilage and allows transport of regulatory cytokines. Synovial 
fluid contains lubricating molecules such as proteoglycan 4, hyaluronan and surface-
active phospholipids [189]. 
The menisci of the knee are crescent-shaped wedges of fibrocartilage located on the 
medial and lateral aspects of the knee joint. The menisci increase the stability of the 
joint, and due to their shape, are able to help disperse force through the knee due to 
hoop stress among other mechanisms [190]. The outer portion of the meniscus 
connected to the joint capsule is called the red zone, which is thickest part of the 
meniscus, the inner most zone is the white zone, and the area between is known as the 
red-white zone. The red zone is vascular and the white zone is avascular. The red zone 
is predominantly comprised of collagen I (approximately 80% dry weight), the white 
zone is about 60% collagen II and 40% collagen I by weight [191].  
There are various ligaments within the knee, attaching the meniscus to the tibial 
plateau, joining the tibia and femur, and forming part of the capsule. The structure and 
content of ligaments are very similar to tendons, which have been described in an earlier 
subchapter.  
1.3.2. The Osteoarthritic Joint 
OA has a complex pathogenesis involving mechanical, inflammatory and metabolic 
factors, which ultimately lead to damage to multiple tissues and failure of the synovial 
joint [192]. The ‘vicious cycle’ in Figure 1.15 is regarded as a good overview for the 
pathophysiological processes that occur during OA. What is unclear is where the ‘entry’ 




Figure 1.15.   The vicious cycle of Osteoarthritis. Taken from Wieland  et al.,  2005 [162]. 
The changes in the OA joint are numerous, Glyn- Jones et al. summarised these changes 
in a figure, which is replicated below [193] (Figure 1.16). 
 
 
Figure 1.16.  Signalling pathways and structural changes in the development of 
osteoarthritis. ADAMTS=a disintegrin and metalloproteinase with thrombospondin-like 
motifs. IL=interleukin. MMP=matrix metal loproteinase. TNF=tumour necrosis factor. 
IFN=interferon. IGF=insulin-like growth factor. TGF=transforming growth factor.  
VEGF=vascular endothelial growth factor. Taken from Glyn- Jones  et al.  [193].  
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1.3.2.1. Articular Cartilage 
As previously stated, healthy articular cartilage exists in a state of homeostasis with a 
balance of synthesis and degradation of the components of the ECM.  OA results from 
an imbalance between synthesis and degradation of the components of the ECM [194]. 
It is not known exactly what initiates the swing toward degeneration, but once it begins 
the ‘vicious cycle’ in Figure 1.15 propagates the process, with synovial macrophages 
taking up the degraded molecules from collagen and proteoglycans from the ECM, which 
stimulates the production of more  catabolic factors, such as TNFα, IL-1 and IL-6, leading 
to further degradation of the cartilage [195]. 
1.3.2.2. Subchondral Bone 
There is a significant increase in bone remodelling at the bone-cartilage interface below 
damaged cartilage in OA. This is what leads to the sclerosis of the subchondral bone. 
This is likely due to the increase mechanical load, due to the loss of the protective 
cartilage, in addition to the increase of cytokines and growth factors within the joint 
cavity [196]. A process called eburnation occurs where spikes of granulation and fibrous 
tissue advance from the calcified cartilage into the articular cartilage [162]. As OA 
progresses this tissue undergoes endochondral ossification, which is where the cartilage 
is converted into bone. The chondrocytes undergo hypertrophy, mineralize and are 
replaced with bone tissue. This ossification alters the subchondral bone architecture and 
decreases cartilage thickness simultaneously [197]. This process is accompanied by 
angiogenesis and can occur even below the areas with minimal cartilage damage.  
Osteophytes are the bony growth that appear at the margins of the joint [198]. Growth 
factors such as TGF-β, fibroblast growth factors (FGFs) and bone morphogenetic 
proteins (BMPs) have all been shown to play a role in osteophyte development [198, 
199].  Osteophyte development is thought to be caused by the excessive proliferation 
of mesenchymal stem cells, stimulated by the previously mentioned growth factors, in 
the periosteum and synovium, which then undergo chondrogenesis and differentiate 
into hypertrophic chondrocytes, before being replaced by osteoblasts which form the 
bone [200]. There is some evidence that absence of osteophytes may be linked to a 
higher risk of disease progress in some patients with OA, which lends credence to the 
theory that osteophyte development may be an adaptive process to stabilise the joint  
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[201]. The development of osteophytes, while thought to be an attempted repair 
process often leads to negative effects such as pain and loss of movement [167]. 
1.3.2.3. Other Joint Components 
Synovial inflammation in OA is thought to develop secondarily to pathological processes 
in cartilage and bone, and is rarely as severe as in rheumatoid arthritis. Synovial 
inflammation tends to occur in areas of the synovial membrane that are close to, or in 
contact with cartilage. Synovitis could be caused by cartilage debris and catabolic 
mediators in the synovial cavity [156]. This could accelerate the damage to the cartilage 
in patients with OA, due to synovial macrophages producing catabolic and pro-
inflammatory mediators, which in turn destabilise the balance of cartilage damage and 
repair [202, 203]. It is thought that the synovium could be the root cause of some of the 
pain suffered by patients with OA, this is because the synovium is highly innervated with 
sensory nerve fibres [204]. 
Pathological changes occurring in the ligaments and in the menisci in OA, include matrix 
disruption, fibrillation, cell clusters, calcification and cell death [161]. 
1.3.3. Genetics of OA 
It has been long been known that there is a genetic component to OA, in 1944 Stecher 
noted sisters of affected women were three times more likely to exhibit Heberden’s 
nodes (a hard swelling in the fingers, indicating OA in the distal interphalangeal joints), 
compared to the population in general [205]. Spector et al. used a twin study to show a 
genetic influence ranging from 39-65% in hand and knee OA, due to the correlation of 
disease state and status being consistently higher in identical twins compared with non-
identical twins [206]. In addition to twin studies and familial aggregation studies, linkage 
studies and genome wide association studies (GWAS) have been used to investigate the 





Figure 1.17.  An overview of strategies for genetic studies. Taken from Valdes and Spector, 
2008 [207].  
Due to the multifactorial nature of OA, there are many ways in which genetic factors can 
affect the development and progression of disease. In addition to the direct effects that 
the genetic factors may have on the joint, they can also play a role in other risk factors 




Figure 1.18.  A simplist ic diagram showing the roles of genes in OA. Taken from Spector 
and Macgregor, 2004 [209] 
The joint can be directly affected by the genetic factors causing skeletal malformations 
leading to changes in joint shape, alignment, or structure. Some developmental defects 
can result in congenital misalignment of joints and lead to loss of articular cartilage and 
damage to other joint structures, due to distinct degrees of biomechanical instability 
[208]. The form and function of cartilage itself can also be affected by the genetic 
factors. 
Genetic linkage occurs when a locus involved in the trait of interest (specific OA 
phenotypes) and alleles at nearby markers are inherited jointly. This allows 
identification of relationships between genetic markers and specific traits or diseases 
[206, 210]. These linkages then provide a good starting point for identifying candidate 
genes for further investigation.  For example, linkage analyses have identified several 
regions which are likely to contain OA susceptibility genes one of which, 2q13-32 
included IL-1 and frizzled related protein 3 (FRZB). These genes are currently the subject 
of further research [211]. 
GWAS studies involve comparing the DNA of two groups of people, normally a control 
group and a group with a specific trait (in this case OA). The individuals are all genotyped 
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for a large number of known single nucleotide polymorphisms (SNPs), and if significantly 
more individuals with a specific allele occurs in the affected group, then the SNP is said 
to be associated with the trait or disease.  These studies have proved very successful in 
associating genes with monogenic disorders, but somewhat less successful with complex 
multifactorial diseases such as OA. The variability of the disease including age of onset 
compounds these issues, as members of the control group, can cease to be controls. 
However, a number of loci have been identified as being associated with OA, for 
example 7q22 which has be found to be associated in multiple studies [212, 213].  
The number of genetic risk loci associated with OA has been increasing dramatically over 
the last few years and now number over 100. However, functional studies are required 
to elucidate the molecular mechanism that cause these variants to increase OA risk [214, 
215]. 
1.3.4. Ageing as a risk factor for OA 
Ageing has been known as the greatest risk factor of OA for many years and is perhaps 
one of the reasons why OA was viewed as a disease of wear and tear, however OA is not 
an inevitable part of growing old [216]. There are many consequences of ageing which 
can increase the likelihood of OA, including direct changes to the cartilage and changes 
to joint function.  Age-related cartilage changes include dissipation of the chondrocytes 
in the superficial region of the ECM, and an increase in chondrocytes in the deep zone, 
leads to decreased hydration of the cartilage [167] and accumulation of advanced 
glycation end-products (AGEs), which crosslink with collagen molecules increasing the 
brittleness of cartilage[216]. Age-related changes to joint function can result from 
sarcopenia, and increased joint laxity [217]. Chondrocyte senescence has also been 
implicated in the degradation of cartilage, both through increased oxidative stress and 
increased secretion of MMPs [218, 219]. 
1.3.5. Mouse Models of OA 
There is currently no consensus model for OA that naturally reflects human disease 
[220]. Ex vivo models are useful for modelling aspects of OA, but are unable to replicate 
the joint environment properly. There are a number of naturally occurring models of OA 
including mice, rabbits, guinea pigs, dogs and horses [221]. Each species has its own 
benefits and drawbacks, for example, mice are easily managed with low cost, which is 
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advantageous, but the cartilage has different cellular structure  and is over 70x thinner 
compared to human cartilage, horses on the other hand have very similar cartilage 
thickness and cellular structure, but are expensive and require more management [220], 
additionally in accordance with the 3Rs principle (reduce, refine, replace) lower order 
animals are preferable if possible. Genetically modified models have been created, 
where genes involved in OA pathogenesis are knocked out, to model elements of OA.  
There are also number of induced models of OA, where disease can be induced 
surgically, chemically, or through non-invasive procedures such as cyclic AC tibial 
compression. A summary of these models is shown in Table 1.6 [221]. 





Spontaneous models, no need for 
intervention, used to study pathogenesis 
of naturally occurring OA, variable in OA 
manifestation such as in human OA 
Time-consuming due to slow 





Spontaneous models, easy to produce, 
used to study the contribution of specific 
genes in OA and develop disease-
modifying treatments 
High cost, production of 
additional cartilage 
abnormalities and potential 




the medial meniscus 
Rapid progression of OA and therefore 
short study timeframe, reproducible, 
induces post-traumatic OA, allows the 
study of various lesions/stages of disease 
and assess therapeutic efficacy of agents 
for OA treatment 
Inappropriate for studies of 
degenerative OA since 
generated by traumatic invasive 
intervention 




Most rapidly progressing OA, easy to 
implement, relatively less invasive than 
surgically induced models, reproducible, 
useful for short-term studies, allows the 
study of various lesions/stages of disease 
and assess therapeutic efficacy of pain-
alleviating agents for OA treatment 
Rapid and widespread changes 
generated by invasive 
intervention, poor correlation 
with the pathogenesis of human 
OA 
Non-invasive models 
-cyclic AC tibial 
compression 
Non-invasive, severity of the lesions can be 
adjusted, low risk of infection, 
reproducible, allows the study of early OA 
changes after acute or chronic overuse 
injuries of joints and the effects of early 
therapeutic intervention 
Equipment is not commonly 
available, several loading cycles 
and episodes are needed to 
induce severe OA changes, still 
in the early stages of 
understanding its application 
 
Table 1.6.  Advantages and disadvantages of in vivo models. Adapted from Samvelyan et 
al.,  2020 [210].  
Animal models of OA are a very important tool for investigating the pathogenesis. Due 
to early OA in humans being difficult to detect, using animal models can help us fill the 
gaps in our knowledge such as: Why and where in the joint is OA initiated? [222]. It is 
unlikely that any one model will mirror all facets of human OA. Nevertheless by 
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combining the knowledge gained from multiple model types, we can have fairly 
comprehensive coverage [222] (Figure 1.19). 
 
Figure 1.19. Pathogenesis map of OA. The map of OA is divided into pain and the different 
pathological processes that can be modelled. Taken from Vincent  et al., 2012 [222]. 
Spontaneous models such as the STR/ort mouse, enable the pathogenesis of the disease 
(in this particular case) to be thoroughly investigated [223, 224]. Spontaneous models 
of OA are not particularly common, and even when they do occur, do not mirror the 
chronic late onset disease seen in humans. New spontaneous models, especially late 
onset/chronic models will likely facilitate the investigation of disease pathogenesis.  
Another advantage of spontaneous or genetic models is the ability to challenge them 
with induced OA, as has previously been done with the STR/ort mouse model, which 
showed that the OA in these animals was unlikely to be due to greater vulnerability to 
mechanical trauma [225]. 
1.4. ENU Mutagenesis 
The use of N-ethyl-N-nitrosourea (ENU) as a potent chemical mutagen in the mouse, 
was first reported by Russell et al. in 1979, producing 5 times the mutation rate as the 
most effective dose of X-ray while retaining fertility [226]. This process was further 
improved by repeated dosing which increased the maximal mutation frequency induced 




ENU acts primarily as an alkylating agent, transferring its ethyl group to nucleotides by 
way of nucleophilic oxygen or nitrogen sites. The transferred ethyl group constitutes a 
DNA adduct that during cell proliferation and DNA replication results in heritable 
mutations [228]. 
At low doses ENU is ineffective as the damage is repaired, and at high doses fertility or 
health is impaired so a balance is required for optimum results [229, 230]. Optimum 
dosing as set out in Blease et al. leads to mutations at a rate of one mutation every 1.-
1.5Mb [231]. Mutation rates for individual genes is size dependent, with larger genes 
having a higher likelihood of being mutated [232, 233]. 
ENU predominantly modifies A/T base pairs (87%) compared to C/G pairs (13%).  Of the 
modifications of A/T the most common is A/T to T/A transversions (44%) followed by 
A/T to G/C transitions (38%), with only a fraction of A/T to C/G transitions (5%). The 
comparatively infrequent transitions and transversions at the C/G site, are primarily G/C 
to A/T transitions (8%), followed by G/C to C/G transversions (3%), and G/C to T/A 
transitions (2%) [228]. Following translation into proteins, these substitutions result 
most commonly in nonsynonymous changes (72%) of which approximately 65% are 
missense changes and the remainder are nonsense or splice mutations. The remaining 
28% are synonymous mutations that do not alter amino acid sequence [234]. 
Large-scale phenotype driven ENU mutagenesis screens have been utilised to explore 
gene function. The premise of these screens was to induce mutations at random, 
identify a phenotype resulting from the mutagenesis, and then identify the causative 
mutation [235, 236]. The unbiased and hypothesis-free nature of phenotype-driven ENU 
screens has proved successful in identifying a large number of novel genes underlying 
the observed phenotypes often uncovering novel mechanisms across a diversity of 
biological systems [237]. 
Different breeding schemes can be used to produce cohorts of mice that are 
heterozygous or wild-type for the mutations (a dominant screen), or homozygous, 
heterozygous and wild-type for the mutations (a recessive screen). Recessive screens 
require larger cohorts of mice but are potentially more informative. 
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1.4.1. The Harwell Ageing Screen 
The Harwell ageing screen was a large-scale phenotype-driven ENU screen, designed to 
identify mutations resulting in age related disease [238]. C57BL/6J males were injected 
with a total dose of 320mg/kg of ENU. After a period of sterility caused by the ENU, 
these C57BL/6J males (now referred to at G0) are crossed to C3H.pde6b+ female animals 
to produce G1 animals. A G1 male animal is selected and again crossed with a C3H.pde6b+ 
female to produce G2 animals. The female G2 animals are then crossed back to the G1 
male to produce a G3 cohort of animals containing animals that are heterozygous, 
homozygous and wild-type for the mutations in the G1 animal. This G3 cohort allows for 
screening of both recessive and dominant mutations. The sperm of the G1 founder 
animal was banked, so that the descendant lines could be re-derived and DNA was also 
archived for whole genome sequencing, should a phenotype be identified in the G3 
cohort derived from this G1 founder. 
A wide variety of phenotyping tests were undertaken longitudinally typically at an early, 
mid and late time point, around 4 months, 12 months and 18 months respectively 
(Figure 1.20). 
 
Figure 1. 20.  An overview of the time scale and phenotyping that were undertaken as part 
of the Harwell Ageing Screen. Additional tests or t ime points were added when required 
to investigate specific phenotypes. Taken from Blease  et al., 2018  [231] 
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Approximately ¼ of all the mutations identified by the ageing screen resulted in a ‘late’ 
phenotype (after 6 months of age), with some phenotyping tests identifying a much 
larger number of late onset phenotype, for example over 60% of skeletal phenotypes 
identified by X-ray were late phenotypes [231].  
 
1.5. Thesis Aims and Objectives 
 
The aim of this thesis is to characterise a novel model of late onset OA (MP-107), caused 
by an ENU induced mutation in the gene Col1a2. Col1a2 is one of the two genes that 
encode the collagen I alpha chains, which make up the Type I collagen. Mutations in 
genes coding for the collagen I alpha chains are known to cause diseases such as 
osteogenesis imperfecta and Ehlers-Danlos syndrome. However, they have not 
previously been known to play a role in OA. 
The objectives include- 
 Phenotypic analysis 
o Characterisation of the phenotypes exhibited by the mice in this line by 
in vivo phenotyping. 
o Mechanistic investigation of ex vivo tissues. 
 Gene identification 
o SNP mapping to identify the region of the genome containing the 
causative mutation. 
o Whole genome sequencing to identify candidate genes. 
o Sanger sequencing and molecular analysis to confirm effects of the 
mutation 
 Investigation into the effect of abnormal type I collagen 
o Phenotyping of a second line, TM44, which contains an ENU induced 
mutation in Col1a1. 
o Phenotyping of a third line, Col1a2-KO, which contains a CRISPR-Cas9 




 Investigation of the epistasis of mutant genes, and null alleles 
o Phenotype compound crosses of MP-107 and Col1a2-KO 
o Phenotype compound crosses of TM44 and Col1a2-KO 
o Phenotype compound crosses of MP-107 and TM44 
The hypothesis tested in this thesis is that the OA phenotype in MP-107 is caused by the 
mutation identified in Col1a2. The aim of this project beyond this initial hypothesis is 
through genetic analysis, to establish the mode of action of all of these mutations and 
through in depth analysis of various tissues, the specific mechanisms by which mutations 
in these genes can lead to the observed phenotypes.  As previously, mentioned COL1A1 
and COL1A2 have not been implicated in the pathogenesis of OA in humans.  It is 
therefore of interest animals with mutations in Col1a1 and Col1a2, appear to develop 
OA. These models could therefore provide valuable insights into the pathogenesis of OA, 
and how genes not previously associated with the disease could play a role. 
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Chapter 2: Materials and Method
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2.1. Materials Lists 
Consumable Supplier Product code 
20% SDS Solution National 
Diagnostics 
EC-874 
2-Mercaptoethanol (50mM) Gibco 31350-010 





70µm cell strainer Greiner bio-one 542070 
96F Without lid Microwell plate Thermo Scientific 269620 
96-Well PCR Plate Non-Skirted 4titude 4ti-0750-25 
Adhesive Film Covers Abgene AB-0558 
Adhesive Sealing Sheets Thermo Scientific AB-0558 
Bovine Serum Albumin Sigma-Aldrich A7906-100G 
Bovine Serum Albumin, fatty acid 
free 
Sigma-Aldrich A8806-5G 
CELLSTAR 10cm Cell Culture Dishes Greiner bio-one 664-160 
CELLSTAR 6 Well Cell Culture Plate, 
Sterile, With Lid 
Greiner bio-one 657-160 
CELLSTAR Cell Culture Flasks 
25cm2, 50ml, Red filter 
Greiner bio-one 690-175 
CELLSTAR Cell Culture Flasks 
75cm2, 250ml, Red filter 
Greiner bio-one 658-175 
cOmplete™ Tablets EDTA-free, 
EASYpack 




DMEM (1x) + GlutaMAX™-1 +4.5g/L 
D-Glucose, -Pyruvate 
Gibco 61965-026 
DPBS (1x) -CaCl2, -MgCl2 Gibco 14190-094 
Dried Skimmed Milk 
  
Ethanol, absolute Fisher Scientific E/0650DF/17 
Foetal Bovine Serum Gibco 10500064 








Illustra™ DNA Extraction Kit BACC2 GE Healthcare RPN-8502 
LCGreen® Plus+ BioFire BCHM-ASY-
0005 
MEM Non-Essential Amino Acids 
Solution (100x) 
Gibco 11140-050 
Methanol Fisher Scientific M/4000/PC17 
MicroAmp® Fast Optical 96-Well 




MicroAmp™ Optical Adhesive Film Applied 
Bioystems 
4311971 
Nitrocellulose Membrane (0.45µm) Invitrogen LC2001 
NP-40 Thermo Fisher 85124 
Nucleon BACC2 Genomic DNA 






NuPAGE™ 4-12% Bis-Tris Gel 
1.0mmx12well 
Invitrogen NP0322BOX 
NuPAGE™ 4-12% Bis-Tris Gel 
1.0mmx15well 
Invitrogen NP0323BOX 
NuPAGE™ Antioxidant Invitrogen NP0005 
NuPAGE™ LDS Sample Buffer Invitrogen NP0007 
NuPAGE™ MOPS SDS Running 
Buffer (20x) 
Invitrogen NP0001 
NuPAGE™ Sample Reducing Agent 
(10x) 
Invitrogen NP0004 




PhosSTOP EASYpack Roche 04 906 837 
001 
Pierce® ECL Western Blotting 
Substrate 
Thermo Scientific 32106 






Precision Plus Protein™ Dual Colour 
Standard 
Bio Rad 1610374 
Propan-2-ol Fisher Scientific P/7490/21 
Proteinase K Solution QIAGEN 19133 
QIAquick Gel Extraction Kit (50) QIAGEN 28704 
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QIAquick PCR Purification Kit (50) QIAGEN 28104 
QIAzol Lysis Reagent QIAGEN 79306 
Quick Start™ Bradford 1x Dye 
Reagent 
Bio Rad 500-0205 
RNeasy® Maxi Kit (50) QIAGEN 75144 
Syringe filter 0.2µm Fisherbrand 09-719c 
TBS (10x) Cell Signaling 
Technology 
12498S 
Triton X-100 Sigma-Aldrich X100-100ML 
Trizma® base Sigma-Aldrich T6066-500G 
Trizma® hydrochloride Sigma-Aldrich T5941-500G 
Trypsin (0.25%) phenol red Gibco 25050-014 
Trypsin-EDTA (0.05%) phenol red Gibco 25300-054 
Tween® 20 National 
Diagnostics 
EC-607 
Ultrapure Agarose Invitrogen 16500-500 
Vectastain- ABC Rabbit IgG Vector 
Laboratories 
PK-6101 






2.2.1. Sequencing Primers for Mutation Validation 








Sectm1a _gDNA_Reverse ACAGTGATGACTCCCACAAGG 
2.2.2. Primers for Validation of Alternative Splicing by Electrophoresis 
Primer Sequence (5’ to 3’) 
Col1a2_cDNA_Mut_Forward GACTTGTTGGTGAGCCTGGTC 
Col1a2_ cDNA_Mut_Reverse CTCCAGGGCTTAGACAGGGCA 
Col1a2_cDNA_WT_Forward GTGCCAGAGGACTTGTTGGT 
Col1a2_ cDNA_WT_Reverse AACCAGGGCTGCCTCTAAGC 
 
2.2.3. Lightscanner Genotyping Primers (Col1a2) 
Primer Sequence (5’ to 3’) 
MP-107 Forward GCCCTGTCTTAGGAAACTCTATC 
MP-107 Reverse ATTACACCAGCTCTGCCATCA 
 
59 
MP-107 Probe CATCTCATGCCCTTTCCAGCAGG 
 
2.2.4. Allelic Discrimination Genotyping Primers (Col1a1) 
Primer Sequence (5’ to 3’) 
TM-44 Forward CTAGGGCGAGAGAGGTTTCC 
TM-44 Reverse CTCACCTTGGCACCATCGTT 
TM-44  WT Probe (FAM) CGTGGTGTACAAGGTCC 
TM-44  MUT Probe (TET) ACGTGGTGTATAAGGTCCC 
 
2.2.5. Copy Number Genotyping Primers (Col1a2-KO) 
Primer Sequence (5’ to 3’) 
Col1a2-DEL2087-MUT Forward GCTTGCTTGTTCAGCATCAATTAC 
Col1a2-DEL2087-MUT Reverse CGTGGTCCTCTGTCTCCAG 
Col1a2-DEL2087-MUT Probe TAGTCACGTGGCCCTTTGCCAT 
Col1a2-DEL2087-LOA-WT Forward GCTTGCTTGTTCAGCATCAATTAC 
Col1a2-DEL2087-LOA-WT Reverse CGTGGTCCTCTGTCTCCAG 
Col1a2-DEL2087-LOA-WT Probe TAGTCACGTGGCCCTTTGCCAT 
Dot1L_Control Forward GCCCCAGCACGACCATT 
Dot1L_Control Reverse TAGTTGGCATCCTTATGCTTCATC 




2.2.6. Gene Expression Primers 




Col1a2_Wild type_Forward TCCCGGAGAAGCTGGATCT 
Col1a2_Wild type_Reverse CATTACACCAGCTCTGCCATCA 
Col1a2_Wild type_Probe CTTAGAGGCAGCCCTG 
 
2.2.7. sgRNAs for CRISPR/cas9 Deletion 






2.2.8. Primers for CRISPR Confirmation 







2.3. Primary Antibodies 
Antibody Species 
/clonality 




Col1a1 Goat Poly Santa-Cruz SC-8784 WB 1:100 139 
Col1a1 Goat Poly Santa-Cruz SC-8784 IHC 1:200  
Col1a2 Rabbit 
Poly 
Abcam Ab96723 WB 1:1000 129 
Col1a2 Rabbit 
Poly 
Abcam Ab96723 IHC 1:200  
Col1 Rabbit 
Poly 




Cell signalling C50B12 WB 1:1000 78 
BIP Rabbit 
mono 
Cell signalling C50B12 IHC 1:100  
Fibronectin Rabbit 
Poly 
Proteintech 15613-1-AP WB 1:1000 250 
Actin Rabbit 
mono 




2.4. Secondary Antibodies 
Antibody Supplier Code Dilution 
IRDye® 680LT Goat 
anti-Rabbit IgG (H + L) 
Li-Cor 926-68021 1:10000 
IRDye® 800CW Goat 
anti-Rabbit IgG (H + L) 
Li-Cor 926-32211 1:10000 
IRDye® 800CW Goat 
anti-Mouse IgG (H + L) 
Li-Cor 926-32210 1:10000 
IRDye® 800CW Donkey 
anti-Goat IgG (H + L) 
Li-Cor 925-32214 1:10000 
 
2.5. Recipes and Buffers 
 
Standard MEF Media: 
DMEM + 10 % FBS + 50um mercaptoethanol + 1x non-essential amino acids + Pen/Strep 
DMEM    - 439.5 mL 
FBS     - 50 mL  
MEM amino acids   -  5.0 mL 
Penicillin + Streptomycin - 5.0 mL 





FBS free MEF Media: 
DMEM + 50um mercaptoethanol + 1x non-essential amino acids + Pen/Strep 
DMEM    - 489.5 mL 
MEM amino acids   -  5.0 mL 
Penicillin + Streptomycin - 5.0 mL 
Mercaptoethanol  - 0.5 mL 
 
Low FBS MEF Media: 
DMEM + 0 .5 % FBS + 50um mercaptoethanol + 1x non essential amino acids + Pen/Strep 
DMEM    - 487.0 mL 
FBS     - 2.5 mL  
MEM amino acids   -  5.0 mL 
Penicillin + Streptomycin - 5.0 mL 
Mercaptoethanol  - 0.5 mL 
 
Transfer buffer 
Transfer Buffer (20X)  - 50 mL 
Antioxidant   - 1 mL 
Methanol   - 100 mL 





TBS (x10)   - 100ml 
ddH20    - 899ml 
Tween    - 1ml 
 
Tendon Digestion solution 
Pepsin(3200-4500units/mg) - 750µg 
0.5M acetic acid    - 30 mL  
 
MOPS running Buffer 
MOPs  (20X)   - 50 mL 
Deionized Water  - 950 mL 













2.6.1. Animal husbandry 
All animals described herein were housed in the Mary Lyon Centre (MLC), a specific 
pathogen free (SPF) mouse facility, within the MRC Harwell Institute. The majority of 
animals were bred and phenotyped on Home office licence 30/3070 “New mouse 
models of human disease”, when this specific licence came to an end, any further mice 
were bred on Home office licence 17/0004 (PE40B1D0F) “Breeding genetically altered 
mice” and then phenotyped on Home office licence 30/3384 “Phenotyping genetically 
altered mice”, under conditions adhering to the MRC ‘Code of practice for the housing 
and care of animals bred, supplied or used for scientific purposes’ (December 2014) and 
subject to review by Animal Welfare and Ethical Review Body (AWERB). 
Animals were housed in individually vented cages (IVCs), with food (Irradiated -RM3 (E)- 
Special Diet Services) and water (mains water purified using reverse osmosis and then 
chlorinated to 9-13 ppm) provided ad libitum. The environment of the IVCs was 
maintained at a temperature of between 19 and 22oC, a humidity of 45-65% and in a 
12:12 light: dark cycle. Welfare checks were performed daily, any welfare issues were 
escalated to the Named animal care and welfare officer (NACWO) and if necessary the 
Named veterinary surgeon (NVS) was consulted. Animals were housed separated by sex 
and with no more than 5 animals to a cage, with the exception of pre-weaning animals, 
and animals in matings.  
2.6.2. MUTA-PED-107 (MP-107) 
The animals in this line were derived from the Harwell Ageing screen, an ENU 
mutagenesis screen designed to identify models of age-related disease. The protocol by 
which mutagenised mice are generated for a recessive screen has been described 
previously [231, 238]. Briefly, C57BL/6J males are injected with a total dose of 320mg/kg 
of ENU, consisting of an initial dose of 120 mg/kg, followed by 2 further doses of 
100mg/kg with a week between each dose.  After a period of sterility caused by the ENU, 
these C57BL/6J males (now referred to at G0) are crossed to C3H.pde6b+ female animals 
to produce G1 animals. A G1 male animal is selected, and again crossed with C3H.pde6b+ 
female to produce G2 animals. The female G2 animals are then crossed back to the G1 
animal to produce a G3 cohort of animals containing animals that are heterozygous, 
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homozygous and wild-type for the mutations in the G1 animal (Figure 2.1). This G3 cohort 
allows for screening of both recessive and dominant mutations [235]. The purpose of 
crossing the ENU mutagenised animal to a different inbred strain, is to enable mapping 
of the causative mutation, using the single nucleotide polymorphisms (SNPs) 
polymorphic between the strains [238]. 
 
Figure 2.1.  A diagram showing the breeding strategy employed in the Harwell Ageing 
screen. TheG3 cohorts contain animals that are homozygous, heterozygous and wild-type 
for the ENU mutations. 
 
2.6.3. Bone-TM44 (TM44) 
The animals in this line were derived from an ENU mutagenesis screen designed to 
identify dominant mutations. The method for producing the mutagenised cohorts of 
animals is the same as detailed in Section 2.6.2, except in this case the G2 animals 





This line was produced using CRISPR Cas9 technology by the Harwell Genome 
Engineering service. Cas9 mRNA and sgRNAs (detailed in Section 2.2.7) were diluted in 
microinjection buffer to a working concentration of 100ng/µl and 50ng/µl respectively. 
This solution was then delivered by pronuclear injection into 1-cell stage embryos. 
Injected embryos were re-implanted into CD1 pseudo-pregnant females, which were 
allowed to litter and rear F0 progeny. An animal with a 2087 nucleotide deletion was 
selected as the founder animal for the line Col1a2-KO. The deletion encompassed exons 
ENSMUSE00001291037, ENSMUSE00001247742 and ENSMUSE00001305705 and 
induced a premature stop codon and a null allele. 
 
2.7. Identifying the Causative Mutations 
2.7.1. DNA Extraction 
DNA was extracted from tail samples post mortem using the Nucleon BACC2 Genomic 
DNA Extraction System (GE Healthcare Life Sciences, USA) according to manufacturer’s 
instructions. Briefly, samples were incubated overnight at 55oC in 200 µl of ‘Reagent B’ 
and 10 µl of Proteinase K (20mg/ml, Qiagen, Netherlands). 50 µl of Sodium Perchlorate 
was added, then inverted 7 times, 200 µl of Chloroform was added, then inverted 7 
times, 30 µl of Nucleon resin was added before the sample was centrifuged at 200rpm 
for 2 minutes.  The upper phase was transferred to a clean microcentrifuge tube, and 2 
volumes of ice cold 100% ethanol were added to precipitate the DNA. The sample was 
then centrifuged at max speed for 2 minutes to pellet the DNA, which was then washed 
with 70% ethanol, before being dried and then re-suspended in 50 µl ddH2O at 4oC 
overnight.  
2.7.2. Linkage Mapping 
200ng of DNA was sent for linkage mapping using the Illumina Golden Gate Mouse MD 
linkage Panel (Gen-Probe Life Sciences Ltd, UK). This linkage panel contains 1449 SNP 
loci that are informative across 10 inbred strains. There are approximately 3 SNPs for 
every 5Mb interval with at least one of these SNPs being informative for each pairwise 
strain combination in 75% of cases.  The ENU mutations are inherited from the C57BL/6J 
G0, meaning that regions containing the mutation will either be homozygous for 
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C57BL/6J for recessive mutations, or heterozygous for dominant mutations. So while not 
all SNPs are informative for our purposes, this panel allows us to map the causative 
mutation to a region. 
2.7.3. Whole Genome Sequencing 
G1 DNA from the line MP-107 was sent for Whole Genome Sequencing (WGS) utilising 
the Illumina HiSeq platform (Oxford Genomics Centre, Wellcome Trust Centre for 
Human Genetics, UK). The reads generated were then aligned to the reference genome 
(NCBIM38/mm10) by the MRC Harwell Bioinformatics team using Burrows-Wheeler 
Alignment [239]. Single nucleotide variants (SNVs) were detected using a customised 
version of the Genome Analysis Toolkit (GATK) [240]. 
2.8. Mutation Validation 
2.8.1. Primer Design 
Sequencing primers were designed using the Primer3Plus software 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi) and were tested 
using an in silico PCR program from University of California Santa Cruz 
(https://genome.ucsc.edu/cgi-bin/hgPcr). These oligonucleotides were then 
synthesised (Eurofins MWG Operon, Germany). The specific primers are detailed in 
section 2.2.1 
2.8.2. PCR Amplification 
The relevant DNA was amplified using a 25 µl PCR reaction using the program as follows- 
Step 1 - 95oC for 10 minutes 
Step 2 - 95oC for 30 Seconds 
Step 3 - 60oC for 45 Seconds 
Step 4 - 72oC for 10 minutes 
Step 5 - Cycle to Step 2 40 more times 
Step 6 - 72oC for 15 minutes 




AmpliTaq Gold® 360 DNA Polymerase (Thermo Fisher) was used in the PCR reaction as 
follows (volumes per 25 µl  reaction) - 
10X Buffer II 2.5 µl 
dNTPs (10mM) 2 µl 
Forward Primer (10µM) 1.25 µl 
Reverse Primer (10µM) 1.25 µl 
MgCl2 (25mM) 1.5 µl 
DNA (10ng/µl) 1.25 µl 
Polymerase 0.125 µl 
ddH20 15.125 µl 
 
5µl of PCR product was then run on a 2% agarose gel to confirm the presence of a 
product the correct size. 
2.8.3. PCR Purification 
PCR products were purified using the QIAquick® PCR purification kit (Qiagen, 
Netherlands) (as per manufacturer’s instructions). Briefly, sample is diluted with 
‘Buffer PB’ (a high salt buffer) in a 5:1 ratio, and placed in a QIAquick column and 
centrifuged at high speed for 1 minute to bind DNA to the silica membrane, flow through 
is discarded. The membrane is then washed using ‘Buffer PE’, again by centrifugation at 
high speed for 1 minute, flow through is discarded. The DNA is then eluted in ‘Buffer EB’ 
(10mM Tris Cl. pH 8.5), by adding buffer to the membrane, leaving for 1 minute, before 






2.8.4. Sanger Sequencing 
Purified PCR products were sent for Sanger Sequencing (Source Bioscience, Oxford, UK). 
PCR Products were supplied at 10ng/µl and sequencing primers (detailed in 2.2.1) were 





Genotyping for the line MP-107 was performed using the Lightscanner (Idaho 
technology, USA) high throughput DNA melting analysis system.  Asymmetric exhaustive 
PCR is performed with a 3’ blocked oligonucleotide (probe) which binds to the site of 
the SNP, in addition to the primer pair in the presence of the double stranded DNA 
binding dye, LCGreen (Biofire). This causes 2 PCR products to be formed, the full PCR 
product between the normal primer pair and a second between the probe and the 
opposite strand. Primers were designed using LightScanner Primer Design Software 
(Idaho technology). 
Due to the probe being designed for the mutant allele, the homozygous sample 
produces the greatest fluorescence, followed by heterozygous samples, and finally the 
wild-type sample (Figure 2.5). 
The PCR reaction using the program as follows- 
Step 1 - 95oC for 2 minutes 
Step 2 - 95oC for 30 Seconds 
Step 3 - 60oC for 30 Seconds 
Step 4 - 72oC for 30 Seconds 
Step 5 - Cycle to Step 2 55 more times 
Step 6 - 95oC for 30 Seconds 
Step 7 -25oC for 30 Seconds 
Step 8 - 15oC for 30 Seconds 




Figure 2.2. Normalized melting curves and peaks, showing how the different genotypes 
can be identified. 
 
2.9.2. Allelic Discrimination 
Genotyping for the line TM44 was performed using the 7500 Fast Real-Time PCR system 
(Applied Biosystems, ThermoFisher,) and 2 custom Taqman assays with differing labels, 
one for the wild-type allele (FAM) and one for the mutant allele (TET). The different 
probes allow for differentiation between the three genotypes. The primer details can be 
found in Section 2.2.4  
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ABI GTX Taqman Master Mix (AB bioscience) was used in the qPCR reaction as 
follows (volumes per 10 µl reaction) - 
ABI GTX Taqman Master Mix 5 µl 
FAM and TET assay (WT probe 5μM, MUT 
probe 5μM  & primers 15μM each) 2 µl 
DNA (10ng/µl) 2.5 µl 
ddH20 0.5µl 
 
2.9.3. Copy Number 
To genotype the Col1a2-KO line, a genotyping strategy was developed to identify the 
genotype by copy number. The presence or absence of each allele is identified by 
recording the number of cycles taken to reach a threshold (CT value), which is inversely 
correlated to the amount of template DNA. 
e.g.  
CT 25 = 2 copies of the template DNA 
CT 26 = 1 copy of the template DNA 
CT >30 = no copies of the template DNA 
 
Using one assay for the wild-type sample and one for the mutant, we are able to 
accurately identify the genotype; control Dot1L is also included. 
WT= 2 copies of the LOA assay template and 0 copies of the mutant assay 
HET= 1 copy of the LOA assay template and 1 copy of the mutant assay 




ABI GTX Taqman Master Mix (AB Bioscience) was used in the qPCR reaction as follows 
with each FAM assay run separately, but in multiplex with the VIC labelled internal 
control (volumes per 10 µl reaction) - 
ABI GTX Taqman Master Mix 5 µl 
Primers Dot1L_2F (20μM) 0.225 µl 
Primers Dot1L_R (20μM) 0.225 µl 
Probe DotL_2M (5μM) 0.2 µl 
FAM assay (probe 5μM & primers 15μM each) 0.3 µl 
DNA (10ng/µl) 2.5 µl 
ddH20 1.55 µl 
 
2.10. Time course Phenotyping 
2.10.1. X-Ray 
X-rays images were generated using a Faxitron MX20- specimen radiography system 
(Faxitron X-ray Corporation, Tucson, AZ). Animals were anaesthetised using a Xylazine 
(Sedaxylan™, 20mg/mg) / Ketamine (Anesketin™, 100mg/ml) /sterile water solution 
made up in the ratio 1:2:17, and administered at 10µl/g of bodyweight intraperitoneally. 
2.10.2. Dual X-ray Energy Absorption (DEXA) 
DEXA images and data were generated using the Lunar PIXImus II Densitometer (GE 
Medical Systems).  Animals were anaesthetised using a Xylazine (Sedaxylan™, 20mg/mg) 
/ Ketamine (Anesketin™, 100mg/ml) /sterile water solution made up in the ratio 1:2:17, 
and administered at 10µl/g of bodyweight intraperitoneally.  
2.10.3. Clinical Chemistry 
Two types of blood collection methods were used for clinical chemistry, for early time 
points blood was collected from the lateral tail vein, and for late, terminal time points, 
blood was collected via retro-orbital bleed. For blood collection from the lateral tail vein, 
animals had EMLA, local anaesthetic cream applied to their tails 30 minutes prior to the 
procedure. The animals were then restrained, and the lateral tail vein cut using a sterile 
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scalpel blade. Blood was then collected using heparin coated microvette tubes( VWR). 
The blood flow was then staunched using pressure, before the animal was returned to 
its home cage. For retro-orbital blood collection, the animal was terminally 
anaesthetised, with an overdose of pentobarbital, once all pedal and corneal reflexes 
had ceased a lithium heparin coated capillary tube was inserted into the retro-orbital 
sinus and  blood was collected in a heparin coated microvette tube. 
Plasma was separated by centrifugation at 5000xg at 4oC, before being pipetted into a 
microcentrifuge tube. Plasma samples were analysed using an Olympus U4000 bio 
analyser.  
2.11. Histology 
2.11.1. Histological Processing of Knee Joints 
Animals were culled, either by cervical dislocation, or by overdose of anaesthetic and 
retro orbital bleed. The limbs were then fixed in 10% neutral buffered formalin, before 
being decalcified in 20% formic acid. Knee joints were then embedded in paraffin wax 
and sections were cut at 5µm using a Finesse ME+ microtome (Thermo Fisher). Sections 
were transferred to charged slides, and either stained with Haematoxylin and Eosin 
(H&E), or Fast green and Safranin O, or left unstained for immunohistochemistry (IHC).  
2.11.2. Histological Analysis of Embryonic Lungs 
Embryos were harvested at 18.5 days post coitum (dpc) from timed intercross matings. 
Embryos were culled by decapitation before dissection and fixation of the lungs in 10% 
neutral buffered formalin. Lungs were then embedded in paraffin wax and sections were 
cut at 5µm using a Finesse ME+ microtome (Thermo Fisher). Sections were transferred 
to charged slides, and stained with H&E.  Analysis was performed using FIJI software. 
2.11.3. Immunohistochemistry 
Knee sections were obtained as outlined in Section 2.11.2. Slides were dewaxed and 
antigen retrieval was carried out by incubating sections in 1mg/ml pronase for 30 
minutes at 37oC, washing in PBST for 5 minutes and then incubating in 5mg/ml 
hyaluronidase 30 minutes at 37oC. Endogenous peroxidases were quenched by blocking 
with 3% hydrogen peroxide in 2-propanol for 15 minutes at room temperature. 
Immunostaining was then carried out using the ABC Anti-rabbit IgG Kit (AK-5001-NB, 
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Vectastain). Sections were blocked with goat serum for 30 minutes at room 
temperature, before incubating with Anti-BiP primary antibody (see section 2.3 for 
details) for 60 minutes at room temperature. The sections were then washed in PBS 
before being incubated in the biotinylated secondary included in the kit for 30 minutes 
at room temperature, before washing again. The sections were then incubated in 
vectastain reagent for 30 minutes at room temperature before a final wash. DAB is then 
used as a chromogen for the secondary antibody, and slides were counterstained using 
haematoxylin. 
2.12. Skeletal Staining 
2.12.1. Sample Collection 
Embryos were harvested at 18.5 dpc from timed intercross matings. The uterus was 
removed from the pregnant animal and placed in ice cold PBS, and then kept on ice for 
20 minutes. The uterus was then transferred into a 10 cm petri dish and covered with 
fresh ice-cold PBS.  The uterus was then opened to allow access to the individual yolk 
sacs. The yolk sac was then carefully cut open to release the embryo and placenta.  A 
sample of yolk sac was taken for genotyping, and the embryo separated from the 
placenta at the umbilical cord and placed in a labelled well of a 6 well plate filled with 
ice cold PBS. This process was repeated until all embryos were in individual wells of PBS. 
Any blood clots that formed at the navel were removed and the embryos were left on 
ice for another few minutes before being thoroughly washed to remove any remaining 
blood, before being placed into fresh wells containing ice cold 95% ethanol. 
2.12.2. Sample Preparation 
Samples were removed from 95% ethanol, then eyes, skin, adipose tissue and internal 
organs were removed, before placing the embryo in acetone overnight at room 
temperature. The acetone further fixes the tissue, permeabilises the tissues and 
dissolves the remaining adipose tissue. The embryo was then transferred to a glass vial 
and covered with 0.03% Alcian blue stain diluted in an 80/20 solution of ethanol and 
glacial acetic acid, and incubated at room temperature overnight. The embryo was then 
destained by washing twice in 70% ethanol, before incubating overnight in 95% ethanol. 
The embryo was then transferred into a solution of 1% potassium hydroxide in distilled 
water for 1 hour at room temperature to pre-clear the tissue. The sample was then 
 
76 
transferred into a solution of 0.005% alizarin red dissolved in 1% potassium hydroxide 
solution and incubated at 4oC overnight.  Finally, the sample is cleared at room 
temperature in a 50/50 clearing solution of glycerol and 1% potassium hydroxide, until 
the excess stain is removed, before placing the sample in 100% glycerol until imaging 
2.12.3. Sample Imaging 
The embryos were initially imaged in glycerol using a Nikon DSLR on a vertical rig, before 
the limbs were dissected from the embryos and imaged using a Zeiss SteREO V20 
discovery microscope with axiocam ERc5s. 
2.13. Transmission Electron Microscopy 
2.13.1. Sample Collection 
18.5 dpc embryos were harvested and decapitated before being fixed in 2% 
glutaraldehyde prepared in 100 mM phosphate buffer (pH 7.0) at room temperature. 
After 30 minutes the embryos were removed from the fixative, the tails were dissected 
from the body of the embryo, and cut into smaller pieces before being placed in fresh 
fixative. Fixation was continued for 2 hours at 4oC, after which the specimens were 
washed (twice) in 200mM phosphate buffer, before being placed in PBS (pH 7.0). 
2.13.2. Sample Imaging 
The fixed samples were then sent to our collaborators in the lab of Prof Karl Kadler at 
the University of Manchester for imaging. Sections (70-nm thick) were examined for 
TEM using an FEI Tecnai 12 instrument fitted with a 2k × 2k-cooled CCD camera (F214A, 
Tietz Video and Image Processing Systems, Gauting, Germany).  Analysis was performed 
using FIJI software 
2.14. Differential Scanning Calorimetry (DSC) 
2.14.1. Harvesting Tail Tendons 
3-month old animals were culled by cervical dislocation and the tail was amputated at 
the base. The skin was scored along the length and then removed to expose the bundles 
of tail tendons. The skinned tail was washed in a Petri dish containing PBS to ensure no 
hairs were attached to the tendon bundles. Using two pairs of robust forceps, the tail 
was held with one set of forceps at the base and sections of the tail with attached 
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tendons were removed by pulling with the second set of forceps upwards to the base in 
sections. The tendons were then dissected from the sections of tail using a sterile scalpel 
blade and then placed in microcentrifuge tubes, and frozen. 
2.14.2. Testing Samples 
DSC testing of the samples took place in the lab of our collaborator Prof Helen Birch at 
the University College of London.  The tendon was thawed and weighed in a 40µl 
aluminium crucible with a lid (ME-26763), which was then sealed. The sample was then 
placed into the DSC1 STARe System (Mettler Toledo, USA) along with an empty 
reference crucible. 
The DSC heating/cooling program is then run as follows- 
25oC-> -40oC @ 5oC per minute 
-40oC -> 90oC @ 5oC per minute 
This produces a thermogram containing peaks as the water content freezes in the 25oC 
-> -40oC step, and then a peak for the melt, and the denaturation of collagen in the -
40oC -> 90oC step. 
The lid of the crucible is then perforated and the DSC heating/cooling program is then 
run as follows- 
Perforated crucible- 
25oC-> 160oC @ 5oC per minute 
This produces a thermogram, containing a peak as the water content evaporates. 
2.14.3. Analysis of Samples 
The thermograms produced from the samples were analysed using the STARe Evaluation 
software (Mettler Toledo, USA). 
A number of parameters can be calculated from the thermograms produced- 
 The percentage free water within the sample can be calculated as the area under 
the freezing curve.  
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 The total water can be calculated as the area under the evaporation curve of the 
perforated crucible.  
 The percentage bound water within the sample can be calculated by subtracting 
the percentage free water from the percentage total water. 
 Collagen denaturation temperature is defined by the height of the denaturation 
peak. 
 Collagen enthalphy (or wet enthalphy) is calculated as the area under the curve 
of the denaturation peak, normalised to weight. 
 Dry enthalphy is calculated as wet enthalphy divided by dry mass (calculated 
from bound water). 
 
2.15. Radiolabelling of Tendons 
The radiolabelling of samples was carried out in the lab of our collaborator Dr Liz Canty-
Laird at the University of Liverpool. 
2.15.1. Harvesting Tail Tendons 
21-day old mice were culled by cervical dislocation and the tails were dissected from the 
body. Each tail was placed in a separate 100mm Petri dish in PBS containing 1% 
penicillin/streptomycin. The skin was scored along the length and then removed to 
expose the bundles of tail tendons. Using two pairs of robust forceps, the tail was held 
with one set of forceps at the base and sections of the tail with attached tendons were 
removed by pulling with the second set of forceps upwards to the base in sections.  
The tail sections with attached tendons were then placed in a fresh Petri dish containing 
cell culture medium containing 1% (v/v) penicillin/streptomycin 
The tendons were then dissected from the sections of tail using a sterile scalpel blade 
and then placed in a new Petri dish containing cell culture medium containing 1% (v/v) 
penicillin/streptomycin.  
2.15.2. Labelling Samples 
The tendons from each mouse was then split between 4 wells of a 24-well plate 
containing sterile cell culture medium (DMEM) containing 1% (v/v) 
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penicillin/streptomycin, 2 mM L-glutamine, 200 µM ascorbate and 400 µM beta-
aminopropionitrile at 37oC and 5% CO2, and left for 1 hour to equilibrate. The tissues 
were then transferred from each well to a fresh well containing fresh cell culture 
medium and 2.5 uCi/ml of [14C]-proline using fine forceps. Tendons for salt extraction 
were labelled for 1 hour for an approximately even distribution of (pro) collagen (I) 
between the intracellular and extracellular extracts. The tendons were then placed 
briefly in unlabelled supplemented medium to rinse residual [14C]-proline and chased 
in unlabelled medium for 3 hours (to allow newly synthesised pro-collagen to be 
processed and transferred to the extracellular fraction). 
2.15.3. Sequential Extractions 
Post chase, the tissue was transferred into 100µl of salt extraction buffer (1M NaCl, 
25mM EDTA, 50 mM Tris-HCl, pH 7.4, containing one Roche mini EDTA-free protease 
inhibitor cocktail tablet per 10ml), the plate was then place on a shaker with agitation 
at 4oC.  Four sequential extractions was performed, using fresh buffer each time, for 
varying lengths of time overnight (S1), 6hrs (S2), overnight (S3) and 6hrs (S4) to ensure 
complete extraction of extracellular labelled collagen before carrying out a final 
extraction (N) overnight in salt extraction buffer containing 1% NP40. After each 
extraction, the extract was transferred to a microcentrifuge tube and stored at -20oC. 
2.15.4. Analysis of Extracts 
The S1, S4 and N extracts were analysed by electrophoresis using 6% Tris-Glycine gels 
(NuPAGE™, Invitrogen, USA). The S1 extract contains the majority of the extracellular 
proteins, and the N extract contains the intracellular proteins, the S4 extract is included 
to confirm the extent of the extraction of extracellular labelled (pro) collagen prior to 
the lysis of the cells with NP40 extraction buffer.  
The gels were then fixed in a solution of 10% methanol and 10% acetic acid for 20 
minutes, before repeating with fresh fixative for a second 20 minutes. 
The gels were then dried on 3M Whatman paper and exposed to a phosphorimaging 
plate (BAS–IP MS) for 24 hours and then a second phosphorimaging plate for a  further 
7 days.  
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The plates were then imaged using a Typhoon FLA7000 Biomolecular imager (GE 
healthcare, USA). 
 
2.16. Gene expression analysis 
2.16.1. Sample Harvest and RNA Extraction 
Embryos were harvested at 18.5 dpc from timed intercross matings. Embryos were 
culled by decapitation. Tail was taken for genotyping, the embryos were split in half then 
each half of the embryo (and head) was snap frozen in liquid nitrogen, and stored at -
80oC. RNA was produced using the RNeasy Maxi kit (Qiagen) according to 
manufacturer’s instructions. Briefly, half of each embryo was homogenised in QIAzol 
lysis reagent (Qiagen) using a Precellys 24 tissue homogeniser (Bertin). gDNA eliminator 
solution was added to the homogenised tissue and shaken vigorously for 15 seconds 
before chloroform was added and the shaking repeated, before centrifugation for 15 
minutes at 5000xg at 4oC.  The upper aqueous phase is then mixed in a one to one ratio 
with 70% ethanol before the RNA is fixed to a membrane using RNeasy spin columns, 
before eluting the RNA with 200µl RNA-free water. RNA was then stored at -80 oC until 
required. 
2.16.2. CDNA Synthesis 
Synthesis of cDNA was performed using a High capacity cDNA reverse transcription kit 
(Applied Biosystems™ 4368814, Thermo Fisher, USA). Each reaction was composed of 
the following- 
10X RT Buffer 2.0µL 
25x dNTP mix (100mM) 0.8µL 
10x RT random primers 2.0µL 
Multiscribe reverse transcriptase 1.0µL 
Nuclease free H2O 4.2µL 




The program used was as follows- 
Step 1 - 25oC for 10 minutes 
Step 2 - 37oC for 120 minutes 
Step 3 - 85oC for 5 minutes 
Step 4 - Hold at 4 oC 
 
The cDNA was stored at -20oC until required 
2.16.3. Real Time qPCR 
The Applied Biosystems™ 7500 Fast Real-Time PCR System and software were used for 
this experiment, with Taqman assays for target and reference genes, and custom 
Taqman assays (primers detailed in Section 2.2.3) used to differentiate between wild-
type and mutant transcript. The reference gene used was Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH). 
The cDNA was diluted to 2ng/µL cDNA; each cDNA sample was run in triplicate for all 
assays. 
2X Taqman fast universal 
PCR master mix 
10µL 
20x Taqman Assay 1µL 
ddH2O 4µL 
cDNA (2ng/µL) 5µL 
 
2.17. Mechanical Testing of Ex-Vivo Tissues 
2.17.1. Mechanical Testing of Tendons 
The mechanical testing of tendons was undertaken in the lab of our collaborator Prof 




2.17.1.1. Sample Collection  
Animals were culled at 3 months of age by cervical dislocations, and the tail was 
amputated at the base. The tails were then wrapped in gauze soaked in PBS, before 
being placed in individually labelled 15 ml falcon tubes and frozen at -20oC until 
required. It has previously been shown that a single freeze–thaw cycle does not affect 
tendon mechanical properties [241]. 
The tails were thawed at room temperature in small batches, the skin was scored along 
the length and then removed to expose the bundles of tail tendons. The skinned tail was 
washed in a Petri dish containing PBS to ensure no hairs were attached to the tendon 
bundles. The tail was held with one set of robust forceps, and with a set of jeweller’s 
forceps, individual fascicles were pulled to extract them from the bundle of tendons, 
fascicles shorter than 30 mm were discarded. Once extracted the fascicles were placed 
in a 10 cm lidded Petri dish, lined with blue roll soaked with PBS, which was then placed 
at 4oC. Fascicles were regularly moistened with PBS from a spray bottle. The diameter 
of each fascicle was measured using a laser micrometer (LSM-501, Mitutoyo, Kawasaki, 
Japan), and cross-sectional area was estimated using the formula πr2. 
2.17.1.2. Sample Testing 
The mechanical properties of the fascicle were determined using an Instron ElectroPuls 
1000 (Instron, USA) electrodynamic testing machine equipped with a 250N load cell.  
The pneumatic grips were modified with a thin layer of rubber and sandpaper, to reduce 
the likelihood of the fascicle slipping. The distance between the grips was set to 20 mm, 
and the fascicle was loaded into the top grip first to ensure the fascicle was close to taut 
and then pre-loaded to 0.2 N, to remove any slack in the sample. Fascicles underwent 
10 cycles of loading and unloading as a preconditioning step using a sine wave at 
frequency of 1 Hz and amplitude of 0.25mm. Immediately after preconditioning, 
fascicles were pulled to failure at a rate of 1mm/s. Force and extension data were 
continuously recorded at 100 Hz during preconditioning and the failure test. 
2.17.1.3. Analysis 
The percentage hysteresis and percentage stress relaxation were calculated between 
the first and last preconditioning cycles of the pre-conditioning data. The sample failure 
properties were calculated from the quasi-static test to failure. The start point was the 
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displacement at which the initial pre-load was reached, prior to preconditioning, and  
stress and strain were calculated using the estimated cross-sectional area and gauge 
length for each sample. A continuous modulus was calculated across every 10 data 
points of each stress strain curve, from which the maximum modulus value was 
determined [38]. 
2.17.2. Three Point Bending of the Humerus 
2.17.2.1. Sample Collection  
3-month old female animals were culled by cervical dislocation, before the skin was 
removed from both forelimbs. Incisions were made into the muscles at the shoulder and 
elbow to allow the separation of the humerus at both joints, any remaining ligaments 
and muscles at the joints were then severed. Each humerus was then wrapped in gauze 
soaked in PBS, before being placed in individually labelled bags and frozen at -20oC until 
required. 
2.17.2.2. Sample Testing and Analysis 
Three point bone bending was performed on both humeri using a Mach-1 Mechanical 
Tester v500cst (Biomomentum, Canada) equipped with a single-axis load cell of 100N 
and a 3-point bending attachment.  The humeri were loaded via the middle pin at 
0.05mm/s until failure. Mach-1 Motion software (Biomomentum, Canada) was used to 
record the displacement and load, before the data was exported to Excel for analysis. 
2.17.3. Tensile Testing of Skin 
2.17.3.1. Sample Collection  
3-month old female animals were culled by cervical dislocation. A large rectangle of skin 
was excised by making an incision in the skin in the centre of the abdomen from the 
pelvis to mid ribcage before cutting laterally around the whole body at top and bottom 
of the initial incision. The skin was then placed on blotting paper soaked in PBS, wrapped 
in gauze soaked in PBS, before being placed in individually labelled bags and frozen at -
20oC until required. 
2.17.3.2. Sample Testing and Analysis 
Samples were tested using the Mach-1 Mechanical Tester v500cst (Biomomentum, 
Canada) with Vertical (Z) stage (ILS100HA), Single-axis load cell of 100N and a tensile grip 
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attachment. The skin sample was thawed and cut into a dumbbell shaped sample, being 
careful that the integrity of the sample was not compromised. The wide edges of the 
sample were fixed in the tensile grip attachment and the sample was subjected to tensile 
rupture tests at 2mm/s. Mach-1 Motion software (Biomomentum, Canada) was used to 
record the displacement and load, before the data was exported to Excel for analysis. 
2.17.4. Micro-Indentation of the Articular Surface 
2.17.4.1. Sample Collection  
Animals were culled by cervical dislocation, before the skin was removed from both hind 
legs. Incisions were made into the muscles at the hip to allow the evulsion of the femoral 
head from the acetabulum, any remaining ligaments and muscles were then severed. 
Each leg was then wrapped in gauze soaked in PBS, before being placed in individually 
labelled bags and frozen at -20oC until required.  
2.17.4.2. Sample Testing and Analysis 
Samples were tested using the Mach-1 Mechanical Tester v500csst (Biomomentum, 
Canada) with Vertical (Z) stage(ILS100HA), Horizontal (x) stage (ILS100CC), and 
Horizontal (y) stage(ILS50BCC), Multi-axis Load cell 17N, spherical indenter and 1.3 MP 
colour camera.  
When required, legs were thawed at room temperature before the femur and tibia were 
separated and the articular surfaces dissected from the rest of the bone at the growth 
plate.  Tibial plateaus and femoral condyles were attached to a testing chamber filled 
with PBS. A camera registration system (Biomomentum, Canada) was used to image the 
tissue and a positional grid was superimposed on the image of the sample. The pixel 
coordinates were then converted into metric coordinates to allow for automated 
surface mapping. 
At each designated position a perpendicular indentation of 30µm is performed by 
moving all 3 orthogonal stages simultaneously and at different speeds resulting in a 
perpendicular indentation speed of 30µm/s. The force is measured using a spherical 
indenter (D=30 µm) attached to a multi-axial load cell (17N range). 
The structural stiffness at each position is calculated by dividing the perpendicular load 
by the perpendicular displacement. The mean structural stiffness of all indentation sites 
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within a designated region of the articular surface is calculated, to give an overall 
structural stiffness for each region.  
2.18. Micro Computed Tomography of Bones 
2.18.1. Sample Collection and Preparation 
Animals were culled at the appropriate time-point via intraperitoneal injection of 
Euthatal. Death was confirmed by cervical dislocation prior to dissection. Skin was 
removed from both forelimbs and hind limbs. Incisions were made into the muscles at 
the shoulder and hip to allow the separation of the limbs from their joints, any remaining 
ligaments and muscles at the joints were then severed. The spine and tail were 
amputated above and below the pelvis. Extra tissues were then trimmed from the bone, 
before placing the pelvis and limbs in 10% neutral buffered formalin for 48 hours before 
being transferred into 70% ethanol.  The femur, tibia and fibula were cut approximately 
6mm away from the knee joint using a Dremel tool and a diamond cutting wheel, before 
being rinsed in PBS to remove bone fragments. 
2.18.2. Sample Scanning 
Samples were wrapped in non-PVC cling film and then placed snugly inside an 
appropriately sized container made from polylactic acid (PLA) which was affixed to a 
brass chuck. The brass chuck was then inserted into the sample holder in the Skyscan 
1172 (Bruker, Belgium). The samples were scanned using a 0.5um Aluminium filter at 
50kV, 200 µA, 2x2 camera binning and pixel size 4.34 µm. Rotational steps were 0.7 
degrees with 2 frame averaging. 
2.18.3. Sample Analysis 
Samples were reconstructed using NRecon (Bruker, Belgium) with a beam hardening 
correction of 20% and a ring artefact correction 10. The resulting stacks were then re-
orientated using Dataviewer (Bruker, Belgium), before analysis and imaging was 
undertaken using CTAn (Bruker, Belgium). Regions of interest (ROIs) were outline in the 
epiphyseal bone, metaphyseal bone, or subchondral bone plate. These ROIs were then 
processed with a higher grayscale index of 66, and custom processing plug-ins of 




2.19. Optical Projection Tomography of Embryos 
Optical Projection Tomography (OPT) is an imaging technique similar to X-ray computed 
tomography, where visible light is used, instead of X-rays, and passed through an 
optically cleared sample. 
2.19.1. Sample Collection  
Embryos were harvested at 12.5 dpc from timed intercross matings. The uterus was 
removed from the pregnant animal and placed in ice cold PBS, and then kept on ice for 
20 minutes. The uterus was then transferred into a 10 cm Petri dish and covered with 
fresh ice-cold PBS.  The uterus was then opened to allow access to the individual yolk 
sacs. The yolk sac was then carefully cut open to release the embryos and placentas.  A 
sample of yolk sac was taken for genotyping, and the embryos separated from the 
placenta at the umbilical cord and placed in a labelled well of a 6 well plate filled with 
ice cold PBS. This process was repeated until all embryos were in individual wells of PBS. 
Any blood clots that formed at the navel were removed and the embryo were left on ice 
for another few minutes before being thoroughly washed to remove any remaining 
blood, before being placed into fresh wells containing ice cold 4% PFA.  The samples 
were then kept at 4oC overnight. The embryos were then embedded in agarose in a 
cylindrical mould, and mounted to a magnetic chuck. The agarose is then dehydrated 
using multiple changes of 100% methanol, before clearing with a solution of 1 part 
benzyl alcohol to 2 parts benzyl benzoate (BABB). 
2.19.2. Sample Scanning and Analysis 
Scanning of the embryos was undertaken by Dr James Cleak in the MRC Harwell 
molecular biology group using a custom built OPT system and software (labview) [242]. 
Images were reconstructed using Nrecon (Bruker). 
 
2.20. Collagen Analysis of Tendons 
2.20.1. Harvesting of Tail Tendons 
4-month old mice were culled by cervical dislocation and the tails were dissected from 
the body. Each tail was placed in a separate 100mm Petri dish in PBS containing 1% 
penicillin/streptomycin. The skin was scored along the length and then removed to 
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expose the bundles of tail tendons. Using two pairs of robust forceps, the tail was held 
with one set of forceps at the base and sections of the tail with attached tendons were 
removed by pulling with the second set of forceps upwards to the base in sections.  The 
tendons were cut away from the bone using dissection scissors, placed in a 
microcentrifuge tube and stored at -20oC. 
2.20.2. Extraction of Collagen 
Tail tendon samples were thawed at room temperature before approximately 15mg of 
each sample was placed in a corresponding 15ml Falcon tube. 3ml Pepsin (25µg/ml)  in 
0.5M acetic acid  was added to each falcon tube and digested at 4oC for 48 hours with 
shaking. 
2.20.3. Analysis of Collagen Content 
The tendon extracts were then diluted to 0.25mg/ml, before diluting 1:3 in LDS sample 
buffer (Nupage). 20µl was then run on 4-12% Tris Bis gel gels at 200V for 100 minutes. 
The gels were then stained using brilliant Coomassie blue for 30 minutes and then de-
stained using a solution of methanol and 0.5M acetic acid in a 50/50 ratio, changing the 
solution as required. The gel was then imaged using the Biorad Gel Doc XR with a white 
light conversion screen and Image lab 5.1 software. 
2.21. Mouse Embryonic Fibroblasts 
2.21.1. Fibroblast Harvest 
Embryos were harvested at 12.5 dpc from timed intercross matings. Embryos were 
culled by decapitation and placed in individual wells of 6 well plates filled with ice cold 
PBS. The organs, including the heart and liver were then removed from the abdominal 
cavity and discarded along with the head, tail tips were retained for genotyping 
purposes. Any blood clots were washed from the embryos, before placing them into 
individual wells of a 6 well plate with 1.5ml of 0.25% Trypsin. The embryos were then 
minced using a sterile scalpel blade, before being incubated for 5 minutes at 37oC in a 
shaking incubator. The embryos were then further homogenised by drawing the minced 
embryo and trypsin solution through a 21G needle 5 times. 5 ml of standard MEF media 
(see section 2.6) was then added to inactivate the trypsin. The plate was then placed in 
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an incubator at 37oC and 5% CO2 overnight to allow the cells to adhere, before changing 
the media for fresh media the next day. 
2.21.2. Cell Growth and Maintenance 
When the cells reached 90% confluence, the cells were transferred to a T25 flask. The 
old media was removed and the cells were gently washed using 2ml of pre-warmed 
DPBS. 1 ml of 0.05% Trypsin-EDTA was added to the well after the removal of the DPBS, 
and the plates were returned to the incubator until the cells had fully dissociated. The 
trypsin was then deactivated by adding 2ml standard MEF media. The 3 ml containing 
the dissociated cells were then transferred to a T-25 flask containing 7ml of standard 
MEF media. The media was then changed for fresh standard MEF media the next day. 
While the cells were growing the media was changed every few days. The media was 
aspirated out of the flask; the cells were then washed gently with pre-warmed DPBS, 
which was then aspirated and then 10 ml pre-warmed standard MEF media was carefully 
added to the flask. 
When the cells reached 90% confluence, the cells were split 1 in 20 using the same 
technique as outlined above. 
To preserve the cell lines at an early passage, a flask from each MEF line was frozen from 
the second splitting of passage 2 cells. 
2.22. Destabilisation of the Medial Meniscus (DMM) 
The surgical method for DMM under aseptic conditions is as described in Blease et al. 
[243]. Briefly, 10-week old animals were anaesthetised using an intraperitoneal injection 
of Ketamine/Xylazine as well as an analgesic injection of 0.1ml of Torbugesic 
(0.25mg/ml) and Vetergesic (0.025mg/ml) via subcutaneous injection. Anaesthesia was 
maintained using isoflurane at 0.5% in oxygen at 2 litres/minute. 
The knee was shaved, and swabbed with chlorhexidine, before an initial incision, 8 to 12 
mm long, was made medially to the knee with a scalpel exposing the parapatellar 
ligament. A secondary incision  was then made medially to the white parapatellar 
ligament. The medial meniscotibial ligament (MMTL) was then identified and severed 
using a microsurgical knife. Any bleeding was staunched with a sterile surgical swab. The 
joint capsule was then closed with a vicryl suture, and the dermal layer was then closed 
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using ethilon sutures. The mice were allowed to recover in a warmed recovery box and 
when weight-bearing returned to their home cage. The animals were culled 6 weeks 
post-surgery by cervical dislocation, and the hind legs fixed in 10% neutral buffered 
formalin for 48 hours before being transferred to 70% ethanol. 
Histological processing of the knee joints was carried out by the histology department 
at the Kennedy Centre for Rheumatology. Safranin O stained sections were then 
evaluated by OARSI scoring by two skilled evaluators. 
2.23. Western Blotting 
Cells were harvested by dissociating cells by adding 0.05% Trypsin-EDTA, when fully 
dissociated the trypsin was deactivated by adding 5ml media, before centrifugation at 
4oC at 800xg for 5 minutes. The media/trypsin was then siphoned off, before washing in 
ice cold PBS.  The cells were then lysed using a pellet pestle (Kimble) and 250µl Cell Lytic 
MT with phosphatase and protease inhibitors. 
Protein concentration was assessed using a Bradford assay using a uQuant plate reader 
(Biotek). 20µg of protein was mixed with LDS sample buffer (NUpage) and reducing 
agent (Nupage) and boiled at 95oC for 10 minutes before being run on a 4-12% Tris-Bis 
gel at 200V for 60 minutes in MOPs running buffer (see section 2.5). Proteins were then 
transferred to a nitrocellulose membrane (Invitrogen) with a 0.45µm pore size in 
transfer buffer (see section 2.5). 
The membrane was then blocked using 5% w/v milk powder in TBST (see section 2.5) for 
60 minutes with shaking. Primary antibodies were diluted in 5% w/v milk powder in TBST 
(see section 2.3 for dilutions) and incubated at 4oC overnight with shaking. The 
membrane was then washed in 3 changes of TBST with shaking for 5 minutes each time 
before incubating with secondary antibodies diluted in 5% w/v milk powder in TBST (see 
section 2.3 for dilutions) for an hour at room temperature. Fluorescent antibodies were 
protected from the light. The membrane was then dried and protected from the light 





2.24. Statistical Analysis 
Statistical analysis was performed using Prism 7 (Graphpad).  Comparisons between 2 
groups were performed using unpaired Student’s t-test. Where more than two groups 
were analysed, either a one-way or a two-way ANOVA was used with Bonferoni 
correction. Chi squared tests were used to assess viability. Mann- Whitney test was used 
were non-parametric tests were required, for example to analyse osteophyte 
development. Results were considered significant at p<0.05.  
2.25. ARRIVE Guidelines 
The ARRIVE guideline (Animal Research: Reporting of In Vivo Experiments) originally 
published in 2010, and subsequently modified in 2020, are a checklist of information to 
include when describing animal research [244].  These guidelines are intended to 
maximise the reliability and quality of research, and to enable better reproducibility and 
transparency. This includes guidelines covering parameters, such as sample size, 
inclusion and exclusion criteria, blinding and statistical methods. The reporting of data 





Chapter 3: Identification and Initial 
Characterisation of Phenotypes 






This chapter describes the identification and characterisation of a novel mutant mouse 
line carrying a mutation in Col1a2.  The mouse line was identified in the Harwell Ageing 
Screen, which was a large-scale N-ethyl-N-nitrosourea (ENU) mutagenesis screen, 
whereby a forward genetics approach was utilised to identify novel mutations. The 
majority of ENU mutagenesis screens age the mice for only a few weeks or months, and 
therefore only identify mutations relating to early onset disease [235, 236, 245]. The 
Harwell Ageing Screen addressed this by ageing the animals to 18 months to facilitate 
identification of mutations causing late onset or chronic phenotypes, in addition to the 
mutations causing early onset phenotypes.  We live in an ageing society with increased 
populations of older people, which has also increased the burden of late onset disease.  
Identifying novel models of disease, and their causative mutations, is an important route 
to therapy, disease prevention and a reduction in this disease burden. 
Sperm and DNA from each G1 founder animal was archived, and two large G3 cohorts 
(totalling ~100 mice) were bred from each G1 founder to ensure, even in lines where the 
causative mutation was recessive, that there were enough animals to identify the 
phenotype and map the mutation without further breeding. The G3 cohorts underwent 
a recurrent phenotyping regimen until a terminal time point at 18 months of age [238]. 
Further work to identify the causative mutations and characterise the mutations were 
undertaken on lines displaying a phenotype. Further details of the ageing screen and 
breeding schemes are detailed in Sections 1.41 and 2.6.2. 
The line Muta-Ped-107 (MP-107), which was initially identified by X-ray imaging as 
having early onset mild bone abnormalities, including curved olecranon at the elbow, 
and splayed ischia at the pelvis, subsequently developed late onset OA at the knee joint. 
The causative mutation was identified as a splice variant in the gene Col1a2.  In addition 
to describing the initial identification of the phenotype in the line MP-107 and the 
determination of the causative mutation; this chapter will also describe a more in-depth 
phenotyping pipeline involving purpose bred cohorts, tailored to the phenotypes 
observed in the original G3 cohort, to further characterise the progression of the 




3.2. Initial identification of Mutants by X-ray Imaging 
As part of the wider Ageing Screen phenotyping pipeline, X-ray imaging was performed 
at 3, 12 and 18 months of age on all females in the G3 cohort, providing the animals were 
sufficiently healthy.  At 3 months of age a number of animals were noted to have mild 
bone abnormalities including a curved olecranon at the elbow, widened or splayed ischia 
at the pelvis, or both.  
The pelvis can be viewed as two halves, known as coxae, with each coxae made up of 
the ischium, ilium and pubis (plurals- ischia, ilia and pubes), which are fused to form a 
single unit, and the two coxae are joined together by the sacrum.  The ischia and pubes 
are the posterior part of the pelvis, with the ischia forming the dorsal section and the 
pubes forming the ventral section. Generally, the ischia of the mice follow the trajectory 
of the ilia in a symmetrical manner, with the tuberosity of ischium (the most posterior 
point of the ischium) aligning with the body of the ilium. Where one or both ischia 
deviate outside of this trajectory, the animals were deemed to have the ‘splayed ischia’ 
phenotype (Figure 3.1). 
 
Figure 3.1. Examples of high-resolution radiographs of affected and unaffected pelvises, 
with annotation to show how the phenotype was defined. The blue l ines denote the 
trajectory of the ilia and pass through the acetabulum, where the tuberosity of ischium 
deviates outside of these paral lel  l ines, the animal  was deemed to have the ‘splayed 
ischia’  phenotype (red arrows). These radiographs are to show how the phenotype was 
defined and are not G3  animals.  
The olecranon is the proximal part of the ulna, and projects beyond the semilunar notch, 
where the trochlear of the humerus is seated. Generally, the olecranon follows the same 
trajectory as the ulna, where the olecranon deviates outside of this trajectory, the 





Figure 3.2.  Examples of high-resolution radiographs of affected and unaffected 
olecranons,  with annotation to show how the phenotype was defined. The blue lines 
denote the trajectory of the ulna and pass through the semilunar notch, where the 
olecranon deviates from the trajectory, the animal was deemed to have the ‘curved 
olecranon’ phenotype (red arrow). These radiographs are to show how the phenotype was 
defined and are not G3  animals.  
 
Analysis of the radiographs revealed that at 3 months of age, 11 of 48 animals exhibited 
the splayed ischia phenotype, and 8 of 48 animals exhibited the curved olecranon 
phenotype (Table 3.1 and Figure 3.32). 
3 months Ischia Olecranon Knee Total 
Affected 11 8 0 15 
Unaffected 37 40 48 33 
Total 48 48 48 48 
Percentage affected 22.92% 16.67% 0% 31.25% 
 
Table 3.1.  Table showing numbers of animals with each phenotype at  3 months of age.  
The phenotypes are recorded in isolation in this table and therefore animals with multiple 
phenotypes may appear in more than one phenotype column, however total number of 





Figure 3.3.  Radiographs showing affected and unaffected animals at 3 months of age. (A) 
The unaffected animals showed no skeletal abnormalit ies. (B) and (C) The affected 
animals either showed a curved olecranon at one or both elbows (Orange arrows),  or 
splayed ischia at the pelvis (Blue arrows) or a combination of both phenotypes.  
At the 12-month time point, in addition to the abnormalities noted at the ischia and 
olecranon at 3 months, some animals appeared to show abnormal bone formation at 
the knee joints. This abnormal bone formation varied in appearance, but the common 
factor was that bone appeared to form in the vicinity of the knee, but outside of the 





Figure 3.4.  Examples of high-resolution radiographs of affected and unaffected knee 
joints, with annotation to show how the phenotype was defined. The blue arrow on the 
unaffected knee marks the fabella, a sesamoid bone which is embedded in tendon behind 
the knee, this is not an example of abnormal bone growth. The red arrow on the affected 
knee marks the abnormal bone growth at the knee. These radiographs are to show how 
the phenotype was defined and are not G3  animals. 
Analysis of the radiographs revealed that at 12 months of age, 10 of 39 animals exhibited 
the splayed ischia phenotype, 6 of 39 animals exhibited the curved olecranon 
phenotype, and 10 of 39 animals exhibited the abnormal bone growth at the knee 
phenotype (Table 3.2 and Figure 3.5).  
12 months Ischia Olecranon  Knee Total  
Affected 10* 6* 10 16 
Unaffected 29 33 29 23 
Total 39 39 39 39 
Percentage Affected 25.64% 15.38% 25.64% 41.03% 
 
Table 3.2. Table showing numbers of animals with each phenotype at 12 months of age.  
The phenotypes are recorded in isolation in this table and therefore animals with multiple 
phenotypes may appear in more than one phenotype column, however total number of 
animals affected are recorded in the last column. The numbers marked with an asterix (*) 
are lower than numbers record at 3 months, due to some animals being on health checks 





Figure 3.5.  Radiographs showing affected and unaffected animals at 12 months of age. 
The unaffected animals (A) showed no skeletal abnormalit ies. The affected animals (B & 
C) either showed a curved olecranon at one or both elbows (not shown in this figure),  or 
splayed ischia at the pelvis (Blue arrows), or abnormal bone growth at the knee joint (Red 




At the 18-month time point, in addition to the abnormalities noted at the ischia and 
olecranon at 3 months, and the abnormal bone formation at the knee joints noted at 12 
months, further animals developed abnormal bone formation at the knee joints.  The 
bone formations noted at 12 months had also increased in size (Table 3.3 and Figure 
3.6). 
18 months Ischia Olecranon Knee Total  
Affected 10* 8 20 21 
Unaffected 29 31 19 18 
Total 39 39 39 39 
Percentage Affected 25.64% 20.51% 51.28% 53.85% 
 
Table 3.3. Table showing numbers of animals with each phenotype at 18 months of age. 
The phenotypes are recorded in isolation in this table and therefore animals with multiple 
phenotypes may appear in more than one phenotype column, however the total number 
of animals affected are recorded in the last column. The number marked with an asterix 
(*) is lower than the number recorded at 3 months, due to some animals being culled for 





Figure 3.6.  Radiographs showing affected and unaffected animals at 18 months of age. 
The unaffected animals (A) showed no skeletal abnormalit ies. The affected animals (B & 
C) either showed a curved olecranon at one or both elbows (not shown in this figure),  or 
splayed ischia at the pelvis (Blue arrows), or abnormal bone growth at the knee joint (Red 





The abnormalities observed at the ischia and olecranon of these animals did not 
progress in severity, or appear at later time points had they not already manifested by 
3 months of age.  Addressing each phenotype individually, the splayed ischia phenotype 
affected between 22 and 26% of animals, the increase in affected animals by percentage 
was due to a reduction in unaffected animals at the later time points. The curved 
olecranon phenotype affected between 16 and 21% of animals, again the increase in 
affected animals by percentage was due to a reduction in unaffected animals at the later 
time point.  The knee phenotype affected between 41 and 54%, this time the increase 
in affected animals by percentage was due to an increase in affected animals rather than 
a reduction in unaffected animals at the later time points. 
3.3. Mapping and Identification of the Causative Mutation in MP-107 
3.3.1. Mapping the Mutation 
In order to map the causative mutation(s), DNA was extracted from post mortem tail 
biopsies from 7 affected animals (with all three phenotypes) and an unaffected control 
animal. 350ng of DNA was sent to Geneseek® to be run on the GigaMUGA panel- 
143,259-probe Illumina Infinium II array.  The GigaMUGA panel identifies Single 
Nucleotide Polymorphisms (SNPs) which are unique to each particular background 
strain. As the G3 animals which underwent phenotyping have a mixed background, it is 
possible to use the SNPs to identify which portions of the genome were inherited from 
each ancestral strain. The original mutation was induced in a C57BL/6J mouse, therefore 
any mutation caused by the ENU will be within the C57BL/6J regions of the genome.  A 
dominant causative mutation would need to be homozygous or heterozygous for 
C57BL/6J SNPs, whereas if the mutation was recessive the region would need to be 
homozygous for C57BL/6J SNPs.  
 
A single region was identified on Chromosome 6 from the SNP rs13478719 located at 
Chr6:38545339 to the proximal end of the chromosome, where all affected animals 
were either heterozygous or homozygous for C57BL/6J, and an unaffected control 
animal was homozygous for C3H.Pde6b+.  This means all affected animals had at least 
one C57BL/6J region which could contain the causative mutation whilst the unaffected 




mutation (Figure 3.7).  The mouse MP-107-2.11d was heterozygous for C57BL/6J at the 
SNPs proximal to SNP rs13478719 and homozygous for C3H.Pde6b+ at SNP rs13478719.  
This indicates the boundary of the region of interest, as any ENU mutation affecting the 
affected animals listed could only occur on the C57BL/6J genome, and therefore cannot 
be after Chr6:38545339. 
 
 
Figure 3.7. SNP mapping panel showing the region of interest on Chromosome 6. All  
affected animals have at least one C57BL/6J SNP in the ~39Mb region at the proximal end 
of Chromosome 6, indicating that the causative mutation or mutations are contained 
within that region. 
At this stage it was not possible to say if all phenotypes were caused by a single 
mutation, however as only one region was identified, if separate mutations are causing 






3.3.2. Whole Genome Sequencing 
Whole genome sequencing (WGS) was performed on DNA from the G1 founder animal, 
to identify all possible ENU induced mutations in the G3 cohort, which can subsequently 
be investigated. WGS was used over exome sequencing as although the ‘majority of 
disease-causing mutations’ are located within exons [246] for the purpose of this screen 
it was important not to be limited to only exonic information. 
The mapping data indicates that the causative mutation(s) must reside within the ~39 
Mb region at the proximal end of Chromosome 6.  The mutations detected within this 
region were assessed for candidates.  A total of 633 mutations were identified in this 
region, which are summarised in Table 3.4. Mutations are ranked by confidence, where 
the high confidence mutations have a quality score over 200 and a read depth of over 
3, medium confidence have a quality score of between 101 and 200 and a read depth of 
over 3, and the remaining mutations are classed as low confidence [238, 247]. Reduced 
read depth or quality scores may reduce confidence that the mutation identified is in 
fact present, and this is reflected in the confidence groups. 
Type of Variant 
Confidence 
Total High Medium Low 
3 prime UTR variant 2 0 5 7 
5 prime UTR variant 0 1 0 1 
Downstream gene variant 2 0 20 22 
Intergenic variant 31 31 253 315 
Intron variant 18 21 204 243 
Missense variant 0 0 0 0 
Non coding exon variant 0 0 1 1 
Synonymous variant 0 0 0 0 
Splice region variant 1 0 0 1 
Upstream gene variant 3 1 39 43 
Total 57 54 522 633 
 
Table 3.4.  Summary of al l mutations identified within the ~39Mb region on the proximal  
end of Chromosome 6, split by confidence (columns) and classification (rows). 





Position Reference Alternate Functional Class Gene 
3215592 A G Intergenic variant - 
3625093 A G Intergenic variant - 
3877828 T G Intergenic variant - 
4228643 A G Intergenic variant - 
4276412 T G Intergenic variant - 
4521226 T A Splice region variant Col1a2 
4833259 T C Downstream gene variant - 
4920383 A T Intron variant Ppp1r9a 
6470041 A T Intron variant Gm20617 
7113185 A G Intergenic variant - 
7403048 A T Intergenic variant - 
7717449 A G Intergenic variant - 
8506789 C T Intron variant Gm16039 
8877658 G A Intergenic variant - 
8960717 A T Intron variant Nxph1 
9317785 C T Intergenic variant - 
9384727 G A Intergenic variant - 
9501174 A C Intergenic variant - 
9806235 T A Intergenic variant - 
10140012 A C Intergenic variant - 
10368340 A G Intergenic variant - 
10611992 A T Intergenic variant - 
11799123 T A Intergenic variant - 
12119199 T A Intergenic variant - 
13926012 G A Intron variant - 
14014424 G A Intron variant - 
14226943 G T Intergenic variant - 
14755277 A G Upstream gene variant Ppp1r3a 
14993940 T C Intron variant Foxp2 
16532319 A G Intergenic variant - 
19222245 G T Intergenic variant - 
20081045 C T Intergenic variant - 
20168585 G T Intergenic variant - 
20457452 C T Intergenic variant - 
23160716 G C Upstream gene variant - 
23445271 A G Intron variant Cadps2 
24374700 C G Intergenic variant - 
24530910 C A Intron variant Asb15 
25590535 C A Intergenic variant - 
26646401 T C Intergenic variant - 
27257089 A T Intergenic variant - 
29618661 G A Intergenic variant - 
29912296 T A 3' prime UTR variant Ahcyl2 
31247325 T C Intron variant 2210408F21Rik 
32653009 C A Intergenic variant - 
33093143 T C Upstream gene variant - 
34361912 C T Intron variant Akr1b8 
34807920 A T Intron variant Agbl3 
35978485 A C Downstream gene variant - 
36263578 C G Intron variant 9330158H04Rik 
37062707 T A Intron variant Dgki 
37160743 A G Intron variant Dgki 
37200104 T C Intron variant Dgki 
37283938 T C Intron variant Dgki 
37837022 A G Intergenic variant - 
38291687 G A 3' prime UTR variant Zc3hav1l 
38568926 T C Intron variant Luc7l2 
 
Table 3.5.  Summary of the 57 high confidence mutations identif ied within the ~39 Mb 
region on Chromosome 6. The Col1a2  mutation highlighted is the most l ikely candidate, 
as it is within 3 bases of a spl ice acceptor site and is therefore the most likely candidate 




Previous publications on ENU mutagenesis screening have found that mutations 
affecting coding regions are the most common cause for detected phenotypes [235, 236, 
238, 245]. In this case, there were no coding mutations at any confidence level, however, 
there was a high confident splice region variant in Col1a2, a thymine (T) to adenine (A) 
transversion at position 4521226.  Splice region variants, can cause coding changes by 
affecting splicing. In this case the mutation is within 3 bases of the splice acceptor site 
flanking exon 22 in Col1a2 and could therefore affect the coding of Col1a2.   
3.3.3. Confirmation of Mutation 
The splice variant in Col1a2, was the candidate deemed to be the most likely to be the 
causative mutation, as there were no coding mutations, and this mutation may have an 
impact on protein sequence or expression. For this reason, Sanger sequencing was used 
to confirm the T to A transversion 3 base pairs from the splice acceptor site downstream 
of Exon 22 in Col1a2 was present.  
Genomic DNA (gDNA) was extracted from tail from the G1 founder animal, an affected 
G3 and unaffected control. This gDNA was sequenced, and both the G1 and affected G3 
proved to be heterozygous for the mutation, whilst the unaffected control was wild-type 
for the mutation (Figure 3.8). This demonstrates that the mutation identified in the G1 
WGS is a real mutation and that it has been inherited by at least one animal exhibiting 
the observed phenotypes.  
 
Figure 3.8. Sequencing data for  affected and unaffected animals. Both the G1 and a G3 
affected animal showed the presence of 2 peaks at the mutation site in both, due to being 
heterozygous for the mutation and therefore having one wild-type allele and one mutant  
allele.  The unaffected G3 animal shows a single peak at the mutat ion site as it  has two 




3.4. Analysis of Initial Phenotyping by Genotype 
Having confirmed the presence of a Col1a2 mutation in the G1 animal and an affected 
G3, a Lightscanner assay was developed to enable quick and efficient genotyping. 
Animals which are homozygous, heterozygous or wild-type for the Col1a2 mutation will 
be referred to as Col1a2107/107, Col1a2+/107, and Col1a2+/+respectively.  The G3 animals 
from the original cohort were then genotyped, and the phenotyping data was then 
correlated to genotype. The genotyping revealed the absence of Col1a2107/107 animals in 
the G3 cohort indicating that the mutation is likely to be homozygous lethal, and this was 
supported by the ratio of the remaining genotypes of 2:1 Col1a2+/107 to Col1a2+/+, which 
is consistent with expected Mendelian ratios [248, 249] (Figure 3.9). 
 
Figure 3.9.  Genotyping data from the original G3 cohort. There were no homozygous 
(Col1a21 0 7/ 1 07) animals present and a 2:1 ratio of heterozygous (Col1a2+/ 10 7)  to wild-type 
(Col1a2+/ +) animals indicating that the mutation is homozygous lethal.  
 
3.4.1. X-ray Imaging of the MP-107 G3 cohort 
Genotyping of the animals imaged by X-ray revealed that all the animals displaying any 
phenotype were heterozygous, with the exception of 3 animals, which were of unknown 
genotype as the animals were culled due to welfare concerns and tissue for genotyping 




were heterozygous, reducing to approximately 28% at 18 months. This data indicates 
that while it is likely that all three phenotypes are caused by the observed mutation in 
Col1a2, the mutation either has reduced penetrance, or is causing changes which are 
not observable using this phenotyping technique.  Although 100% of the affected 
animals with genotyping data are heterozygous for this mutation, it does not exclude 
the possibility that a separate mutation within this region could be causing any of these 
phenotypes.  
 
Table 3.6.  A table showing numbers of affected and unaffected animals at each t ime point, 
and the genotypes of those animals. A total of 5 animals included in the table were not 
genotyped, as they were culled for welfare reasons before the terminal time point, and 
there was no t issue available for genotyping. 
 
3.4.2. Dual Energy X-ray Analysis (DEXA) of the MP-107 G3 cohort 
DEXA, known as DXA in human studies, uses dual energy x-rays to analyse the body 
composition including BMC, BMD, fat and lean mass, and percentage fat. As part of the 
ageing screen pipeline, DEXA scans were performed on female animals at 3, 12 and 18 
months.  Length of the mouse from the nose tip to the base of the tail was measured 
and the animals were weighed prior to DEXA scan (10). The majority of the data 
collected showed no significant difference between the genotypes with the exception 
of BMD at the 12-month time point (WT-Mean-0.06441, StDev-0.0027, n-10; HET-Mean-
0.05786, StDev-0.004865, n-11; P=0.002, Student t-test), and length at 18-month time 
point (WT-Mean-10.85, StDev-0.32, n-11; HET-Mean-11.16, StDev-0.28, n-16; P=0.02, 
Student t-test).  Length was measured from nose to the base of tail using a ruler to the 
nearest millimetre, as such the measurement is not exact and subject to variability, and 





Figure 3.10.  Graphs showing the DEXA data from female wild types and heterozygotes at 
3-,  12- and 18-month time points. (A) No significant difference in bone mineral content 
between genotypes at any time point. (B) Heterozygotes (HET, Col1a2+/ 1 0 7) have a 
significantly reduced bone mineral density at the 12-month t ime point compared to wild 
type (WT, Col1a2+/+).  (C) Heterozygotes (HET, Col1a2+/ 10 7) have a significantly higher 
length at the 18-month time point compared to wi ld type (WT, Col1a2+/ +).  No significant 
difference between genotypes at any time point in (D) Weight, (E) Fat mass, (F) Lean Mass 




At 12 months, the heterozygous animals exhibited a reduced BMD compared with the 
wild-type animals, however at 18 months there was no significant difference between 
genotypes.  Comparing the means across the time points indicate that the heterozygous 
BMD increased between the 12-month and 18-month time points, meaning there was 
no difference at 18 months (Table 3.7). 
 Wild types Heterozygotes 
  
P Value 
 Mean SD N Mean SD N  
3 Months 0.060733 0.002531 9 0.05938 0.004296 10 0.446 
12 Months 0.06441 0.002715 10 0.057864 0.004865 11 0.002 
18 Months 0.064391 0.005814 11 0.062692 0.004787 12 0.605 
 
Table 3.7.  A table showing mean BMD for female animals of both genotypes across the 
three time points.  SD= standard deviation and N = numbers of heterozygotes (Col1a2+ / 1 0 7) 
and wild types (Col1a2+/ +)  across the three t ime points. Student T-test Significant P<0.05. 
It is possible that this was the result of 2 separate phenotypes, the mutation could be 
causing a reduction in BMD which is statistically significant at 12 months, this reduction 
is then mitigated due to the extra ossified tissue observed at 18 months by X-ray (Figure 
3.3.), which could increase the BMD. 
Although the male animals were not part of the X-ray/DEXA pipeline it was decided, 
after noting the extra bone growth at the knee in 12-month female animals, to scan 
male animals at 18-months.  As there are no other time points to compare the data to, 
the data is displayed with the 18-month female data, previously shown in Figure 3.10 
(Figure 3.11). 
It appears the only parameters with significant differences between genotypes in the 
male animals are to do with adiposity, as both % Fat (WT-Mean-18.61, StDev-3.498, n-
3; HET-Mean-26.33, StDev-4.360, n-9; T-Test-P=0.029) and Fat mass (WT-Mean-7.94, 
StDev-1.34, n-3; HET-Mean-12.58, StDev-2.84, n-9; T-Test-P=0.032) were significantly 
different between genotypes. The low n number of the wild types (3) coupled with one 
animal being considerably leaner (13.7% Fat) than the other animals sharing its 






Figure 3.11 .  Graphs showing the DEXA data from wild types and heterozygotes of both 
sexes at the 18-month time point. No significant difference in (A) Bone mineral content  
or (B) Bone mineral density between genotypes in either sex (C) Female heterozygotes 
(HET, Col1a2+ /1 0 7)  have a significantly higher length compared to female wi ld types (WT, 
Col1a2+ /+).  (D)  No significant difference in weight between genotypes in either sex. Male 
heterozygotes showed a signif icant increase in (E) Fat mass, and (G) Percentage Fat 
compared to male wild types, no significant differences were identified in females. (F) No 





3.4.3. Clinical Chemistry of the MP-107 G3 cohort 
Blood was collected for a limited clinical chemistry panel at 6 and 12 months from 
female animals, from the lateral tail vein, and for a larger panel at the 18-month terminal 
time point, from the retro-orbital sinus.  The reason for only performing a limited panel 
at the earlier time points, is that this was part of a longitudinal study and therefore the 
amount of blood that could be collected was limited due to welfare regulations at 6 and 
12 months. There were no restrictions on the amount of blood that could be collected 
at the terminal time point, which enabled a larger panel of tests. Male animals in these 
pipelines were used for metabolic testing, and therefore not available for clinical 
chemistry. 
The plasma from these blood samples were separated via centrifugation and analysed 
by the clinical chemistry department at MRC Harwell using an Olympus AU400 
Bioanalyser (Table 3.8).  
To summarise the data presented below in Table 3.8- No significant differences between 
genotypes were detected in the following assays at any time point: urea, creatinine, 
calcium, inorganic phosphates, alkaline phosphatase (ALP), alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), amylase, 
creatine kinase (CK), sodium, potassium, total cholesterol, low-density lipoproteins 
(LDL), glucose, triglycerides, glycerol, free fatty acids, iron, uric acid, fructose. 
Significant differences were detected in 5 assays, but no assays showed significant 
differences at more than one time point. Details of these assays are listed below- 
 Total protein - The heterozygous animals displayed a significantly elevated level 
when compared with the wild-type animals in the 12-month cohort. No 
difference was identified in either the 6- or 18-month panel. 
 Albumin - The heterozygous animals displayed a significantly elevated level 
when compared with the wild-type animals in the 12-month cohort. No 
difference was identified in either the 6- or 18-month panel. 
 Bilirubin - The heterozygous animals displayed a significantly reduced level when 




identified in the 12-month panel and this parameter was not included in the 6-
month panel. 
 Chloride - The heterozygous animals displayed a significantly elevated level 
when compared with the wild-type animals in the 18-month male cohort. This 
parameter was not included in either the 6- or 12-month panel. 
 High-density lipoproteins (HDL) - The heterozygous animals displayed a 
significantly reduced level when compared with the wild-type animals in the 18-
month cohort. This parameter was not included in either the 6- or 12-month 
panel. 
The significant differences that were identified in the 12-month samples, total protein 
and albumin, were not replicated in the 18-month samples, indicating that the 
differences noted between genotypes are either transient or false positives.   The 
chloride and HDL assays were only measured at 18 months and therefore it is not 
possible to know if these results are a late onset phenotype, or if these changes occurred 
in heterozygous animals from an earlier age. The significant difference in bilirubin only 
occurred at 18 months and there was no significant difference at 12 months indicating 




































































































































































































3.4.4. Histology of the MP-107 G3 cohort 
To investigate the changes observed by X-ray, knee joints from heterozygous and wild-
type animals from the G3 cohort were fixed in 10% neutral buffered formalin before 
being processed for histology. Initial histology of heterozygote sagittal sections showed 
the observed bone growth appeared to be severe osteophyte formation, and that there 
was an absence of cartilage at the load bearing region of the tibial plateau and the 
femoral condyle (Figure 3.12). 
 
Figure 3.12.  H&E stained sections of knee joints from wild types and heterozygotes at 18 
months.  (A) The wild-type (WT, Col1a2+ /+) knee joint shows normal healthy carti lage at 
the articular surface (Blue arrow).  (B) The heterozygote (HET,  Col1a2+/ 1 07) knee joint 
shows severe osteophyte formation (Yellow arrow) and an absence of articular carti lage 
on the femoral condyle and tibial plateau (Red arrow).  
Due to the two-dimensional nature of histological sections, further sections on a 
different plane (coronal) were taken from knee joints from heterozygous and wild-type 








Figure 3.13.  Safranin O stained sections of knee joints from wild types and heterozygotes 
at 18 months.  (A) The wild-type joint (WT, Col1a2+/+) shows normal healthy carti lage at 
the articular surface (Blue arrow).  (B) The heterozygote knee (HET, Col1a2+/ 10 7) shows 
severe osteophyte formation (Yellow arrow) and an absence of articular cartilage on the 
femoral condyle and tibial plateau (Red arrow).(Medial  side indicated by M, Lateral side 
indicated by L).  
These coronal sections also showed the cartilage loss and severe osteophyte formation 
in heterozygotes.  However, it showed that the cartilage loss was not uniform across 
both tibial plateaus and femoral condyles, as appeared in the initial sections. This 
histology indicates a late onset OA phenotype develops in the heterozygotes. Col1a2 
mutations have previously been associated with osteogenesis imperfecta and Ehlers-
Danlos syndrome, but not with OA. 
3.5. Investigating the Effect of the Col1a2 Mutation on Coding DNA 
Having established the phenotypes present in this line, and that the Col1a2 mutation is 
present in all affected animals with genotyping data available, it is important to 
investigate what specific effect this mutation in the genomic DNA is having downstream. 
3.5.1. Sequencing of Embryo DNA Confirms the Homozygous Lethal 
Phenotype 
Genotyping of the original G3 cohort revealed that no homozygotes were present in the 
animals that were genotyped, and the ratios of heterozygotes to wild types indicated a 
homozygous lethal phenotype.  To investigate if this was the case, timed intercross 
matings between male heterozygotes (HET, Col1a2+/107) and female heterozygotes (HET, 




dpc embryos indicated that homozygotes (HOM, Col1a2107/107) were present.  Sanger 
sequencing of genomic DNA (gDNA) was used to confirm the presence of the mutation, 
that was indicated by the genotyping by Lightscanner (Figure 3.14).  The Sanger 
sequencing showed that in addition to the previously noted double peak for adenosine 
and thymine in the heterozygote and the single peak for thymine in the wild type, the 
homozygote displayed a single peak for adenosine, confirming that two copies of the 
mutation are present in these animals, and no wild-type allele is present. 
 
Figure 3.14.  Chromatographs showing the nucleotides present at position 4521226 for 
wi ld types, heterozygotes and homozygotes. The wild type (WT, Col1a2+/ + )  shows a single 
‘T’ peak indicating the presence of thymine on both alleles, the heterozygotes (HET,  
Col1a2+ /1 0 7) show a ‘T’ and an ‘A’ peaks indicat ing the presence of a thymine on one al lele 
and adenosine on the other, the homozygote (HOM, Col1a21 07 / 1 0 7)  shows a single ‘A’ peak 




3.5.2. Predicting the Impact of the Mutation on the Transcription of 
the Col1a2 Gene 
Splicing plays an essential role in the transcription of genomic sequence to coding 
sequence. Mutations in the splice region, either within or close to, the splice donor or 
acceptor site can have a profound effect on the splicing, leading to issues such as frame 
shifts and premature stop codons. Splice site prediction software was utilised to predict 
how this T to an A transversion might affect the coding DNA (cDNA) (Table 3.9). 
Using the reference sequence, the three software packages; Fruitfly, Netgene and ASSP, 
predicted 2 splice acceptor sites. One of which (AG2) was located immediately adjacent 
to the exon and was predicted by all three software packages, the other (AG1) was over 
80 bases away from the exon and was only predicted by one software package (Fruitfly). 
Using the mutant sequence, containing the T to an A transversion, 3 possible splice 
acceptor sites were predicted. The two mentioned in the paragraph above, which were 
identified in the reference sequence, and a third splice acceptor site (AG3) which was 
created by the T to an A transversion.  It should be noted that while Netgene and ASSP 
both predicted the novel splice acceptor site (AG3), they also predicted the splice 











Intron       Exon       Predicted splice acceptor site       Site of  T to A transversion 
Software Type Score Confidence Cut off reached Predicted splice site Splice site 
FruitFly a Acceptor - 0.67# Yes cctgtcttAG^gaaactc AG1 
Acceptor - 0.94# Yes tttcctgcAG^ggcagcc AG2 
NetGene b Acceptor - 1* Yes tttcctgcAG^ggcagcc AG2 
ASSP c Acceptor 11.11 0.658 Yes tttcctgcAG^ggcagcc AG2 





Intron       Exon       Predicted splice acceptor site       Site of  T to A transversion 
Software Type Score Confidence Cut off reached Predicted splice site Splice site 
FruitFly a Acceptor - 0.67# Yes cctgtcttAG^gaaactc AG1 
Acceptor - 0.8# Yes tttccAG^cagggcagcc AG3 
NetGene b 
 
Acceptor - 0.34* Yes tttccAG^cagggcagcc AG3 
Acceptor - 0.97* Yes tttccagcAG^ggcagcc AG2 
ASSP c Acceptor 7.867+ 0.468 Yes tttccAG^cagggcagcc AG3 
Acceptor 8.5+ 0.359 Yes tttccagcAG^ggcagcc AG2 
AG- Splice acceptor site         ^ Intron/Exon boundary 
Splice site predictor software 
a http://www.fruitfly.org/cgi-bin/seq tools/splice.pl (#Acceptor site cut off : 0.4) 
b http://www.cbs.dtu.dk/services/NetGene2 (*Acceptor site cut off:  0.2) 
c  http://wangcomputing.com/assp/evaluation.html (+Acceptor site cut off : 2.2) 
 
Table 3.9. A table showing the predicted splice acceptor sites from three different 
predictor tools.  All  three spl ice site prediction tools predicts an additional splice acceptor 
site in the mutant transcript,  created by the T to an A transversion 5 bases upstream of 





This alternative splice acceptor site, occurring in the mutant sequence, is located 3 bases 
upstream of the original splice site, if this splice acceptor site is used three bases of 
intronic sequence would be incorporated into the exon as an extra codon. This is 
demonstrated in Figure 3.15 
 
Figure 3.15.  A diagram showing how the Col1a2  mutation affects the exon. The T to an A 
transversion creates a new splice acceptor site, leading to the incorporation of 3 bases 
of intronic sequence into the exon as an extra amino acid glutamine (Q).  
Collagen I alpha chains contain a repeating glycine motif, whereby every third amino 
acid is a glycine. This is very important for the formation of the tight triple helix of the 
heterotrimer. Disruption of this repeating motif is very often deleterious and causes a 
range of conditions including osteogenesis imperfecta (OI), Ehlers-Danlos Syndrome 
(EDS), and an overlap condition with elements of both diseases (OI/EDS). The 
incorporation of 3 intronic bases into Exon 22 will disrupt the repeating glycine motif, as 
the intronic bases ‘CAG’ codes for the amino acid Glutamine (Q), when incorporated into 
the exon.  This is demonstrated in Figure 3.16. 
 
Figure 3.16.  A diagram showing the disruption of the repeating glycine motif.  The 
alternative splice acceptor site disrupts the repeating glycine motif in the middle of the 
helical domain of Col1a2  by the insertion of the amino acid glutamine (Q). The glycines 




3.5.3. Confirmation of Effect of the Col1a2 Mutation on Coding DNA 
All splice site prediction tools used, predicted the creation of a novel splice acceptor site, 
which would be likely to cause the inclusion of intronic sequence as an extra amino acid. 
To validate this prediction Sanger sequencing of cDNA was used (Figure 3.17) 
The forward sequence using a 5’ primer (Figure 3.17A) shows the presence of two traces 
in both the heterozygous sample and in the homozygous sample, from the Exon 21/22 
boundary. The reverse sequence using a 3’ primer (Figure 3.17B) showed differences in 
the traces when compared with the forward sequence using a 5’ primer.  This is due to 
the 5’ primer starting to align the sequence in Exon 21 and then showing 2 traces from 
the splice site into Exon 22 and the 3’ primer starting to align the sequence in Exon 22 
and then showing 2 traces from the splice site into Exon 21.  In both cases the presence 
of the second trace is triggered at the Exon 21/22 boundary. 
The presence of a double trace in the heterozygous sample was expected as there is one 
wild-type allele and one mutant allele.  However, in the homozygous sample, where 
both alleles are mutant it was expected there would only be the single trace including 
the intronic sequence. The presence of a second trace indicates that, even in the 
presence of two copies of the mutant gDNA transcript, both splice sites located close to 
Exon 22 (AG2 and AG3 in Table 3.9), are being used. It is likely that this is because 
although a second splice site was created, the original splice site was not destroyed and 
the spliceosome is using both to some degree. It was predicted by 2 of the splice site 
prediction softwares (Netgene and ASSP) that the mutation would still allow for splicing 







Figure 3.17.  Sanger sequencing chromatograms from all three genotypes using both 
forward (5’->3’ primer) and reverse (3’->5’ primer). (A) Traces from wild type (WT, 
Col1a2+ /+),  heterozygotes (HET, Col1a2+ /1 0 7) and homozygotes (HOM, Col1a21 0 7/ 10 7) cDNA 
in the 5’->3’ direct ion.  The wild type displays the reference sequence only, and the 
heterozygote and homozygote display both the reference sequence and the mutant 
sequence (including the additional ‘CAG’ incorporated from the alternative splic ing), with 
multiple traces visible in  the region coding for Exon 22. (B) Traces from wild type (WT, 
Col1a2+ /+),  heterozygotes (HET, Col1a2+ /1 0 7) and homozygotes (HOM, Col1a21 0 7/ 10 7) cDNA 
in the 3’->5’ direct ion.  The wild type displays the reference sequence only, and the 
heterozygote and homozygote display both the reference sequence and the mutant 
sequence (including the additional ‘CAG’ incorporated from the alternative splic ing), with 




3.5.3.1. Confirmation of Alternative Splicing Using PCR 
Sanger sequencing confirmed the hypothesis that the mutation in Col1a2 would lead to 
alternative splicing and three bases of intronic sequence being incorporated into the 
cDNA, resulting in the insertion of an extra amino acid at the beginning of Exon 22. 
However, the sequencing chromatograms containing two separate traces are difficult to 
visualise, and could be interpreted incorrectly.  To confirm that the presence of multiple 
traces in the sequencing was due to the presence of multiple transcripts produced by 
the use of alternative splice acceptor sites, primers were designed across the Exon 21-
22 boundary to identify and confirm the alternative transcripts. One of the primers for 
the mutant primer set incorporated the inserted CAG, meaning that it would only 
amplify the mutant transcript with the insertion in the cDNA, the primers for the wild-
type primer set did not incorporate the inserted CAG, meaning that it would only amplify 
the wild-type transcript. The PCR products were then imaged on a gel (Figure 3.18). The 
results indicated that the homozygous and heterozygous animals contain both wild-type 
and mutant transcript, as previously seen in the sequencing chromatographs, and the 
wild type animal contains only the wild-type transcript. 
 
Figure 3.18.  PCR products showing the wild-type and mutant  transcripts across all  three 
genotypes. Mutant transcript was detected in heterozygous (HET, Col1a2+/ 10 7),  and 
homozygous (HOM, Col1a21 0 7/ 10 7) cDNA. Wild-type transcript was detected in wild-type 
(WT, Col1a2+/+),  heterozygous (HET, Col1a2+/ 1 07),  and homozygous (HOM, Col1a210 7/ 1 07) 
cDNA, despite the lack of wild-type alleles in the homozygous gDNA. For the primers used,  
see Section 2.2.2. 
3.5.3.2. Confirmation of Alternative Splicing Using qPCR 
The PCR of cDNA demonstrated that there was still wild-type transcript being produced 




allele.  In order to examine if the alternative use of the splice acceptor sites were uniform 
or random, relative expression of the 2 alternative transcripts were measured using 
custom Taqman probes (Figure 3.19). The expression data again showed that wild-type 
transcript was present in the homozygous mutant samples, however the wild-type 
transcript was present in much lower levels than in the heterozygous sample, indicating 
that the splicing occurs at the novel splice site preferentially.  The reason why splicing 
still occurs at the original splice site is unclear.  
 
Figure 3.19.  Graphs showing relative expression of wild-type and mutant transcript using 
custom Taqman probes across all three genotypes.  (A) The relative expression of the wild-
type transcript was shown to be significantly higher in wild types (WT, Col1a2+ /+),  than 
heterozygotes (HET, Col1a2+/ 10 7) and homozygotes (HOM, Col1a210 7/ 1 0 7),  and significantly  
higher in heterozygotes (HET, Col1a2+/ 1 07)  than homozygotes (HOM, Col1a210 7/ 1 07).  Note 
that homozygotes are producing wild-type transcript.  (B) The relat ive expression of the 
wild-type transcript was shown to be significantly lower in wild types (WT, Col1a2+/ +),  
than heterozygotes (HET, Col1a2+ /1 0 7) and homozygotes (HOM, Col1a21 0 7/ 10 7),  and 
significantly lower in heterozygotes (HET, Col1a2+/ 10 7) than homozygotes (HOM, 
Col1a21 07 / 1 0 7) . Note that wild types are not producing mutant transcript. (For all 
genotypes n=8, One-way Anova-*P<0.05, **P<0.01, *** P<0.001,  **** P<0.0001, ***** 
P<0.00001. For Taqman probe details see section 2.2.5).  
 
As previously stated, the disruption of the glycine repeating motif can have a severe 
effect on the collagen I heterotrimer. To investigate if the expression of Col1a1 was 
altered due to the mutation in Col1a2, relative expression of Col1a1 and Col1a2 was 
measured using Taqman probes (Figure 3.20). There is no significant difference between 
genotypes in the relative expression of Col1a2. The relative expression of Col1a1 is 
significantly reduced in the homozygotes, when compared to the heterozygotes and 
wild types.  This data likely means that in the homozygous Col1a2107/107 animals Col1a1 
is downregulated. The reason for this downregulation is unclear, however it may be 




α1 and pro α2 chains interact. Col1a1 expression has been found to be downregulated 
in chondrocytes of a mouse model of OI with a mutation in Col1a2 (G610C) [250].  
This reduction in relative expression may be dose dependant, as there is no difference 
between wild type and heterozygotes in Col1a1 expression, even with the increased 
levels of mutant transcript and decreased levels of wild-type transcript in the 
heterozygotes when compared with wild type. 
 
 
Figure 3.20.  Graphs showing relative expression of Col1a2  and Col1a1 across all three 
genotypes.  (A) There was no signif icant difference in relative expression of Col1a2 
between any of the genotypes.  (B) The relative expression of Col1a1 was shown to be 
significantly reduced in homozygotes (HOM, Col1a21 0 7/ 10 7),  when compared to 
heterozygotes (HET, Col1a2+/ 10 7) and wild types (WT, Col1a2+/ +),  there was no significant 
difference between to heterozygotes (HET,  Col1a2+/ 10 7) and wild types (WT, Col1a2+/ +).  
(For all genotypes n=8,     One-way ANOVA **P<0.01. Taqman probe used were Col1a1- 
Mn00801666_g1, Col1a2-Mm00483888_m1).  
 
3.6. Col1a2107/107 Phenotypes 
3.6.1. Identification of Perinatal Lethality in MP-107 Homozygotes 
We observed that there were no adult homozygous Col1a2107/107 animals in the G3 
cohort, or in subsequent cohorts produced. However, viable homozygous Col1a2107/107 
embryos were present at 18.5 dpc, indicating a perinatal lethal phenotype. In order to 
investigate the lethality and the phenotypes present in the homozygous Col1a2107/107 
embryos, intercross mating between heterozygous Col1a2+/107 male and heterozygous 




were recorded, and then genotyped 21 days postnatally (P21), and a subsequent cohort 
was harvested and genotyped at 18.5 dpc (Figure 3.21). 
The numbers of each genotype observed at 18.5 dpc do not differ significantly from 
Mendelian ratios (χ2= 5.13, 2df, P<0.05) and indicate that the homozygous animals are 
viable throughout gestation.  
By comparison, the analysis of P21 mice arising from the intercross mating between 
heterozygous Col1a2+/107 male and heterozygous Col1a2+/107 female MP-107 animals 
demonstrated a complete lack of homozygous Col1a2107/107animals. The numbers of 
surviving mice, heterozygotes and wild-type, conform to a 2:1 mendelian ratio that 
would be expected if homozygotes are embryonic lethal (χ2= 1.04, 1df, P<0.3).  In these 
intercross cohorts, the number of animals that were recorded at birth, but subsequently 
went missing prior to weaning were significant (11/50 animals born) suggesting that the 
Col1a2107/107 animals die shortly after birth.  If these missing animals were assumed to 
be homozygotes then the numbers conform to the expected mendelian ratio (χ2= 1.32, 
2df, P<0.5).   
In one subsequent litter, two animals were observed gasping and were culled for welfare 
reasons on the day of birth. Genotyping of these animals indicated that these animals 







Figure 3.21.  Genotyping data of embryonic and weaned animals indicate a perinatal lethal 
phenotype. (A)Genotyping data from the original G3  cohort show that there were no 
homozygous (HOM, Col1a21 0 7/ 10 7) animals present and a 2:1 ratio of heterozygous (HET, 
Col1a2+ /1 0 7) to wild-type (WT, Col1a2+/+) animals indicating that the mutation is 
homozygous lethal. (B) Genotyping data for P21 animals produced from intercross 
matings between heterozygous Col1a2+/ 1 07  male and heterozygous Col1a2+/1 0 7  female MP-
107 animals showed that there were no homozygous (Col1a210 7/ 1 07) animals present.  
However, 22% of animals recorded at birth were found to be missing by weaning and were 
therefore not genotyped at P21. At P21 the heterozygous (Col1a2+/ 10 7)  to wild-type 
(Col1a2+/ +)  animals were not signif icantly different from the expected 2:1 Mendel ian 
ratios that would be expected if homozygotes are embryonic lethal (χ2= 1.04, 1df, P>0.3).   
(C) Genotyping data of the 18.5 dpc embryos collected from intercross mating between 
heterozygous Col1a2+/ 10 7  male and heterozygous Col1a2+/ 1 07  female MP-107 animals 
showed that homozygous (Col1a21 07 /1 0 7)  animals were viable at 18.5 dpc. The number of 
genotypes did not differ significantly from Mendelian rat ios (χ2= 5.13,  2df, P>0.05).   
 
3.6.2. Embryonic Lung Phenotype in MP-107 Homozygotes 
The perinatal lethal phenotype of the Col1a2107/107 animals could have a variety of 
causes. However, the observation of Col1a2107/107 pups gasping indicated that the 
respiratory system could be the cause. To investigate this, 18.5 dpc embryos were 
harvested and the lungs fixed for histological processing. Initial evaluation of H&E 
stained sections of the lungs showed a thickened interstitial mesenchyme with 





Figure 3.22.  Histological  sections of 18.5 dpc embryonic lung t issue of wild-type and 
homozygous embryos. Homozygous animals (HOM,  Col1a21 0 7/ 10 7)  (B&D) show a thickened 
interstit ial mesenchyme, and narrowed airways, compared to the wild-type animals (WT,  
Col1a2+ /+)  (A&C). Sections stained with haematoxylin and eosin (H&E), magnification of 
10x (A&B) and 40X (C&D). 
To quantify these apparent differences, the diameters of the airways and the number of 
airways were measured at X40 magnification [251] (Figure 3.23).  
 
Figure 3.23.  Analysis of airway size and airway number in the lungs of the three 
genotypes.  (A) Homozygotes (HOM, Col1a210 7/ 1 07) had significantly reduced airway 
diameters, when compared with wild types (WT, Col1a2+ /+),  no difference was detected 
between the heterozygotes (HET, Col1a2+/ 10 7  and the other two genotypes. (B) No 
significant difference was detected between genotypes in airway number. (ANOVA, * 
P<0.05, N- WT=8, Het=15,Hom=12).  
It was observed that the number of airways did not significantly vary between 




compared with the Col1a2+/+ animals.  There was no significant difference between the 
Col1a2+/107 animals, and either Col1a2+/+ or Col1a2107/107 animals.  This reduction in the 
size of the airways was likely due to the thickened interstitial mesenchyme expanding 
into the airways in the Col1a2107/107 animals. 
3.6.3. Whole Mount Embryonic Skeletal Staining of MP-107 Embryos 
Due to the lethal phenotype, it was not possible to observe any bone phenotype in the 
adult Col1a2107/107 animals. To investigate if there were any bone phenotypes in the 
Col1a2107/107 embryos, 18.5 dpc embryos were harvested and fixed, before undergoing 
skeletal staining using Alizarin red and Alcian blue. This staining allows the skeletal 
structure of the embryo to be visualised. Alizarin red binds to calcium, causing bones to 
be stained red, and Alcian blue binds to sulphated glycosaminoglycans present in 
cartilage, causing cartilaginous tissue to be stained blue [252] (Figure 3.24). 
 
Figure 3.24.  Whole-mount embryonic skeletal staining, of 18.5 dpc embryos of al l three 
genotypes using Alizarin red and Alcian blue.  All three genotypes, (A) wild type (WT,  
Col1a2+ /+),  (B) heterozygote (HET,  Col1a2+ /1 0 7) and (C) homozygote (HOM, Col1a210 7/ 1 07)  
show similar gross morphology at 18.5 dpc.  
There were no overt differences in size, including crown to rump length, however it was 
noted that the homozygous (Col1a2107/107) animals had some evidence of deformation 
in the long bones, including bones being angled rather than straight (Figure 3.25). The 
defects observed in the humeri and femurs are likely caused by breakage of the bones 




presence of extra bone.  The presence of breaks in these bones indicate that the 
homozygous Col1a2107/107 mutation is leading to an OI phenotype. 
 
Figure 3.25 .  Dissected limbs of 18.5 dpc embryos of all three genotypes stained using 
Alizarin red and Alcian blue. (A) Wild type (WT,  Col1a2+ /+) and (B) heterozygotes (HET,  
Col1a2+ /1 0 7)  show no deformity of the long bones. (C) The humerus and femur of the 
homozygotes  (HOM, Col1a210 7/ 1 0 7)  shows apparent breakage, indicated by deeper red 
staining and a deviation in angle (red arrows) compared with the straight  bones seen in 
wi ld types (WT,  Col1a2+/+),  and heterozygotes (HET,  Col1a2+ /1 0 7) . Scale bar=5mm 
 
3.7. Deep Phenotyping of MP-107 Over a 2-18 Month Time Course 
3.7.1. Overview of Animals and Time Points 
The initial phenotyping cohort showed early mild bone abnormalities, and a late onset 
OA phenotype.  The main focus of this phenotyping was to investigate the OA 
phenotype, due to the progressive nature of the phenotype, and its clinical relevance. 




The presence of osteophytes was detectable by X-ray in a number of animals at 12 
months of age; however, the earliest point of detection is likely at some point between 
3 and 12 months. As part of an ageing pipeline, it was not possible to do histology on 
the joints until the terminal time point at 18 months, meaning there was no data on the 
early progression of the disease, only of late-stage OA. In order to overcome this, a time 
course was established with 7 cohorts, consisting of 10 wild type animals (5 of each sex) 
and 10 heterozygous animals (5 of each sex), totalling 140 animals.  These animals were 
aged to specific time points before undergoing a phenotyping pipeline, culminating in a 
terminal bleed, and harvesting of tissues to enable ex vivo analysis such as µCT and 
histology (Figure 3.26).  The time points chosen were 2, 4, 6, 9, 12, 15 and 18 months 
old.   
The fact that each cohort was bred only for a specific time point, not as part of a 
longitudinal study, has the benefit of allowing in-depth histology and µCT analysis at 
each time point, however it is not without its drawbacks. As previously mentioned, the 
splicing, and therefore effect of the mutation, varies and therefore there will be some 
variation between individual animals in each phenotype. The cohort size was designed 
to allow sufficient numbers for analysis, and to balance the logistics of ageing multiple 






Figure 3.26. A diagram showing the seven different cohorts and the phenotyping 
pipeline which each underwent. Each cohort was made up of 5 animals of each 
sex/genotype- (Male Het n=5, Male WT n=5, Female Het n=5, Female WT n=5), a ll 
animals underwent all  procedures, except a-only 4-, 9-,12- and 18-month cohorts, b-only 
4-,  9- and 18-month cohorts.  
 
3.7.2. X-ray Imaging of MP-107 Animals 
Each cohort underwent X-ray imaging to examine the bone phenotypes at the assigned 
time point. The main purpose of this imaging was to assess when the abnormal bone 
growth at the knee first presented, as the G3 cohort indicated the early phenotypes do 
not change in severity. Radiographs were taken under terminal anaesthesia, so that the 
resolution, and number, of images were not limited due to Home Office licence 
restrictions, and were evaluated for any abnormalities, blind to the genotype.   
High-resolution radiographs of examples of wild type and heterozygote pelvises at each 
of the time points, show evidence of splayed ischia in some heterozygotes at every time 
point (Figure 3.27), emphasising the variability in these phenotypes.  
High-resolution radiographs of examples of wild type and heterozygotes elbow joints at 




every time point, with the exception of the 9-month time point where no animals 
exhibited the curved olecranon phenotype (Figure 3.28).  Additionally, radiographs of 
two heterozygous animals, one in each of the 4- and 6-month cohorts, which exhibited 
the curved olecranon, also exhibited evidence of a fracture in the ulna (shown in Figure 
3.28). While a break was only visible by X-ray in two of the animals exhibiting the curved 
olecranon phenotype, the phenotype may be the result of a fracture in the ulna, while 
the bone was growing. This could explain the variability in the phenotype, as only 
heterozygotes that sustained a fracture would develop this phenotype. 
High-resolution radiographs of examples of wild type and heterozygotes knee joints at 
each of the time points show evidence of abnormal bone growth at the knee in 
heterozygotes at the 9-, 12-, 15- and 18-month time points (Figure 3.29). 
Lower resolution full body radiographs of heterozygotes and wild types at each time 






Figure 3.27.  Examples of high-resolut ion radiographs of wild-type (WT, Col1a2+/+) and 
heterozygous (HET, Col1a2+/ 10 7) pelvises at each of the time points. At every time point,  





Figure 3.28.  Examples of high-resolution radiographs of wi ld-type (WT, Col1a2+/+) and 
heterozygous (HET, Col1a2+/107) elbow joints at each of the time points. At every time 
point, with the exception of the 9-month time point, at least one heterozygote exhibited 
the phenotype. Two heterozygotes exhibiting the curved olecranon at 4- and 6-months 






Figure 3.29.  Examples of high-resolut ion radiographs of wild-type (WT, Col1a2+/+) and 
heterozygous (HET, Col1a2+/ 10 7) knee joints at each of the time points. At every time point 
after the 9-month t ime point, at least 50% of heterozygotes exhibited the abnormal bone 
growth phenotype (Blue arrows). At the 2-, 4- and 6-month t ime points no evidence of 




Incidences of the three phenotypes observed by X-ray often coincided with each other.  
Figure 3.30 shows the number of animals in each cohort with each phenotype or 
collection of phenotypes. 
 
Figure 3.30.  A diagram displaying how many animals of each genotype displayed each 
phenotype, or combination of phenotypes at each of the time points: (A)2 Months, (B)4 
Months, (C)6 Months, (D)9 Months, (E)12 Months,  (F)15 Months, (G)18 Months.  
Heterozygote animals (Col1a2+ /1 0 7)  are displayed in purple and wild-type animals 
(Col1a2+/ +) are displayed in orange. 
The variable nature of the splice mutation, coupled with the resulting mixture of early 




a phenotype.  Collating the X-ray data across all time points enables an estimation of the 
percentage of animals that display a phenotype.  
Approximately 78% of heterozygotes develop some form of phenotype identifiable by 
X-ray imaging. 65% of heterozygotes exhibit the splayed ischia, 22 % exhibit the curved 
olecranon, and 37% exhibit the abnormal bone growth at the knee (Table 3.10). The 
olecranon and ischia phenotypes are early onset phenotypes and therefore will be 
evident in heterozygotes of all ages, however the knee phenotype, which was originally 
identified as a late onset phenotype, is first identified in this time course experiment at 
9 months and becomes increasingly prevalent as the animals age. The incidence in all 
heterozygotes was 37%, and rises to 65% in heterozygotes above 9 months of age  
All time points  Ischia (%) Olecranon (%) Knee (%) Any phenotype (%) 
Male - Heterozygotes 65 17 34 80 % 
Male - Wild types 0 0 0 0% 
Female - Heterozygotes 65 25 40 77% 
Female - Wild types 0 0 0 0% 
Combined - Heterozygotes 65 22 37 78% 
Combined - Wild types 0 0 0 0% 
 
Table 3.10.  A table showing the percentage of affected animals across all genotypes and 
time points. 
The position of the abnormal bone growth raises the possibility that the abnormal bone 
growth could be due to ossification of ligaments and/or joint capsule, this will be 
discussed further in a later section. 
3.7.3. DEXA Analysis of MP-107 Animals 
DEXA scans were used to evaluate the body composition in each of the seven cohorts 
previously described and listed in Table 3.9. DEXA analysis allowed BMD and BMC to be 
calculated giving information about the skeleton of the animals and to compare 
genotypes.  In addition to these skeletal parameters, the DEXA analysis also allows 
calculation of lean and fat mass.  The weight and length, from base of tail to tip of nose, 
were determined immediately prior to DEXA scan. 
The results of all of these parameters are detailed in Table 3.11. The significant results 




 Weight - In two cohorts, 4-month male animals and 12-month female animals, 
the heterozygous animals were significantly lighter than the wild-type animals. 
In one cohort, 15-month male heterozygous animals were significantly heavier 
than the wild-type animals. 
 Length - In one cohort, 4-month female animals, the heterozygous animals were 
significantly shorter in length than the wild-type animals 
 Lean Mass - In one cohort, 12-month female animals, the heterozygous animals 
had significantly lower lean mass than the wild-type animals. 
 BMC - In two cohorts, 4-month male animals and 6-month female animals, the 
heterozygous animals had significantly lower BMC than the wild-type animals. 
 BMD - In three cohorts, 4-month male animals, and 15- and 18-month female 
animals, the heterozygous animals had significantly lower BMD than the wild-
type animals.  
There was only one parameter where a significant difference was found in 2 consecutive 
time points of the same sex. Heterozygous female mice in the 15- and 18-months had 
significantly lower BMD than the wild-type mice at the same time points. 
It should be noted that this was not a longitudinal study and each cohort was only used 
for that specific time point. As seen in other phenotyping data, the mutation does not 
necessarily always result in a phenotype, and this coupled with the limited cohort size 




































































































































































































3.7.4. Clinical Chemistry of MP-107 Animals 
Clinical chemistry data from the G3 cohort was limited due to the nature of a longitudinal 
study, and the quantity of blood that can be taken, for both the health of the animals 
and to comply with Home Office Licence regulation. As this study was cross sectional 
and each cohort was culled at a different time point, it was possible to extract a much 
higher volume of blood via a retro-orbital bleed performed under terminal anaesthetic, 
than was possible in the initial screen.  The higher volume of blood collected enabled a 
large panel of assays to be run at each time point. The plasma from these blood samples 
were then separated via centrifugation and the plasma analysed by the clinical 
chemistry department at MRC Harwell using an Olympus AU400 Bioanalyser.  It should 
be noted that due to a freezer failure the samples from the 18-month cohort were 
unusable, and are therefore not included here. 
The means, standard deviation and n numbers for each cohort and parameters are 
presented in the Tables 3.12a and 3.12b. In addition to this data the P values from 
student t tests comparing genotypes in each cohort are also displayed.  
To summarise the data- No significant difference between genotypes in any of the 
cohorts was detected in the following assays– sodium, chloride, alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), total protein, albumin, total 
cholesterol, high-density lipoproteins (HDL), low-density lipoproteins (LDL), free fatty 
acids, glycerol, total bilirubin, lactate dehydrogenase (LDH), amylase, creatine kinase 
(CK), fructose and uric acid.   
Significant differences were detected in 9 assays, however only 2 assay showed 
significant differences in more than one cohort, creatinine and calcium, and in the case 
of creatine, in one cohort the level was elevated and in the other reduced. Details of 
these assays are listed below: 
 Potassium - The heterozygous animals displayed a significantly reduced level 
when compared with the wild-type animals in the 6-month male cohort. 
 Urea - The heterozygous animals displayed a significantly elevated level when 
compared with the wild-type animals in the 6-month female cohort. 
 Creatinine - The heterozygous animals displayed a significantly reduced level 




in the 9-month male cohort, the heterozygous animals displayed a significantly 
elevated level when compared with the wild-type animals. 
 Calcium - The heterozygous animals displayed a significantly reduced level when 
compared with the wild-type animals, in the 2-month and 6-month male cohorts. 
 Inorganic Phosphate - The heterozygous animals displayed a significantly 
elevated level when compared with the wild-type animals in the 15-month male 
cohort. 
 Alkaline phosphatase (ALP) - The heterozygous animals displayed a significantly 
elevated level when compared with the wild-type animals in the 6-month male 
cohort. 
 Glucose - The heterozygous animals displayed a significantly reduced level when 
compared with the wild-type animals in the 2-month male cohort. 
 Triglycerides - The heterozygous animals displayed a significantly elevated level 
when compared with the wild-type animal in the 6-month female cohort. 
 Iron - The heterozygous animals displayed a significantly elevated level when 
compared with the wild-type animals in the 2-month female cohort. 
One of the disadvantages of this study is that as each cohort is independent, the result 
of each assay is only statistically analysed within each cohort, rather than across the 
time course.  Despite this, as each cohort contains the same number of animals of each 
genotype, it is reasonable to expect authentic results to be somewhat replicated across 
time points.  The vast majority of significant results occur at only one time point/sex, 
and are therefore not indicative of a clinical chemistry phenotype, especially when the 
clinical chemistry analysis from the original ageing cohort is taken into account. This 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.8. Micro Computed Tomography of MP-107 Animals 
Ex vivo 3D imaging, such as micro computed tomography (µCT) is a far better tool for 
understanding the excess bone growth around the knee joint than the X-ray imaging 
used in vivo. µCT allows not only 3D imaging of bone at higher resolution, but also allows 
analysis of the trabecular bone, subchondral bone and subchondral bone plate. This 
analysis of the bone structure can inform about the changes the Col1a2+/107 mutation is 
causing prior to the overt phenotype observed. 
At the terminal time point, the limbs and pelvis were removed and fixed in 10% neutral 
buffered formalin for 48 hours before being transferred into 70% ethanol for storage. 
µCT was used to image examples of the elbow joint and pelvis of a wild-type and 
heterozygous animals. The early onset phenotypes including the splayed ischia and 
curved olecranon do not appear to progress in severity and for this reason only an early 
time point (2-months) was used. The knee phenotype consisting of abnormal bone 
growth and culminating in OA develops over time, so µCT was used to image the knee 
joints from both male and female animals in the 4- , 9- and 18-month cohorts, to 
investigate the progression of the OA phenotype and the formation of excess bone 
around the joint.  The three time points were chosen for the following reasons: the 4-
month cohort, as this was prior to any observed bone changes at the knee by X-ray; the 
9-month cohort, as this was the first time point where changes at the knee were 






3.8.1.  3D Imaging of Bone Phenotypes in of MP-107 Animals 
Curved olecranons were noted in radiographs of some heterozygotes, however, as the 
images are two-dimensional, it is not possible to know from the X-ray imaging the full 
extent of the bone abnormality.  µCT imaging of elbow joints from an affected 
heterozygote and an unaffected wild type were used to better understand the abnormal 
bone structure in three dimensions (Figure 3.31). 3D imaging revealed that in the 
heterozygote elbow, the ‘curved olecranon’ phenotype observed in the radiograph, was 
the result of the olecranon deviating from the trajectory of the ulna, in the direction of 
the humerus. 
In both the 4- and 6-month cohorts, evidence of a fracture in the ulna was identified in 
two individual heterozygotes exhibiting the curved olecranon phenotype.  There was no 
evidence of fracture in the radiographs of any of the 2-month old heterozygote animals 
exhibiting the curved olecranon phenotype. However, in the 3D rendering of the elbow 
joint of the randomly selected heterozygote from the 2-month cohort (MP-107-
C3H\58.1i), there is evidence of a fracture in the ulna that was not visible by X-ray 






Figure 3.31. 3D reconstructions of the elbow joints of a wild type (WT, Col1a2+/ +) (A-D) 
and a heterozygote (HET, Col1a2+ /1 0 7) (F-H) from the 2-month cohort. (E&F) show the clear 
curvature of the olecranon in the heterozygote, which is not present in the wild type 
(A&B).  (F&G) show evidence of fracture in the ulna of the heterozygote (red arrows).  
A cut through of the 3D reconstruction indicates that the evidence seen on the surface 
of the reconstruction is not an artefact, and that the fracture penetrates the whole way 







Figure 3.32. 3D reconstructions of the elbow joints of a wild type (WT, Col1a2+/+) (A&B) 
and a heterozygote (HET,  Col1a2+/ 1 0 7) (C&D) from the 2-month cohort with cutaway. Wild 
type shows no evidence of fracture either in the whole 3D reconstruction (A) or  the 
sectioned reconstruction (B).  Heterozygote shows evidence of fracture in both the whole 
3D reconstruction (C) or the sectioned reconstruction (D)(red arrows)  
Radiographs in Section 3.7.2 (Figure 3.28), show the presence of fractures in some 
heterozygotes presenting the curved olecranon phenotype. Figure 3.31 and Figure 3.32 
show evidence of fracture in a heterozygote, presenting with the curved olecranon 
phenotype, which was not detectable by X-ray. 
While no conclusion can be drawn from presence of a fracture in these 3 heterozygote 
animals presenting with the curved olecranon phenotype, it does raise the possibility 
that fractures, even if undetectable by X-ray, could be the root cause of the curved 
olecranon phenotype and warrants further study. 
Splayed ischia were noted in radiographs, however, as the images are 2D and the ischia 
are just the dorsal section of the posterior part of the pelvis, it is not known exactly how 
the observed ‘splayed ischia’ relate to other parts of the pelvis.  µCT imaging of the pelvis 
from an affected heterozygote and an unaffected wild type were used to better 
understand the abnormal bone structure in three dimensions. 3D rendering showed the 




the radiographs (Section 3.7.2, Figure 3.27), the ischia in the wild type appear to follow 
the trajectory of the ilia (Figure 3.33). 
 
 
Figure 3.33. 3D reconstructions of the pelvis of a wild type (WT, Col1a2+/+) (A&B) and a 
heterozygote (HET, Col1a2+/ 10 7) (C&D) from the 2-month cohort in  the dorsal and ventral 
views. Wild type shows no evidence of splayed ischia in either the dorsal (A), or the 
ventral (B) position.  Heterozygote shows evidence of splayed ischia in both the dorsal 




Viewing the 3D rendering from both anterior and posterior aspects revealed that in 
addition to splayed ischia, the pubis was also deformed in the heterozygote (Figure 
3.34). 
 
Figure 3.34. 3D reconstructions of the pelvis of a wild type (WT, Col1a2+/+) (A&B) and a 
heterozygote (HET, Col1a2+/ 10 7) (C&D) from the 2-month cohort in the anterior and 
posterior views. Wild type shows no evidence of an abnormal pubis in either the anterior 
(A), or the posterior (B) position.  Heterozygote shows evidence of a deformed pubis in  
both the anterior (A),  and the posterior (B) position (blue arrows).  
Cross sections of the 3D rendering in the transverse plane showed evidence of marked 
asymmetry in the heterozygous pelvis, where the wild-type pelvis showed no evidence 
of asymmetry.  The cross sections indicate that the divergences of the trajectories of the 
two coxae are anterior to the acetabulum, indicating that changes in the ilia are also 






Figure 3.35. Cutaways on the transverse plane of 3D reconstructions of the pelvis of a 
wi ld type (WT, Col1a2+/+)  (A-C) and a heterozygote (HET, Col1a2+/ 10 7) (D-F) from the 2-
month cohort.  Wild type shows no evidence of asymmetry in the transverse plane at the 
sacrum (A), the acetabulum (B), or the pubes (C).  Heterozygote shows no evidence of 
shows no evidence of asymmetry in the transverse plane at the sacrum (A), however there 
is evidence of marked asymmetry at both the acetabulum (B), and the pubes (C)(red 
arrows). This indicates the changes in the pelvis are also present in the ilia. An artefact 
from the reconstruction is present  in the image F (blue arrow); 3D imaging confirms this 






No evidence of fractures was found, however micro-fractures leading to deformation of 
the bone cannot be ruled out. 
The X-ray images initially used to identify the abnormal bone growth at the knee only 
allowed a two-dimensional view of the joint, meaning that due to positioning it was 
possible to miss abnormal bone growth.  This proved to be the case in one of the 4-
month heterozygous animals, which was scored as unaffected by X-ray, but 
reconstructed 3D scans of the knee showed calcification of the medial collateral 
ligament (MCL), with possible involvement of the joint capsule (Figure 3.36). The earliest 
any abnormal bone growth or calcification had been observed by X-ray imaging was 9 
months of age (see Section 3.7.2, Figure 3.29). 
 
Figure 3.36. 3D reconstructions of the left knees of wild-type and heterozygous animals 
from the 4-month cohort. (A) Wild-type (WT, Col1a2+/+) knee joint with no obvious 
abnormal bone growth or calcification. (B)  Heterozygous (HET, Col1a2+ /1 0 7) knee 




In the 9-month cohort, abnormal bone growth was observed in 50% (5) of the 
heterozygous animals by X-ray imaging, and the 3D reconstructed scans confirmed these 
observations as calcification of the MCL, with involvement of the synovium and/or 
capsule. The calcification seen in the 9-month heterozygous animals were, where 
present, more severe than seen in the 4-month cohort. No calcification was observed in 
the wild-type scans (Figure 3.37). 
 
Figure 3.37.  3D reconstructions of the left knees of wild-type and heterozygous animals 
from the 9-month cohort. (A) Wild-type (WT, Col1a2+/+) knee joint with no obvious 
abnormal bone growth or calcification. (B)  Heterozygous (HET, Col1a2+ /1 0 7) knee 
exhibiting evidence of major calcif ication of the medial  collateral ligament and 
synovium/capsule, as wel l as osteophytes originating in the bone (red arrows).  
 
In the 18-month cohort, abnormal bone growth was observed in 60% (6) of the 
heterozygous animals by X-ray imaging, and the 3D reconstructed scans confirmed these 




possibly synovium, and meniscus. Some calcification of the ligaments was observed in 
the wild-type scans, albeit very mild and similar in appearance to the calcification 
observed in the 4-month heterozygous scan (Figure 3.38). 
 
Figure 3.38. 3D reconstructions of the left knees of wild-type and heterozygous animals 
from the 18-month cohort. (A) Wild-type (WT, Col1a2+ /+) knee joint appears normal and 
exhibits some minor calcification of the ligaments (blue arrows). (B)  Heterozygous (HET,  
Col1a2+ /1 0 7)  showed evidence of major calcif ication of the medial collateral ligament, 
synovium, capsule and menisci as well  as large osteophytes originating in  the bone (red 
arrows).  
The µCT imaging of the knee joints has shown that there is evidence of calcification at 
an earlier time point than detected by X-ray imaging, and that animals without the early 
onset splayed ischia phenotype develop the abnormal calcification, indicating that the 





    X-Ray X-Ray µCT 
   
N 
number Ischia Knee Knee 
4 months Female WT 5 0 0 0 
  HET 5 3 0 5 
 Male WT 5 0 0 0 
  HET 5 5 0 2 
9 months Female WT 5 0 0 0 
  HET 5 3 4 5 
 Male WT 5 0 0 0 
  HET 5 3 1 4 
18 months Female WT 5 0 0 1* 
  HET 5 4 2 4 
 Male WT 4 0 0 2* 
  HET 5 4 4 5 
 
Table 3.13.  A table displaying the number of animals phenotyped at each time point and 
the  number of animals presenting with each phenotype. The µCT imaging showed that 
some heterozygotes (HET, Col1a2+/ 1 07),  which did not appear to show the abnormal bone 
growth at the knee by X-ray, actually did have abnormal bone growth at the knee. Some 
heterozygotes developed abnormal bone growth in the knee in the absence of the ischia 
phenotype. *At 18 months 3 wild types (WT, Col1a2+ /+) showed some very minor 
calcification of the MCL as see in Figure 3.34A. 
 
A comparison of the incidence of abnormal bone formation between genotypes of each 
sex, at each time point was carried out using the Mann-Whitney U test (Table 3.14) 
Statistical analysis revealed a significant difference between genotypes at 4 and 9 
months in female animals and at 9 months in male animals. At 18 months the minor 
calcification identified in 3 wild type animals (1 female and 2 males), meant that despite 







   N Abnormal U P Value 
   number bone identified   
4 months Female WT 5 0 25 0.004 
  HET 5 5 0  
 Male WT 5 0 17.5 0.177 
  HET 5 2 7.5  
9 months Female WT 5 0 25 0.004 
  HET 5 5 0  
 Male WT 5 0 22.5 0.020 
  HET 5 4 2.5  
18 months Female WT 5 1* 20 0.093 
  HET 5 4 5  
 Male WT 4 2* 15 0.128 
  HET 5 5 5  
 
Table 3.14.  A table comparing the number of animals identified with the abnormal bone 
phenotype at the knee,  by µCT at each time point. Statistical analysis revealed a 
significant difference between genotypes at 4 and 9 months in female animals and at 9 
months in Male animals. *At 18 months 3 wild types (WT, Col1a2+/ +) showed some very 
minor calcification of the MCL as see in Figure 3.34A. 
The µCT imaging of the elbow joint has shown additional evidence of ulna fractures in 
heterozygotes exhibiting the curved olecranon phenotype, and it is possible that the 
fractures lead to the curved olecranon phenotype. The µCT imaging of the pelvis has 
shown that there is evidence of asymmetry between the 2 sides of the pelvis in the ilia, 
ischia and pubes, and that the phenotype was more severe than the radiographs 
indicated.  No evidence of fractures was detected in the heterozygotes; however, 
fractures cannot be ruled out as a cause.  
3.8.2. Metaphyseal Trabecular Analysis of MP-107 Animals 
Analysis of the trabecular bone can help elucidate what changes the mutation may be 
having on the bone structure, and whether any changes could be leading to the 
phenotypes observed in the line MP-107. To explore whether there were changes to the 
underlying bone structure of the knee, a region of interest was identified in the 
trabecular bone below the growth plate of the tibia. Automated analysis of this region 
allowed comparison between genotypes at all three time points. The drawing of the 
region of interest was performed blind to genotype, and the genotypes were only 




Analysis of the trabecular bone in the tibia revealed a number of trends in males 
across time points (Figure 3.39). All results for µCT analysis available in Appendix  2. 
Heterozygotes consistently appeared to have lower bone volume fraction (Bone 
volume/trabecular volume- BV/TV) than wild-type animals, with a significant 
difference at both 9 months (WT Mean-10.75, SD-1.83, N-5, HET Mean-7.07, SD-
2.03, N-5, P=0.028) and 18 months (WT Mean-9.28, SD-2.72, N-4, HET Mean-5.15, 
SD-2.42, N-7, P=0.043) and difference just short of significance at 4-months (WT 
Mean-15.11, SD-1.44, N-5, HET Mean-12.54, SD-1.80, N-5, P=0.056). 
Heterozygotes consistently had a higher trabecular separation than wild-type 
animals, with a significant difference at both 4 months (WT Mean-0.161, SD-0.010, 
N-5, HET Mean-0.187, SD-0.015, N-5, P=0.028) and 9 months (WT Mean-0.205, SD-
0.016, N-5, HET Mean-0.253, SD-0.032, N-5, P=0.0257).  
Heterozygotes had a significantly higher trabecular thickness than the wild types at 
4 months (WT Mean-0.039, SD-0.0006, N-5, HET Mean-0.045, SD-0.0025, N-5, 
P=0.0028) with no significant difference at either 9 or 18 months, and there was no 
clear trend in trabecular thickness. 
Heterozygotes consistently had a significantly lower trabecular number than wild 
type animals at 4 months (WT Mean-3.84, SD-0.34, N-5, HET Mean-2.82, SD-0.47, N-
5, P=0.008), 9 months (WT Mean-2.58, SD-0.40, N-5, HET Mean-1.67, SD-0.48, N-5, 
P=0.020), and 18 months (WT Mean-2.04, SD-0.59, N-4, HET Mean-1.03, SD-0.56, N-
7, P=0.030).   
Bone volume fraction (BV/BT) and trabecular number appeared to decline with age 
in both genotypes and trabecular separation appeared to increase with age in both 
genotypes, however as each cohort was independent no statistical analysis was 







Figure 3.39. µCT analysis of trabecular bone in male animals. (A) Heterozygotes (HET,  
Col1a2+ /1 0 7) show a reduction in the bone volume fraction when compared with wild types 
(WT, Col1a2+ /+)  at 9- and 18-months. (B) Heterozygotes (HET, Col1a2+ /1 07) show an 
increase in the trabecular separation when compared with wild types (WT, Col1a2+ /+) at 
4- and 9-months. (C) Heterozygotes (HET, Col1a2+ /1 07) show an increase in the trabecular 
thickness when compared with wild type (WT, Col1a2+ /+) at 4-months.  (D) Heterozygotes 
(HET, Col1a2+/ 1 07) show a reduction in the trabecula number when compared with wild 
types (WT, Col1a2+/ +) at 4-, 9- and 18-months. Student T-test *P<0.05, **P<0.01 
 
Analysis of the trabecular bone in the tibia revealed similar trends in females across time 
points, however the number of significantly different features was reduced compared 
to the males (Figure 3.40). 
The bone volume fraction (BV/TV) followed a similar pattern to that seen in the males 
with heterozygotes’ bone volume fractions appearing lower than wild-type animals, 
however there were no statistically different results. 
The trabecular separation followed a similar pattern to that seen in the males with 
heterozygotes’ bone volume fractions being higher than wild-type animals, however 
there was only one statistically significant difference at 9 months (WT Mean-0.151, SD-




Heterozygotes had a significantly higher trabecular thickness than the wild types at 9 
months (WT Mean-0.054, SD-0.005, N-5, HET Mean-0.063, SD-0.005, N-5, P=0.029), with 
no significant difference at either 4 or 18 months, there was no clear trend in trabecular 
thickness. 
The trabecular number followed a similar pattern to that seen in the males with 
heterozygotes’ trabecular number being lower than wild-type animals, however only 
the difference at 9 months was significant (WT Mean-3.56, SD-0.63, N-5, HET Mean-
2.17, SD-0.78, N-5, P=0.024). 
Bone volume fraction (BV/BT) and trabecular number appeared to decline with age in 
both genotypes and trabecular separation appeared to increase with age in both 
genotypes, however as each cohort was independent no statistical analysis was 







Figure 3.40. µCT analysis of trabecular bone in female animals. (A) No significant 
difference in the bone volume fraction of heterozygotes (HET,  Col1a2+/ 1 07) was detected 
when compared with wild types (WT, Col1a2+/+) at any time point. (B) Heterozygotes (HET,  
Col1a2+ /1 0 7) show an increase in the trabecular separation when compared with wild types 
(WT, Col1a2+ /+) at 9-months. (C) Heterozygotes (HET, Col1a2+ / 1 0 7) show an increase in the 
trabecular thickness when compared with wild type (WT, Col1a2+/ +)  at 9-months.   (D) 
Heterozygotes (HET, Col1a2+ /1 0 7) show a reduction in the trabecula number when 
compared with wild types (WT, Col1a2+ /+) at 9- months. Student T-test *P<0.05. 
The analysis of the trabecular bone indicates that in the male heterozygote mice at 
various time points the bone volume fraction and trabecular number is reduced and the 
trabecular separation and trabecular thickness is increased. The female results were less 
consistent than the males; however, there were some time points that also showed 
these trends. Reduced bone volume fraction is seen in osteoporotic bones [253] and in 
a study of osteoporotic men, increased trabecular separation and decreased trabecular 
number were associated with an increased fracture risk [254]. This indicates that the 





3.8.3. Epiphyseal Trabecular Analysis of MP-107 Animals 
Analysis of the epiphyseal bone can help elucidate what changes the mutation may be 
having on the subchondral trabecular bone structure. The subchondral trabecular bone 
is directly below the subchondral bone plate.  Changes to this trabecular bone may have 
an impact on both the subchondral cortical bone and the articular cartilage 
To explore whether there were changes to the structure of the subchondral trabecular 
bone, a region of interest was identified between the subchondral bone plate and the 
growth plate for analysis. Automated analysis of this region allowed comparison 
between genotypes at all three time points. The drawing of the region of interest was 
performed blind to genotype and the genotypes were only synched with the data for 
comparison between genotypes. 
Analysis of the subchondral bone in the tibia revealed a number of trends in males across 
time points (Figure 3.41). 
Heterozygotes had a significantly lower bone volume fraction (BV/TV) than wild-type 
animals at 9 months (WT Mean-27.71, SD-1.53, N-5, HET Mean-23.44, SD-1.27, N-5, 
P=0.0026), there were no differences at 4 or 18 months. 
Heterozygotes had a significantly higher trabecular separation than wild-type animals at 
both 4 months (WT Mean-0.141, SD-0.009, N-5, HET Mean-0.159, SD-0.006, N-5, 
P=0.0091), and 9 months (WT Mean-0.146, SD-0.008, N-5, HET Mean-0.174, SD-0.006, 
N-5, P=0.0005). 
Heterozygotes had a significantly higher trabecular thickness than wild-type animals at 
both 4 months (WT Mean-0.023, SD-0.0003, N-5, HET Mean-0.026, SD-0.0008, N-5, 
P=0.0006) and 9 months (WT Mean-0.025, SD-0.0009, N-5, HET Mean-0.027, SD-0.0007, 
N-5, P=0.0425).  
Heterozygotes had significantly lower trabecular number than wild-type animals, at 
both 4 months (WT Mean-11.45, SD-0.51, N-5, HET Mean-9.91, SD-0.36, N-5, P=0.0011) 
and 9 months (WT Mean-10.92, SD-0.59, N-5, HET Mean-8.75, SD-0.43, N-5, P=0.0004). 






Figure 3.41. µCT analysis of the subchondral trabecular bone in male animals. (A) 
Heterozygotes (HET, Col1a2+ /1 0 7) show a reduction in the bone volume fraction when 
compared with wild types (WT, Col1a2+/+) at 9-months. (B) Heterozygotes (HET, 
Col1a2+ /1 0 7) show an increase in the trabecular separation when compared with wild types 
(WT, Col1a2+/+) at 4- and 9-months. (C) Heterozygotes (HET, Col1a2+/ 10 7) show an increase 
in the trabecular thickness when compared with wi ld type (WT, Col1a2+ / +)  at 4- and 9-
months.   (D) Heterozygotes (HET,  Col1a2+/ 1 0 7) show a reduction in the trabecula number 
when compared with wi ld types (WT, Col1a2+ /+)  at 4- and 9-months. Student T-test 
*P<0.05, **P<0.01, ***p<0.001. 
    
Analysis of the subchondral bone in the tibia revealed a number of trends in females 
across time points (Figure 3.42). 
Heterozygotes had a significantly lower bone volume fraction (BV/TV) than wild-type 
animals at 4 months (WT Mean-27.13, SD-0.78, N-5, HET Mean-24.04, SD-0.65, N-5, 
P=0.00028), there were no differences at 9 or 18 months. 
Heterozygotes had a significantly higher trabecular separation than wild-type animals at 
4 months (WT Mean-0.171, SD-0.008, N-5, HET Mean-0.200, SD-0.006, N-5, P=0.00045), 
at 9 months the difference was trending towards significance (WT Mean-0.177 SD-0.013, 
N-5, HET Mean-0.193, SD-0.005, N-5, P=0.054). 
Heterozygotes had a significantly higher trabecular thickness than the wild types at 9 




with no significant difference at either 4 or 18 months, there was no clear trend in 
trabecular thickness. 
Heterozygotes showed a significantly lower trabecular number than wild-type animals 
at 4 months (WT Mean-10.18 SD-0.41, N-5, HET Mean-8.71, SD-0.63, N-5, P=0.0045), 
and 9 months (WT Mean-10.01 SD-1.00, N-5, HET Mean-7.79, SD-0.36, N-5, P=0.0031), 
the 18-month cohort showed no difference. 
There did not appear to be any obvious trends with age as seen in the metaphyseal 
trabecular bone. 
 
Figure 3.42.  µCT analysis of the subchondral  trabecular bone in female animals. (A) 
Heterozygotes (HET, Col1a2+ /1 0 7) show a reduction in the bone volume fraction when 
compared with wild types (WT, Col1a2+/+) at 4-months. (B) Heterozygotes (HET, 
Col1a2+ /1 0 7) show an increase in the trabecular separation when compared with wild types 
(WT, Col1a2+ /+) at 4-months. (C) Heterozygotes (HET, Col1a2+ / 1 0 7) show an increase in the 
trabecular thickness when compared with wild types (WT, Col1a2+ / +)  at 9-months.   (D) 
Heterozygotes (HET, Col1a2+ /1 0 7) show a reduction in the trabecula number when 
compared with wild types (WT, Col1a2+/+) at 4- and 9-months. Student T-test *P<0.05, 
**P<0.01, ***p<0.001. 
The analysis of the subchondral trabecular bone is very similar to the metaphyseal 
trabecular bone indicating that the subchondral bone is osteopenic and at increased risk 




the 18-month cohort, where you would perhaps expect more differences due to 
sclerosis. 
3.8.4. Subchondral Bone Plate Analysis of MP-107 Animals 
The subchondral bone plate (SBP) was assessed for average thickness for both the 
medial and lateral condyle of the tibial plateau. This measurement actually consists of 
the SBP and the zone of calcified cartilage (ZCC). An increase in thickness could be 
indicative of increased mineralisation of the un-mineralised cartilage by the ZCC or 
sclerosis of the SBP [180]. To explore whether there were changes to the SBP of the 
lateral and medial tibial plateaux, regions of interest were identified and outlined. 
Automated analysis of these regions allowed thickness be measured, and a comparison 
between genotypes made at all three time points (Figure 3.43).  The drawing of the 
region of interest was performed blind to genotype, and the genotypes were only 
synched with the data for comparison between genotypes. 
 
Figure 3.43. µCT analysis of the thickness of the subchondral bone plate (SBP) of the 
lateral and medial t ibial  plateaux. (A) No signif icant difference was detected in the 
thickness of the medial SBP between heterozygotes (HET, Col1a2+/ 10 7) and wild types (WT, 
Col1a2+ /+) females at any time point. (B) No significant difference was detected in the 
thickness of the lateral SBP between heterozygotes (HET, Col1a2+/ 1 07) and wild types (WT, 
Col1a2+ /+) females at any time point. (C) A significant increase in the thickness of the 
medial SBP was detected in the male heterozygotes (HET, Col1a2+/ 1 07) when compared 
with the male wild types (WT, Col1a2+ /+) at 4-months, no significant difference was 
detected at any other t ime point. (D) No signif icant difference was detected in the 
thickness of the lateral SBP between heterozygotes (HET, Col1a2+/ 1 07) and wild types (WT, 





No significant difference in thickness of the subchondral bone was detected in any 
cohort with the exception of the 4-month male cohort, where the medial condyle of 
male heterozygotes was increased compared to the wild types. The absence of any 
differences at later time points indicates that the heterozygotes are not developing 
thickened sclerotic subchondral bone plates.  
The differences detected between heterozygotes and wild types in the metaphyseal and 
epiphyseal trabecular bone indicates that the bone is osteopenic, and structurally 
weaker in the heterozygotes.  
3.9. Time Course Histology of MP-107 Animals 
The µCT imaging indicated that there were changes occurring in the tissues surrounding 
the knee joint of heterozygote mice much earlier than was visible in radiographs. 
Histology was performed on the knee joints from animals in the 4-, 9-, 12- and 18-month 
cohorts, to investigate whether the changes seen in the µCT imaging led to changes 
within the joints, and whether the OA observed in the G3 cohort, occurred earlier than 
18 months.  
3.9.1. Histological analysis of MP-107 knee joints at 4 Months 
Histological analysis of Safranin O stained coronal section of knee joints from wild-type 
(WT, Col1a2+/+) and heterozygous (HET, Col1a2+/107) animals at 4 months of age show no 





Figure 3.44.   Safranin O stained histological section of knee joints from wild-type and 
heterozygous animals at 4 months of age. (A+B) Wild-type (WT, Col1a2+ /+) and (C-D) 
heterozygous (HET, Col1a2+/ 10 7) animals at 4 months of age show no differences in the 
articular carti lage, or signs of osteophytes. (Scale bar A+C-1mm, B+D 100µm, Medial and 
Lateral sides labelled with M and L respectively).  
 
3.9.2. Histological analysis of MP-107 knee joints at 9 Months 
Histological analysis of Safranin O stained coronal section of knee joints from wild-type 
(WT, Col1a2+/+) and heterozygous (HET, Col1a2+/107) animals at 9 months of age show 
that the heterozygotes have regular healthy articular cartilage; however there is 
evidence of osteophyte formation and hypertrophy of the soft tissues. The wild types 







Figure 3.45.   Safranin O stained histological section of knee joints from wild-type and 
heterozygous animals at 9 months of age. (A+B) Wild types (WT, Col1a2+/ +) have smooth 
healthy articular cartilage and no evidence of osteophyte formation,  Safranin O staining 
appears weaker, however there is no evidence of damage to cartilage. (C-D) Heterozygous 
(HET, Col1a2+/ 1 07) sections have smooth healthy articular carti lage, but also show 
evidence of hypertrophy of soft t issue (Black arrows) and some evidence of osteophyte 
formation (Yellow arrow). (Scale bar A+C-1mm, B+D 100µm, Medial and Lateral sides 
labelled with M and L respectively).  
 
3.9.3. Histological analysis of MP-107 knee joints at 12 Months 
Histological analysis of Safranin O stained coronal section of knee joints from wild-type 
(WT, Col1a2+/+) and heterozygous (HET, Col1a2+/107) animals at 12 months of age show 
that the heterozygotes have regular healthy articular cartilage however there is 
evidence of osteophyte and chondrophyte formation, and soft tissue ossification. The 
wild types have regular healthy articular cartilage and no evidence of osteophyte 
formation. The osteophytes in the heterozygous joints appear to be affecting the 
alignment of the joint and are having an effect on the quality of some of the 






Figure 3.46.   Safranin O stained histological section of knee joints from wild-type and 
heterozygous animals at  12 months of age. (A+B) Wild types (WT, Col1a2+/ +) have smooth 
healthy articular cartilage and no evidence of osteophyte formation. (C-D) Heterozygotes 
(HET, Col1a2+/ 1 07) have smooth healthy articular carti lage, evidence of chondrophyte 
formation (Black arrows) and some evidence of osteophyte formation (Yellow arrows). 
(Scale bar A+C-1mm, B+D 100µm, Medial and Lateral sides labelled with M and L 
respectively).  
 
3.9.4. Histological analysis of MP-107 knee joints at 18 Months 
Histological analysis of Safranin O stained coronal section of knee joints from wild-type 
(WT, Col1a2+/+) and heterozygous (HET, Col1a2+/107) animals at 18 months of age show 
that the heterozygotes have irregular and damaged articular cartilage, large 
osteophytes, hypertrophy of the soft tissues and a damaged meniscus. The wild types 
have regular healthy articular cartilage and no evidence of osteophyte formation.  
Previous µCT imaging did appear to show some calcification of ligaments, but this was 






Figure 3.47.   Safranin O stained histological section of knee joints from wild-type and 
heterozygous animals at 18 months of age. (A+B) Wild types (WT, Col1a2+/ +) have some 
minor signs of fissuring and no evidence of osteophyte formation. (C-D) Heterozygotes 
(HET, Col1a2+/ 10 7) have irregular severely damaged articular cartilage (red arrows), 
evidence of hypertrophy of the soft  tissues (Black arrows) and evidence of osteophyte 
formation (Yellow arrows). The meniscus is severely damaged. (Scale bar A+C-1mm, B+D 
100µm, Medial and Lateral sides label led with M and L respectively).  
Histological sections of heterozygous knees show evidence of abnormal bone formation, 
typically involving the ligament and joint capsule, and synovial fibrosis. This is similar to 
the effects observed by µCT.  Despite this, OARSI scoring of histological sections [255] 
reveals that there is only a difference in the cartilage between heterozygotes and wild 
types at 18 months (Figure 3.48).  The observed changes in the MCL and osteophyte 
development were visible as early as 9 months, both on histological sections and µCT, 







Figure 3.48.   Maximum OARSI scores of Safranin O stained histological section of knee 
joints across the four time points. (A-C) No significant differences were observed between 
genotypes of either sex at the 4-,  9- and 12-month time points.  (D) In both sexes 
heterozygotes (HET, Col1a2+/ 10 7) had significantly higher max OARSI scores than their wild 
type (WT, Col1a2+/+) counterparts. (All group n=5, with the exception of 18M male WT 
n=4, 9M male HET n=4, 9M male WT n=4, scoring included medial and tibial  sides of the 
femur and tibia. Statistical test used was Mann-Whitney * P<0.05, ** P<0.01- 18M males 
P=0.0095, 18M females P= 0.0317)  
3.10. Discussion 
The mutant line MP-107 was identified from the Harwell Ageing screen, with mild, early 
onset bone abnormalities, including splayed ischia and a curved olecranon. As the line 
was aged, a number of animals developed abnormal bone growth at the knee joint and 
histological analysis of the knee joint showed damaged articular cartilage, in addition to 
the abnormal bone growth. 
SNP mapping revealed a region on Chromosome 6 likely to contain the causative 
mutation, and WGS identified a splice region variant in Col1a2.  Subsequent Sanger 
sequencing confirmed that the affected animals, where DNA was available, were all 
heterozygous for this mutation. No homozygotes were identified in the G3 cohort, and 




The observed perinatal lethality of the Col1a2107/107 animals appears to be attributable 
to respiratory insufficiency. This conclusion was reached due to the observation of a 
number of new-born Col1a2107/107 pups gasping and needing to be culled for welfare 
purposes, coupled with the reduction in airway size in the Col1a2107/107 animals. 
Histological analysis of embryonic lungs revealed that the airways of homozygous lungs 
were smaller than those of wild-type and heterozygous lungs, due to thickened 
interstitial mesenchyme. The alveolar walls and interstitium are primarily comprised of 
type I and III collagen, which provide a structural framework and contribute to the lung 
mechanics. Type I collagen provides mechanical stability and structure, and therefore 
abnormal collagen I may impair the ability of the alveoli to expand and contract properly, 
and fulfil their function [256]. The whole mount skeletal staining of 18.5 dpc embryos 
clearly show breaks in the long bones of Col1a2107/107 embryos, which indicate an 
osteogenesis imperfecta (OI) phenotype.  The perinatal lethality due to the lung 
phenotype and the in utero breakage of the long bones is very similar to the Brittle IV 
mouse model of OI [80]. 
The mutation was predicted to be a splice region variant, creating a new splice acceptor 
site affecting the splicing between Exon 21 and Exon 22. PCR and Sanger sequencing of 
cDNA showed that the mutation did cause a new splice acceptor site to be formed, 
causing 3 bases from the intron to be incorporated as a new amino acid within Exon 22, 
in effect causing an insertion of Glutamine into the protein disrupting the repeating 
glycine motif. Where normally there are two amino acids between each glycine (G-X-Yn), 
in this case there were three.  A large proportion of osteogenesis imperfecta cases are 
caused by glycine substitutions, which also cause the repeating glycine motif to be 
disrupted[46-48]. Glycine substitutions result in 5 amino acids between two glycines 
rather than the normal two [73]. This could explain the apparent mildness of the bone 
phenotypes in this line compared to those often seen in humans.  
A complicating factor was found to be that as the original splice site is not destroyed, 
the spliceosome produces both mutant and wild-type transcripts even when both alleles 
are mutant.  It appears that the amount of wild-type and mutant transcript varies 
between mice of the same genotype, which could account for the variability of the 




to cause OI phenotypes in human, 210 splice variants in COL1A1, and 84 in COL1A2 [46-
48]. 
An experiment was designed to allow more in-depth investigation of the phenotypes 
seen in the heterozygotes across a number of time points.  X-ray imaging confirmed that 
the incidence of the splayed ischia and curved olecranon did not increase at later time 
points, and that the incidences of the knee phenotype did. The phenotypes observed at 
the pelvis and the elbow are similar to those seen in some mouse model of OI, including 
the Brtl model, the phenotype observed in these lines were also variable [80, 81]. 
The experiment also showed the variability in phenotype: in the 15-month male cohort 
80 % of animals showed a phenotype including 4 animals with the knee phenotype, one 
of which also displayed the curved olecranon, but no animals displayed the splayed 
ischia phenotype. The X-ray imaging also indicated that some heterozygotes showed 
detectable bone growth at the knee as early as 9 months. 
Neither the DEXA analysis nor the clinical chemistry analysis produced any parameters 
that were consistently significantly different between genotypes. 
µCT imaging at 4, 9 and 18 months confirmed the presence of abnormal bone growth as 
early as 4 months, and that this phenotype develops over time. The mouse model of OA, 
Str/ort, exhibits similar abnormal bone growth, although this line exhibits a more severe 
phenotype at early timepoints[257]. A similar phenotype has also been identified in the 
experimental line known as Ubr5mt, UBR5 was shown to play a role in maintaining 
cartilage homeostasis and supressing metaplasia [258].  Analysis of the 3D imaging of 
trabecular bone revealed that male heterozygous animals had a significantly reduced 
bone volume fraction and trabecular number, and a significant increase in trabecular 
separation at multiple time points, in addition to a significant increase in trabecular 
thickness at a single time point.  This trend was replicated in the female heterozygotes, 
albeit with fewer significant results and both male and female heterozygotes showed 
similar trends in the subchondral bone. There was only a single time point where there 
was any significant difference in the cortex thickness of the tibial plateau.  The variability 
in the statistical difference is likely due to the small cohort size and the variability of the 
phenotype within heterozygotes.  However, the µCT results do indicate that the 




imperfecta. The Brtl mouse model of OI has been shown to exhibit similar phenotypes 
including reduced bone volume fraction and trabecular thickness in 6 month old 
animals, when compared to wild-types, although this analysis was performed on femoral 
trabecular bone, rather than tibial [259, 260]. 
Histology indicated that OA does develop in heterozygotes in the later cohorts, indicated 
by the damaged articular cartilage. However, the osteophytes, ossification of ligament 
and synovial inflammation seen in earlier cohorts without cartilage damage indicates 
that in this mutant line, these changes precede the articular cartilage damage.  It is 
therefore possible that the cartilage lesions could be a result of ossification of ligaments 
and meniscus, or the synovial inflammation that preceded them [261, 262]. 
The evidence in this chapter indicates that an ENU induced A to T transversion in the 
gene Col1a2 leads to a disruption of the repeating glycine motif in Col1a2. The 
homozygotes are lethal and the heterozygotes develop different bone structure leading 
to mild bone abnormalities and evidence of fracture. Although, heterozygotes develop 
OA, from the data in this chapter it is not possible to discern the specific mechanisms 












The previous results chapter established that the MP-107 mutant, carrying a splice 
mutation in Col1a2, developed mild bone abnormalities and OA. Collagen I is a major 
constituent of bone, and therefore bone phenotypes arising from a mutation in Col1a2 
is not surprising. One of the major diseases associated with mutations in Col1a1 and 
Col1a2 in humans is Osteogenesis Imperfecta (OI), a disease characterised by brittle, 
fragile bones. In addition to OI, some types of Ehlers Danlos Syndrome (EDS) can also be 
caused by mutations in Col1a1 and Col1a2. EDS are a group of connective tissue 
disorders, primarily caused by abnormalities in the structure, production or processing 
of Collagens (including I, III, V). A common feature in many types of EDS is hypermobile 
joints and elastic skin.  
Col1a1 and Col1a2 mutations are not normally associated with OA.  However, as OA is 
an arthropathy involving all the various tissues of the joint, it is surprising that genes 
causing defects in bone and connective tissue are not always associated with the 
disease. 
In this chapter, I focus on investigating the phenotypes and behaviour of collagen I and 
collagen I rich tissues, such as bones, tendons and skin. I hypothesise that the mutation 
in Col1a2 is causing the phenotypes described in Chapter 3 as a result of an OI/EDS 
phenotype. If such phenotypes are observed it will be important to establish the 
relationship, if any, between the phenotypes observed in the Col1a2+/107 and reported 
in Chapter 3 and the spectrum of OI/EDS-like phenotypes. 
4.2. Mechanical Testing  
Collagen I is a very important protein in a wide range of tissues, especially those with 
mechanical function. Collagen I forms the organic matrix, which is then mineralised to 
give bones their strength, stores elastic energy in tendons and ligaments, and transmits 
force between tissues.  As such, observing how collagen I rich tissues behave in the MP-
107 mutant could elucidate the mechanisms by which a mutation in Col1a2 leads to the 
observed phenotypes. It is known that some mutations in collagen I genes lead to bone 
brittleness and breakage in OI, or joint laxity in EDS, it is therefore possible that the 




tested in this section include skin, tendon fascicles, bone and the articular surface of the 
tibial plateau and femoral condyles (subchondral bone and cartilage).  Due to the 
lethality observed in the homozygous Col1a2107/107 animals, mechanical testing was only 
performed on heterozygous Col1a2+/107 and wild-type Col1a2+/+ animals.  
4.2.1. Mechanical Testing of Tail Tendon Fascicles of MP-107 Animals 
Mechanical testing of tendon fascicles enables measurements of tensile strength and 
elasticity in the fascicles of the tendon.  As around 70-80% of the dry weight of tendons 
is collagen I, changes to the collagen I trimer are likely to have an impact in how this 
tissue behaves [28]. 
Fascicles were dissected from tail tendons of heterozygous Col1a2+/107 and wild-type 
Col1a2+/+ mice at 3 months of age and subjected to mechanical testing consisting of 10 
cycles of loading and unloading, followed by a pull to failure [38]. Before testing, the 
diameter of each fascicle was measured, and the cross-sectional area (CSA) calculated 
to facilitate the calculation of various mechanical parameters post-testing. 
Heterozygous fascicles had a significantly larger CSA than the wild-type fascicles 
(P=0.045, Figure 4.1).  The larger CSA of the heterozygous fascicles could be due to the 
disrupted glycine repeating motif causing micro-unfolding or a kink in trimers containing 
the mutant protein, increasing the diameter of the molecules, and in turn the collagen 
fibres. Another explanation could be that the abnormal protein causes an increase of 
water within the tissue, leading to a larger CSA. It is not possible at this point to 






Figure 4.1. Calculated cross sectional area (CSA) of both heterozygous (HET,  Col1a2+/ 1 0 7) 
and wild-type  (WT, Col1a2+/+) fascicles.  The CSA from heterozygous (HET,  Col1a2+/ 10 7) 
fascicles were significantly larger than wild-type (WT, Col1a2+/+) fascicles (WT n=4 
animals, HET n=5 animals, replicates min 12 fascicles per animal). T-test *= P<0.05  
The data from the mechanical testing was analysed in two parts, the ‘cyclic loading’ 
phase and the ‘pull to failure’ phase. Parameters derived from cyclic loading included: 
1) maximum force at cycle 1, 2) stress relaxation and 3) hysteresis. Parameters derived 
from the pull to failure included: 1) failure stress, 2) failure strain, 3) failure load, 4) 
maximum modulus and 5) strain at maximum modulus. 
To view how the fascicles behave initially, force/extension data from the cyclic loading 
and unloading is plotted (Figure 4.2). The heterozygous fascicles appear to allow an 
initial extension under very little load (shown by the ‘toe’ near the origin), indicating a 






Figure 4.2.  Representative force-extension graphs from wild-type  (WT, Col1a2+/ +) (A) and 
heterozygous (HET,  Col1a2+/ 10 7) (B) fascicles. The heterozygous fascicle (B) shows an 
altered ‘toe’ of the graph (red box) indicating an extension for very litt le force after the 
first loading, suggesting altered viscoelastic properties of the heterozygous fascicle when 
compared with the wild-type fascicle (A).  
In addition to this change in the force/extension behaviour, the area between the 
loading and unloading curves is reduced in the heterozygous animals, indicating a 
change in viscoelasticity.  This change can be calculated as percentage hysteresis, which 


















Figure 4.3.  Percentage hysteresis of wild-type  (WT, Col1a2+ /+)  and heterozygous (HET, 
Col1a2+ /1 0 7)  fascicles.  The heterozygous (HET,  Col1a2+ /1 0 7)  fascicles exhibit  a significant 
reduction in  percentage hysteresis,  when compared with wild-type  (WT, Col1a2+/ +)  
fascicles (WT n=4 animals, HET n=5 animals, replicates min 12 fascicles per animal).  
Student T-test *= P<0.05 
At least 12 fascicles from each animal were tested, and the mean value for each animal 




hysteresis in the fascicles of heterozygous Col1a2+/107 animals when compared with 
fascicles from wild-type Col1a2+/+ animals (P=0.219).  
The stress relaxation was also calculated as another measure of viscoelastic behaviour; 
however, the stress relaxation data were not analysable.  In all samples regardless of 
genotype, some fascicles produced negative stress relaxation values. This was caused by 
excessive noise in the load channel due to the small scale of mouse tail tendon fascicles. 
The maximum force exerted in the primary cycle of the cyclic loading was measured, as 
a constituent of the stress relaxation calculation, and there was no significant difference 
between genotypes (Figure 4.4) 
 
Figure 4.4.  Maximum force of wi ld-type (WT, Col1a2+/ +) and heterozygous (HET, 
Col1a2+ /1 0 7)  fascicles. No signif icant difference was detected in the maximum force 
between genotypes (WT n=4 animals, HET n=5 animals, replicates min 12 fascicles per 
animal). T-test*= P<0.05 
There were no significant differences between genotypes in any of the parameters 
derived from the pull to failure including: 1) failure stress, 2) failure strain, 3) failure load, 





Figure 4.5.  Graphs showing parameters from the ‘pull to failure’ phase of wild-type and 
heterozygous fascicles. (A) failure Strain, (B) failure Load,  (C) fai lure Stress, (D) maximum 
modulus and (E) strain at maximum modulus showed no significant difference between 
heterozygous (HET, Col1a2+/ 10 7) and wild-type  (WT, Col1a2+/+) samples, (WT n=4 animals,  
HET n=5 animals, replicates min 12 fascicles per animal). T-test*= P<0.05 
The lack of significant differences in the ‘pull to failure’ parameters indicate that the 
heterozygous fascicles are not inherently weaker or stronger than the wild-type 
fascicles. The significant difference in hysteresis between genotypes suggests a 
difference in the viscoelastic mechanical properties of collagen I in these mice.  
Hysteresis in tendons is generally thought of as a re-ordering of the multilevel fibre 




[263]. A reduced percentage hysteresis enables higher elastic energy return [264]. In 
behaviours where mechanical energy is absorbed, rather than stored and returned, such 
as absorbing impacts, a higher hysteresis is beneficial [265]. This means that the 
heterozygous tendons are likely to be less effective at absorbing impacts than the wild-
type tendons. 
It should be noted that the mice analysed were a mixture of males and females, however 
the literature suggests that there is no significant difference in the mechanical 
properties of tendons between sexes [266]. 
4.2.2. Three-point Bone Bending of MP-107 Animals 
The three-point bending test is a mechanical test of flexural strength, in bones a 
reduction of flexural strength could indicate brittle bones [267]. Due to limited 
resources, it was not possible to perform all mechanical tests on both sexes; female 
animals were selected over male animals, as previous studies indicate that the BMD is 
lower in females than males, and therefore any effect present would be more likely to 
be identified in females [268].  Humeri were harvested from 5 female heterozygotes 
Col1a2+/107 and 5 female wild types Col1a2+/+ at 3 months old.  
Three-point bending of these humeri using the Mach-1 multi-axial mechanical tester 
revealed a decrease in maximum flexural load (P=0.0136) and work to fracture (P=0.325) 
in the heterozygous animals, when compared to the wild-type animals (Figure 4.6).  This 
indicates that the bones of the heterozygotes are more brittle and fragile than the 
wildtypes. Coupled with the evidence of fracture in some of the heterozygous mice 
phenotyped indicates a mild OI phenotype in the heterozygotes, in addition to the OI 





Figure 4.6.  Three-point bending analysis of wild-type and heterozygous humeri. In  
heterozygotes (HET,  Col1a2+/ 10 7) work to fracture (A),  and maximum flexural  load (B) were 
significantly reduced when compared to wild types (WT, Col1a2+ / +) . No signif icant 
difference was detected between genotypes in bending slope (C), outer diameter (E) and 
cortical wall  thickness (F).  (D) Shows a typical load-displacement graph showing the 
parameters in (A-C). T-test *P<0.05 (For all genotypes n=5).  
 
4.2.3. Tensile Skin Testing of MP-107 Animals 
Tensile skin testing is a mechanical test of tensile strength and elasticity [269]. Changes 
in elasticity or strength could be indicative of an EDS phenotype.  Abdominal skin was 
harvested from the same animals described in three-point bone bending (Section 4.2.2.), 
5 female heterozygotes Col1a2+/107 and 5 female wild types Col1a2+/+. 
Tensile rupture testing of this abdominal skin using the Mach-1 multi-axial mechanical 
tester showed no significant difference in load at rupture or elastic slope. However, 




animals when compared with wild type animals (Figure 4.7). This is very similar to the 
behaviour seen in the mechanical testing of fascicles, where there is an initial 
displacement for very little force (See section 4.2.1). 
 
 
Figure 4.7.   Tensile testing analysis of wild-type and heterozygous skin. No significant 
difference was detected between genotypes in elastic slope (A) or load at rupture (C). In 
heterozygotes (HET, Col1a2+/ 10 7) init ial elastic slope (B) was significantly reduced when 
compared to wild types (WT, Col1a2+/+).  (D) Shows a typical load-displacement graph 




4.2.4. Micro-Indentation of the Articular Surface of MP-107 Animals 
Micro indentation can be used to investigate the structural stiffness of a material [270]. 
The articular cartilage of the femoral condyles and tibial plateau are often damaged in 
OA, and information about the structural stiffness of the tissues that make up these 
surfaces could inform about any underlying phenotypes that could be contributing to 
the MP-107 heterozygous animals developing OA. 
Whole hind legs were harvested from the same animals described in three-point bone 
bending (Section 4.3.3.), 5 female heterozygotes Col1a2+/107 and 5 female wild types 
Col1a2+/+.  The tibial plateaux and femoral condyles from these whole legs underwent 
automated indentation analysis using the Mach-1 Mechanical Tester (Figure 4.8). 
 
Figure 4.8 .  Structural stiffness analysis of the femoral condyles and tibial plateaux of 
heterozygotes and wild types. The medial femoral condyle of heterozygotes (HET,  
Col1a2+ /1 0 7)  exhibited increased structural sti ffness compared to wi ld types (WT, 
Col1a2+ /+).  No other region exhibited significant  differences between genotypes.  T-test 






The indentation analysis reveals that the medial femoral condyles of heterozygous 
animals exhibit higher structural stiffness than those of wild-type animals. No other 
region exhibited significant differences between genotypes. 
While the medial femoral condyle of heterozygotes exhibits a higher structural stiffness 
than the wild types, it should be noted that as the tissue tested included both articular 
cartilage and subchondral bone, it is not possible to attribute the change in the 
structural stiffness to either cartilage or bone specifically. 
 
4.3. Differential Scanning Calorimetry of MP-107 Tail Tendons 
Differential scanning calorimetry (DSC) is a method of thermal analysis. Heat flow is 
measured as the temperature in the crucible is varied, which can then be used to 
calculate a range of parameters which can inform the material analysed. Mechanical 
testing of fascicles extracted from tail tendons showed that the heterozygous fascicle 
behaved differently than wild type fascicles. DSC can provide information about the 
collagen heterotrimer within the tendon, and whether there is altered collagen 
heterotrimer in the heterozygotes [271].  
Tail tendons were harvested from female heterozygous Col1a2+/107 and wild-type 
Col1a2+/+ animals at 3 months of age and frozen at -80oC. Samples were later thawed 






Figure 4.9.  Representative differential scanning calorimetry thermograms from wild type 
and heterozygote tendons. The wild type (A) and heterozygotes (B) thermograms show 
similar peaks for the melt curve (Blue arrows) and the denaturation of collagen (Green 
arrows).  
 
The thermograms were then used to calculate a number of parameters including dry 








Figure 4.10.  Differential scanning calorimetry analysis of heterozygous and wild-type tai l 
tendons. (A) A significant reduction in dry enthalpy of heterozygous (HET,  Col1a2+ / 1 0 7)  
tendons was detected when compared with wild-type (WT, Col1a2+/ +)  tendons. No 
significant difference was detected between genotypes in (B) wet enthalpy, (C) 
percentage bound water,  or (D) collagen denaturation temperature. T-test*=P<0.05 (Wt 
n=3, Het n=4).  
The tendons showed no significant difference in collagen denaturation temperature, 
percentage bound water, or the wet enthalpy. However, there was a significant 
reduction in the dry enthalpy (P=0.398) of heterozygous samples compared to wild-type 
samples. This difference indicates that less energy is required to break apart the 
heterozygous trimer, due the trimer being less stable.  It is unknown at this time what is 
causing the increased instability in the heterozygous sample. It is likely for one of two 
reasons, either that there is homotrimer, consisting of three α1 chains, present due to 
the mutant α2 chain not being incorporated into the collagen I trimer, or the disrupted 





4.4. Collagen Secretion Analysis of MP-107 Tendons 
Radiolabelling using 14C- Proline can be used to investigate the composition of collagen 
I in tail tendons, and if there is impaired secretion [272]. This technique can answer the 
question raised by the DSC of what is causing the destabilisation of the Collagen trimer. 
The radiolabelled bands of the Proα1 (ProCol1a1), Proα2 (ProCol1a2), pCα1 (ProCol1a1 
with N terminal propeptide cleaved), pCα2(ProCol1a2 with N terminal propeptide 
cleaved), show no difference between genotypes in either intracellular or extracellular 
extracts.  This indicates that the mutant α2 chain is not being retained intracellularly, as 
if this was the case the extracellular band in the heterozygous samples would be lighter 
and the intracellular bands would be darker.  
 
Figure 4.11. Images of radio labelled collagen extracted from wild-type and heterozygous 
tendons. Similar levels of proα1, proα2 pCα1, pCα2 in the N (final detergent extract)  and 
S1(first salt extract) extracts in wild-type (WT1, WT3, WT3,  Col1a2+/ +) samples and 
heterozygous (HET1, HET2, HET3,  Col1a2+/ 10 7)  samples, indicate that the Collagens are 
being secreted normally. The S4 extract (fourth salt extract) is included to show that the 
majority of the extracel lular  collagens had been extracted prior to the N extraction 
indicating that the collagens found in the N extraction were intracellular collagens.   
(proα1 indicates an alpha I procol lagen with both n and c propeptides attached, pCα1 
indicates an alpha I procollagen with only the C propeptide attached.) The lanes of the 
gels were re-ordered for ease of viewing, the unmodified images of the gels are included 
in Appendix 1.  
SYPRO Ruby total protein staining of S1 (first salt extract) and N extracts (final detergent 
extract) show a similar amount of protein was extracted in samples of each genotype, 
in both the intracellular and extracellular extracts (Figure 4.12).  This confirms that any 
difference or similarity seen in the radiolabelling is not due to differences in protein 






Figure 4.12.  Sypro Ruby total protein stained gels of tendon extracts.  S1 (first Salt extract)  
and N extracts (final detergent extract) run on Tr is-Glycine gels and stained with Sypro 
Ruby total protein stain,  show that there are similar levels of proteins extracted from 
both wild-type (WT1, WT3, WT3,  Col1a2+/+) samples and heterozygous (HET1, HET2,  HET3,  
Col1a2+ /1 0 7)  samples.  
The radiolabelling reveals that the mutant collagen is not being retained intracellularly 





4.5. Transmission Electron Microscopy of MP-107 Embryonic Tail Tendon 
The mutant α2 chain appears, from previous experimental data (Section 4.6), to be 
incorporated into the collagen I molecule, and that this is having an effect on the stability 
of the heterotrimer (Section 4.5) and on the mechanical behaviour of tendon fascicles 
(Section 4.3.1).  Transmission electron microscopy (TEM) enables highly magnified 
viewing of the tendons, including the arrangement of the collagen I fibrils and the 
tenocytes. This imaging allows differences between the tenocytes and collagen fibrils to 
be identified [273]. Embryonic tail was harvested at 18.5 dpc and used for TEM, to 
enable the comparison between all three genotypes (Figure 4.13). TEM images show 
that the Endoplasmic Reticulum (ER) in the tenocytes is swollen and distended in the 
homozygotes and heterozygotes, when compared to the wild types.  It should be noted 
that the degree of swelling in the ER was more variable in the heterozygotes. The 




Figure 4.13. TEM images of embryonic tail tendon from homozygous, heterozygous and 
wild-type embryos.   Homozygous (HOM, Col1a21 0 7/ 10 7)  and heterozygous (HET, 
Col1a2+/ 10 7)  samples show bloated Endoplastic Reticulum (ER) when compared with wi ld-
type (WT, Col1a2+/ +),  indicating ER stress within the cells. The homozygotes appears to 
be more affected by this ER stress than the heterozygotes (red arrows).  The bundles of 
collagen I fibres in the homozygous Col1a21 07 / 1 0 7 also appear to be less densely packed 
than those in either the heterozygous Col1a2+/ 10 7  or the wildtype Col1a2+/ +  samples 
(yellow arrows).For higher magnif ication TEM images see Appendix 4 (For all genotypes 




The bundles of collagen fibrils appeared to be smaller and more disorganised in the 
heterozygous and homozygous samples, when compared to the wild-type samples. To 
quantify this observation, the number of fibrils per bundle were counted blind to 
genotype, and subsequently assigned a genotype. (Figure 4.14). 
 
 
Figure 4.14.  Quantitat ive analysis of collagen fibri ls in TEM images of embryonic tail  
tendons from homozygous, heterozygous and wild-type embryos.  Collagen fibrils per 
bundle were counted in TEM images of embryonic tail tendons from animals of each 
genotype homozygote, heterozygote and wild type.  Homozygous (HOM, Col1a21 0 7/ 10 7) 
and heterozygous (HET, Col1a2+ /1 0 7) samples exhibit reduced number of f ibrils per f ibri l 
bundle when compared with wild-type (WT, Col1a2+ /+) samples. One-way ANOVA: ** 
P<0.01 (n=3 for all genotypes).  
Statistical analysis revealed that the heterozygote and homozygote had significantly 
fewer collagen fibrils per bundle than the wild type (P=0.0053).  There was no difference 
between heterozygote and homozygote. It should be noted that no determination was 
made on the sex of the embryos used for TEM. 
4.6. Analysis of ER Stress in MP-107 Mouse Embryonic Fibroblasts (MEFs) 
TEM imaging revealed evidence of ER stress in heterozygous (HET, Col1a2+/107) and 
homozygous (HOM, Col1a2107/107) tenocytes. To further investigate the ER stress, that 
the bloated ER implied was present, MEFS were harvested 2 days post confluence and 
homogenised in Cell lytic™  with the addition of phosphate inhibitors and protease 
inhibitors using a Pellet Pestle.  A positive control was created by treating wild-type 




A western blot was run using cell lysate from each genotype and the positive control 
sample (Figure 4.15). 
 
Figure 4.15.  Western blot showing levels of BIP in MP-107 MEF cel l lysates. Untreated 
wild-type (Col1a2+/+),  heterozygous  (Col1a2+ /1 0 7) and homozygous (Col1a21 0 7/ 10 7) cell 
lysates run along with Thapsigargin treated wild type cell lysates label led with BIP and 
Act in (See section 2.3 for antibody details). Heterozygous  (Col1a2+/ 10 7) and homozygous 
(Col1a21 0 7/ 1 07) cell  lysates appear to show elevated levels of BIP protein when compared 
to wild-type (Col1a2+/+) lysates.  The uncropped gel is shown in Appendix 5.  
The western blot suggests that there BIP is present at higher levels in the heterozygous 
and homozygous samples, although not in as high levels as the thapsigargin treated 
sample. BIP (Binding immunoglobulin protein) is a chaperone protein located in the 
endoplasmic reticulum, and is commonly used as a marker of ER stress. The increased 
levels of BIP is another indication of ER stress in the heterozygous and homozygous MP-
107 cells. 
4.7. Immunohistochemistry Analysis of ER Stress in MP-107 Articular 
Cartilage 
Previous studies have shown that OA induction by destabilisation of the medial 
meniscus increases ER stress in chondrocytes [276]. Additionally, markers of ER stress 
such as BIP and Bag-1 have been shown to be upregulated in articular cartilage from OA 
patients with advanced disease [277]. It is therefore possible that any increase in 
markers of ER stress noted in the chondrocytes of animals with OA, could be as result of 
the cartilage degradation rather than the cause of it. It was therefore more appropriate 




in heterozygotes. As previously discussed, not all heterozygotes develop the ossification 
observed  by X-ray and µCT. 
Histological sections from MP-107 wild-type (WT, Col1a2+/+) and heterozygous (HET, 
Col1a2+/107) knee joints which showed no sign of OA by histology at 18 months were 
assessed, by immunohistochemistry, using an Anti-BIP Antibody as a marker of ER stress 
(for details see Section 2.3), before secondary antibodies and DAB staining were used to 
visualise the distributions of the protein. 
A negative control for this experiment was created by incubating a wild-type section 
with serum without the primary antibody. Neither wild-type section, either incubated 
with the primary antibody or without, showed any DAB staining in the chondrocytes. 
Some chondrocytes in the heterozygous section, which was incubated with the primary 
antibody, appeared to be stained with the DAB (Figure 4.16). 
The enhanced staining in the MP-107 heterozygotes suggests that the chondrocytes may 





Figure 4.16.  Immunohistochemical staining of wild-type and heterozygous knee sections 
using BIP antibody. (A) Negative control wild-type (WT, Col1a2+/ +) section without primary 
antibody, (B) Wild-type (WT, Col1a2+/ +) section with primary antibody, (C) Heterozygous 
(HET, Col1a2+/ 1 0 7) section with primary antibody. Dark brown staining is only visible in the 
chondrocytes of the heterozygous section (black arrows), indicating increased levels of 
ER stress in the heterozygote chondrocytes. It  should be noted that only one 18-month 
heterozygous animal showed no evidence of joint  damage, and was therefore used for 
IHC, and therefore no statistical testing was carr ied out. For higher magnification images 




4.8. Destabilisation of the Medial Meniscus (DMM) in MP-107 Knees 
DMM surgery is a method of surgically inducing OA, by severing the medial menisco-
tibial ligament to destabilise the medial meniscus [278]. This technique induces OA as a 
result of destabilising the joint, leading to accelerated damage.  In this case we are using 
DMM surgery as a challenge to investigate if the MP-107 heterozygotes (Col1a2+/107) are 
predisposed to developing OA as a result of joint instability. 
Cohorts of heterozygous and wild-type animals underwent DMM surgery to investigate 
if the mutation in Col1a2 increased the susceptibility to surgically induced OA.  Surgery 
was performed at 8 weeks of age, and animals were culled 6 weeks post-operatively, to 
take joints for histology. 
Histological analysis of Safranin O sections of DMM treated animals show damage to the 
articular cartilage in both heterozygotes (HET, Col1a2+/107) and wild types (WT, 
Col1a2+/+), in addition the heterozygotes displayed osteophytes. Histological analysis of 
H&E sections of sham treated animals show no increase in damage to the articular 
cartilage or  increase in the presence of osteophytes in heterozygotes (HET, Col1a2+/107) 






Figure 4.17.  Safranin O stained histological section of knee joints from DMM operated 
and sham operated wild-type and heterozygous animals. DMM-treated animals show 
damage to the articular cartilage (Blue arrows) in both heterozygotes (HET, Col1a2+/ 1 07) 
and wild types (WT, Col1a2+ /+),  in addition the heterozygotes displayed severe 
osteophytes (black Arrows).  Sham-treated animals show no damage to the articular 
cartilage or osteophytes in either heterozygotes (HET, Col1a2+/ 1 07) or wild types (WT, 
Col1a2+ /+).   Medial and tibial orientation indicated by M and T respectively.  
As with other phenotypes observed in MP-107, the histology of the DMM treated 
heterozygotes was variable, with some animals having severe cartilage loss and others 
comparable cartilage loss to wild types. An F test between genotypes, reveals that there 
is a significant variance in the females, but not the males (Female- F-74.76, DFn-4, DFd-
3, P=0.0049, Males- F-1.316, DFn-2, DFd-4, P=0.3496). The histology from the operated 
and sham operated samples were scored using the OARSI scoring system [279], 
unfortunately no OARSI scoring data is available for the female sham operated animals.  
There was no significant difference detected between the DMM operated 
heterozygotes (HET, Col1a2+/107) and wild types (WT, Col1a2+/+) in either sex. In males, 
where sham operated OARSI scoring data was available there was a significant increase 
in OARSI score in the DMM operated wild types (WT, Col1a2+/+) compared with the sham 
operated wild types (WT, Col1a2+/+), but no significant difference with the DMM 





Figure 4.18.  Histological analysis of Safranin O stained histological section of knee joints 
from wild-type and heterozygous animals including from DMM operated and sham 
operated. No significant difference in carti lage damage was detected between the 
heterozygotes (HET, Col1a2+/ 10 7) and the wild types (WT, Col1a2+/ +) in either sex.  Where 
the OARSI data for Sham surgery was available, there was a significant increase in OARSI 
scores in  the DMM operated wild types (WT, Col1a2+/ +) compared to the sham operated 
wild types (WT, Col1a2+/ +).  
It should be noted that although the OARSI scoring did not reveal a significant difference 
in the cartilage, all heterozygotes of both sexes that were DMM operated showed 
osteophytes in the histology. Incidence of osteophytes in the wild-type DMM operated 
animals varied between 33% (1/3 males) and 50% (2/4 female). Statistical testing using 
the Mann-Whitney U test found that there was no statistical difference between 
genotype, this is likely due to the small cohort sizes making this experiment 
underpowered (Males-WT- n=3, U-12.5, HET- n=5, U-2.5, P=0.076; Females-WT- n=4, U-
15, HET- n=5, U-5, P=0.128). The relatively early end-point for this experiment of 6 weeks 
post-surgery may have led to less severe cartilage degradation than would have been 






The mechanical testing of bones indicated that the humeri of heterozygous Col1a2+/107 
animals were significantly more brittle than the humeri of wild-type Col1a2+/+ animals, 
indicating a mild OI phenotype  [80]. Bone fractures were only observed by X-ray in the 
humeri of two heterozygotes, which also exhibited the curved olecranon phenotype, 
however µCT imaging revealed further evidence of fracture in the humerus of another 
heterozygote exhibiting the curved olecranon phenotype.  These examples of fractures 
occurring in tandem with the olecranon phenotype, coupled with the observation of in 
utero fractures leading to bone deformation in homozygous embryos Col1a2107/107 (See 
Section 3.5.3), raise the possibility that minor fractures in utero, while not visible by X-
ray, could be leading to the mild bone abnormalities observed, including the curved 
olecranon and splayed ischia seen in the heterozygotes [280]. It is also conceivable that 
the OI phenotype could be related to microfractures in the subchondral bone, although 
these have not been observed at this time. 
Mechanical testing of tendon fascicles and skin indicate that both tissues have altered 
viscoelastic properties.  Both tissue types have an altered initial elastic slope and the 
tendon fascicles also had a reduction in hysteresis, meaning that there is less energy loss 
on each cycle. While this can be viewed as advantageous in terms of higher elastic 
energy return [264], it reduces the ability of the tendon to absorb energy [265]. These 
changes to the visco-elastic properties could be indicative of an EDS phenotype, where 
skin is often hyperextensible, and joints are hypermobile [281, 282]. The model 
proposed by Frantzl et al. indicates that initial extension is a result of the removal of the 
macroscopic crimp followed by straightening of molecular kinks in the gaps between 
Collagen molecules [36].  It is likely that the altered mechanical properties are a result 
of micro-unfolding at the site of the repeating glycine motif disruption. This could 
explain why the initial elastic slope differs between genotypes, but the elastic slope does 
not (see section 4.2.3). This demonstrates that the MP-107 heterozygotes exhibit an 
EDS-like phenotype in addition to the OI phenotype.  Some models of osteogenesis 
imperfecta, such as oim exhibit changes in the tendon mechanical strength, which while 
not replicated here, does demonstrate the connected phenotypes [283, 284]. It should 




delicate, they can dry out quickly which can affect mechanical properties, and can 
increase noise on the load channels [285]. 
The differential scanning calorimetry (DSC) data showing a reduced dry enthalpy in the 
heterozygotes Col1a2+/107 when compared with the wild types Col1a2+/+, could explain 
why these tissues exhibit these behaviours. The reduced stability indicated by the 
reduced dry enthalpy could be due to micro unfolding of the collagen I heterotrimer, or 
the presence of homotrimers [271]. The radiolabelling of tendons indicated that there 
was no issue with α2 chains being retained intracellularly, and that the levels of α1 and 
α2 in the extracellular extract were similar in both genotypes [272]. This demonstrates 
that the α2 is being incorporated into the trimer, and micro-unfolding is likely impairing 
the formation of the collagen fibres and fibrils, leading to altered visco-elastic 
properties.  The DSC data also showed that there was no significant difference between 
bound water content in the tendons between genotypes. This indicates that the 
increased CSA of fascicles observed in Section 4.2.11, is unlikely to be due to increased 
water content. 
TEM imaging shows enlarged, bloated endoplasmic reticulum (ER), a marker of ER stress, 
in the heterozygotes and homozygotes, which can be indicative of physiologic or 
pathological stress [286]. Protein analysis of cell lysates from MEFs indicated that there 
was increased ER stress in homozygous and heterozygous MEFs. MEFs are a useful tool 
to enable investigation of the homozygotes despite a lethal phenotype, however there 
are limitations in using MEFs including  phenotypically heterogeneous subtypes of MEFS, 
and the potential for other cell types to be present in the culture [287]. Immunostaining 
indicated an increase BIP staining in chondrocytes in the heterozygous articular 
cartilage, compared to the wild-type articular cartilage, however due to a lack of suitable 
samples, only sections from one heterozygous animal were used, and therefore while 
this information appears to support other evidence of ER stress, no conclusions should 
be drawn from the IHC alone. TEM imaging of dermis of EDS patients has shown 
evidence of ER stress, including dilated ER in fibroblasts of dermis of patients with EDS 





The radiolabelling and DSC results indicate that mutant protein is being secreted; 
however, it is possible that a fraction of the mutant protein is being retained 
intracellularly, and this could be causing an unfolded protein response, leading to ER 
stress. Boot-Handford et al. have stated that it is rare ERAD causes upregulation of BIP, 
indicating that this is probably not what is causing the ER-stress [70]. The biosynthesis, 
folding and secretion of collagens is a very complicated process, and delays in the 
processing can also lead to ER stress, and therefore further investigation into what is 
causing the ER stress is warranted. Quantification of the collagen fibrils in the tendons 
demonstrated that both heterozygote and homozygote tendons contain significantly 
fewer collagen fibrils per bundle. Micro-unfolding due to the disrupted glycine motif 
could explain this phenotype, in addition to the mechanical behaviours and reduced 
stability of the heterozygotes, as the micro-unfolding will cause the collagen 
heterotrimer, and in turn the collagen fibres and fibrils to require more space. 
Indentation analysis indicates that there are some regions of the articular surface which 
have increased structural stiffness in the heterozygous Col1a2+/107 animals when 
compared with the wild-type Col1a2+/+ animals. The articular cartilage is primarily made 
up of collagen II, with only small amounts of collagen I, it is therefore unlikely that the 
changes are directly due to changes in the collagen I protein in the articular cartilage. It 
is more likely we are either observing a difference in the subchondral bone, or a 
secondary change in the articular cartilage perhaps caused as a by-product of ER Stress. 
[291]. The µCT data (Section 3.6.5.3) does indicate the subchondral bone of the 
heterozygotes is structurally altered, however this does not rule out ER stress as a cause, 
and this warrants further investigation. 
The DMM experiment was likely underpowered, and the results were inconclusive. The 
severe OA and osteophytes observed in some heterozygotes were not replicated in all 
heterozygotes, and there was no significant difference between genotypes.  
There are four types of EDS caused by mutations in COL1A1 and COL1A2. A specific 
arginine to cysteine mutation (Arg134Cys) in COL1A1 has been observed to cause a 
classical EDS phenotype [96]. Mutations in COL1A2, leading to a complete deficiency of 
pro α2 (I) collagen, including splice mutations and nonsense mutations have been shown 




previously mentioned example(Arg134Cys) as well as others (including Arg312Cys, 
Arg574Cys, Arg1093Cys) in COL1A1 have been observed to cause a vascular EDS 
phenotype, possibly due to the extra cysteine residue causing additional intermolecular 
bonding [96, 101]. Mutations in COL1A1 and COL1A2 preventing the cleavage of the N-
propeptide (most commonly skipping exon 6) leads to arthrochalasia EDS. Due to the 
mutation in MP-107 being in Col1a2, only cardiac-valvular EDS and arthrochalasia EDS 
subtypes would fit with this mutation. However, the mutation in MP-107 does not cause 
a deficiency in pro α2 (I) collagen and is unlikely to impair the cleavage of N-propeptide 
due to the location of the mutation being in the middle of the helical domain. It is 
therefore unlikely that MP-107 is modelling one of these EDS subtypes. 
In addition to EDS caused by mutations in COL1A1 or COL1A2, there is also an OI/EDS 
overlap disorder, where symptoms of both disorders were observed. Until recently 
OI/EDS overlap disorder was associated only with mutations preventing or delaying the 
cleavage of the procollagen N-propeptide. However, a different type of OI/EDS overlap 
syndrome was identified where the mutations did not affect the cleavage of the N-
propeptide [115]. Over 20 patients were identified from 13 families, with this novel type 
of EDS, with mutations identified right across both COL1A1 and COL1A2, including in the 
c-terminal half of the helical domain, and subsequently named COL1-related overlap 
disorder. Interestingly, even in families where all individuals carried identical mutations 
in COL1A1 or COL1A2, the phenotypes presented varied. The presence of phenotypes 
associated with both OI and EDS in MP-107 heterozygotes indicates that rather than 
modelling OI or EDS, the line MP-107 likely models Col-1 related overlap disorder as 
described in Morlino et al., 2019 [115]. 
A mouse model of OI/EDS (published prior to the term Col-1 related disorder) called Jrt 
published by Chen et al. [117] showed similar phenotypes at the ischia and olecranon to 
those seen in MP-107, which were again attributed to fractures. The presence of the 
phenotypes was variable across animals of the same phenotype (Col1a1Jrt/+), and the 
affected animals showed altered mechanical and material properties of skin, indicating 
skin fragility. This adds further weight to the hypothesis that MP-107 heterozygotes have 





These results show a novel association of an osteoarthritis phenotype with a Col-1 
related disorder caused by a mutation in Col1a2. In addition to providing knowledge 
about the genotype/phenotype relationship in Col-1 related disorder, this model could 





Chapter 5: Identification and Initial 
Characterisation of Phenotypes 







Prior to the start of the Harwell Ageing Screen, several ENU mutagenesis screens were 
undertaken at MRC Harwell [235, 245, 292]. One of these was a G1 dominant screen, 
whereby cohorts of G1 animals underwent phenotyping to identify any early onset 
phenotypes caused by dominant mutations. To produce the G1 mice, C57BL/6J male 
animals (G0) were injected with ENU, and mated with C3H females to produce cohorts 
of mice (G1) heterozygous for the mutations induced in the spermatogonia of the G0 
animal. Once a phenotype had been identified, the G1 animal was crossed with C3H, to 
produce a cohort of G2 animals to confirm the phenotype and identify the causative 
mutation, see Section 2.6.2, Figure 2.1 for the breeding scheme. 
Among the phenotyping procedures was X-ray imaging, and a G1 animal was identified 
as having mild bone abnormalities.  The subsequent G2 line was named Bone-TM\44. 
The initial phenotyping, mapping and exome sequencing of this line was performed prior 
to the start of this project by Dr Chris Esapa. The line was then banked and no further 
work was undertaken. Where work was previously carried out by Dr Esapa, it will be 
noted.  Due to the similarities between early phenotypes in this line, and the early 
phenotypes in the line MP-107, this line was re-derived to allow further phenotyping 
and analysis of the mutations. For ease, the line was renamed TM44 upon re-derivation.  
The aim of this chapter is to establish if the phenotypes in this line mirror those observed 
in MP-107 and if the causative mutation affects the Collagen I heterotrimer. 
5.2. Identification of Early Phenotype in the line TM44 
X-ray imaging at 4 months of age revealed that a female G1 animal displayed mild bone 






Figure 5.1.  An X-ray image of the G1  founder animal of the l ine TM44.  The animal displays 
curved olecranon at both elbows (orange arrows) and splayed ischia at the pelvis (blue 
arrows).   
A G2 cohort was established by crossing the G1 founder female animal with a male C3H 
animal to produce 4 litters of progeny, comprising 19 females and 19 males.  This cohort 
was phenotyped by X-ray imaging at 3 months of age.  Of these 38 animals, 12 animals, 
8 males and 4 females showed skeletal abnormalities, including curved olecranon and 
splayed ischia, in isolation or in combination (C.Esapa) (Figure 5.2).  
No further phenotyping was performed on the G2 cohort at this time.  DNA was 
extracted from tissue harvested from affected animals, and sperm from the affected 





Figure 5.2.  Representative X-ray images showing affected and unaffected animals. (A) An 
unaffected animal with a normal olecranon and ischia. (B&C) Affected animals showing 
curved olecranon (orange arrows) and splayed ischia at the pelvis (blue arrows), in  
combination or isolation.  
5.3. Mapping and Identification of the mutation in the line TM44 
5.3.1. Mapping the Mutation in TM44 
DNA from 8 affected animals underwent SNP mapping to identify a region which would 
contain the causative mutation (C.Esapa). As the G2 animals which underwent 
phenotyping have a mixed background, it is possible to use the SNPs to identify which 




was created in a C57BL/6J mouse, therefore any mutation caused by the ENU will be on 
the C57BL/6J regions of the genome. The original phenotype was identified in a G1 
animal, which must be heterozygous for any ENU induced mutation; therefore, the 
mutation must be dominant. The G2 cohort, being an outcross cohort, will only contain 
animals that are wild-type or heterozygous for the mutation and a dominant causative 
mutation would need to be heterozygous for C57BL/6J SNPs.   A region was identified 
on Chromosome 11, from 82.70 Mb to the distal end of the chromosome, where all 
affected animals were heterozygous, indicating that the causative mutation was within 
this region at the distal end of Chromosome 11 (Figure 5.3). 
 
 
Figure 5.3. SNP mapping panel showing the region of interest on Chromosome 11. All  
affected animals have one C57BL/6J allele and one C3H al lele in the ~40Mb region at the 
distal end of Chromosome 11, indicating that  the causative mutation is dominant and 





5.3.2. Exome Sequencing of TM44 
Exome sequencing performed by C.Esapa identified two high confidence mutations 
within the region on Chromosome 11. The first was a cytosine to thymine transition at 
base 2029 (C2029T), causing a premature stop in place of a glutamine (Gln677Stop) in 
Exon 31 of the gene Col1a1.  The second was an adenine to a guanine transition at base 
413 (A413G), causing an amino acid change, a glutamic acid in place of a glycine  
(Glu138Gly) in Exon 4 of the gene Sectm1a. 
5.3.3. Confirmation of Mutations in the line TM44 
The two mutations identified by exome sequencing were subsequently confirmed using 
Sanger sequencing in affected animals, showing the animals to be heterozygous for both 
mutations (C.Esapa). Unfortunately, at the time, unaffected animals were not 
sequenced so the reference trace included in Figure 5.4 and Figure 5.5 is from an 
unaffected animal from the re-derived TM44 line at a later date. This confirms that these 
mutations were only present in affected animals and that one of these mutations is likely 
causative. 
 
Figure 5.4.  Sanger sequencing traces confirming the presence of a heterozygous mutation 
in Col1a1  in affected animals. An affected animal from the G2 cohort shows two peaks 
indicating a heterozygous mutation and an unaffected animal from the re-derived line 







Figure 5.5.  Sanger sequencing traces confirming the presence of a heterozygous mutation 
in Sectm1a  in affected animals. An affected animal from the G2 cohort shows two peaks 
indicating a heterozygous mutation and an unaffected animal from the re-derived line 
showing no mutation in Sectm1a (indicated by a blue arrow).  
 
5.3.4. Segregation of Mutations in the line TM44 
Due to the nature of the ENU mutagenesis screen, the line TM44 was on a mixed 
C3H/HeH and C57BL6/J background. To reduce the amount of C57BL6/J and segregate 
the different mutations, the line was backcrossed to C3H/HeH for multiple generations. 
Sequencing of the two identified mutations at backcross 6 (BC6) showed segregation of 
the mutations eliminating Sectm1a as a candidate gene (Figure 5.6).  Much of the work 
in this chapter was carried out prior to the successful segregation of mutations. To 
indicate where animals with the segregated mutation are used, the designation of both 
genes will be used i.e., the affected animal TM44\14.1d from Figure 5.6 would be 






Figure 5.6.  Sanger sequencing traces showing the segregation of mutations in affected 
animals. Affected animals from backcross 6 were heterozygous for the Col1a1  mutation 
(C/T), but wild-type for the Sectm1a mutation (A/A); and unaffected animals were wild-
type for both the Col1a1  mutation (C/C), and wild-type for the Sectm1a mutation (A/A).  
The sites of the mutations in both genes are marked by blue arrows. 
 
5.4. Identification of a Lethal Phenotype in TM44 Homozygotes 
The G2 cohort only contained heterozygotes and wild types, due to being the product of 
matings between the heterozygote G1 founder female animal with a male wild-type 
C3H/HeH animal. It was therefore unknown what phenotypes the homozygote would 
display.  The line was re-derived using banked G2 sperm and C3H/Heh oocytes, to 
produce wild-type and heterozygous offspring. After genotyping to confirm genotype, 
intercross matings between male heterozygotes (Col1a1+/TM44) and female 
heterozygotes (Col1a1+/TM44) were set up to produce to an intercross (IC) cohort 
containing homozygotes (Col1a1TM44/TM44), heterozygotes (Col1a1+/TM44) and wild types 
(Col1a1+/+).  Genotyping of the IC cohort at P21 revealed that there were no 
homozygotes present (Figure 5.7).  The proportion of heterozygous animals to wild-type 
animals was 2:1, indicating a homozygous lethal phenotype; a Chi squared test shows 
that the numbers are statistically different from the expected (χ2= 9.91, 2df, P<0.01). 





Figure 5.7  Proport ions of animals of each genotype at weaning (stage P21). Heterozygotes 
(HET, Col1a1+/ T M4 4) making up 65% percent of the offspring and wild types (WT, Col1a1+/ +)  
making up 35% is indicative of a homozygous lethal phenotype.  
To investigate the time point of the embryonic lethality, analysis of 14.5 dpc embryos 
from intercross matings between male heterozygotes (Col1a1+/TM44) and female 
heterozygotes (Col1a1+/TM44) was undertaken.  At 14.5 dpc homozygous embryos were 
present at the expected ratios (χ2= 0.67, 2df, P>0.5), however none of the homozygous 
embryos were alive and there was evidence of reabsorption (Figure 5.8). The animals 






Figure 5.8.  Proportions of embryos of each genotype at 14.5 days post-coitum. (A) The 
ratios of the total number of homozygote (HOM, Col1a1TM 4 4/ T M 44),  heterozygote (HET, 
Col1a1+/ TM 4 4)  and wild type (WT, Col1a1+/+) embryos does not differ from expected values 
from an intercross mating (χ2= 0.67, 2df, P>0.5). (B) When dead animals were excluded,  
the ratios of the l iving embryos mirrored that of the IC P21 cohort, with no homozygotes 
(HOM, Col1a1T M4 4/ TM 4 4)  present, and heterozygotes (HET, Col1a1+ /T M 44 )  accounting for 67% 
and wild types (WT, Col1a1+/+) 33%. 
 
Having established that homozygous embryos were not viable at 14.5 dpc, further 
embryos were analysed at 12.5 dpc. Homozygous embryos were found to be alive and 
present in the expected ratios at this embryonic stage (χ2= 0.73, 2df, P>0.5) (Figure 5.9), 





Figure 5.9.  Proportions of embryos of each genotype at 12.5 days post coitum. The ratios 
of the total number of homozygote (HOM, Col1a1T M 44 / T M 44),  heterozygote (HET,  
Col1a1+/ TM 4 4)  and wild type (WT, Col1a1+/+) embryos does not differ from expected values 
from an intercross mating (χ2= 0.73, 2df, P>0.5).  This indicates that the point of lethal ity 
is between 12.5dpc and 14dpc.  
 
5.5. Optical Projection Tomography of TM44 Embryos 
We employed optical projection tomography (OPT) imaging to analyse the phenotypes 
of the homozygous embryos.  OPT is a useful technique as it allows 3D imaging without 
the laborious preparation involved in µCT imaging of whole embryos. The resulting 
images can be reconstructed to allow 3D modelling and segmentation to allow for 
examination of specific planes throughout the embryo [293]. Initial measurements such 
as crown to rump length showed no significant difference between genotypes (Figure 






Figure 5.10.  A graph showing the measured crown to rump length of wild-type (WT, 
Col1a1+ /+) and homozygous (HOM, Col1a1T M4 4/ T M 4 4) embryos.  Statistical analysis showed 
no signif icant difference in length between the two genotypes. (T-test) 
Further analysis demonstrated that a number of homozygous animals had enlarged 
conical skulls, and in some cases evidence that a build-up of pressure had forced a large 
hole to appear in the skull.  Segmentation revealed that in a number of cases this 
pressure, likely caused by a build-up of cerebrospinal fluid (CSF) in the skull, was leading 







Figure 5.11.  Representative OPT imaging of wild-type and homozygous embryos. (A-C) The 
wild-type (WT, Col1a1+/+)  embryos display a normal gross morphology for embryos at this 
stage when viewed in 3D, and a 2D section through the brain shows normal ventricles. (D-
F) The homozygous (HOM, Col1a1T M 44 /T M 44)  embryos display abnormal gross morphology 
when viewed in 3D, including elongated, conical skulls (blue arrows) in (D-F),  in addition 
one homozygote (E) showed evidence of damage to the skull in what appears to be a 
release of pressure from within the skull (yellow arrow) and one homozygote (F) shows 
evidence of deformation inwards (red arrow).  2D section through the brains of the 
homozygotes shows abnormal brain and ventricles in (D-F).  
 
5.6. Phenotyping of the TM44 line 
X-ray imaging from the original G2 Cohort identified early onset mild bone abnormalities, 
including curved olecranon and splayed ischia. To investigate whether the line TM44 
also displayed a late onset OA phenotype, similar to that seen in MP-107, a cohort of re-
derived animals was aged to 18 months and underwent X-ray imaging and DEXA analysis 




the successful segregation of the Col1a1 and Sectm1a mutations in the TM44 line, a 
small cohort uniquely carrying the Col1a1 mutation was bred for phenotyping at 2 
months of age in order to confirm that the Sectm1a mutation was not causative, and to 
allow a direct comparison of early phenotypes with MP-107.  Unfortunately, due to the 
segregation of mutations occurring late in the project, it was not possible to age animals 
with solely the Col1a1 mutation.  
5.6.1. X-ray Imaging of TM44 Animals 
X-ray imaging of animals with the segregated mutations at 2 months of age revealed 
that animals that were heterozygous for the Col1a1 mutation in the absence of the 
Sectm1a mutation (HET, Col1a1+/TM44, Sectm1a+/+) exhibited the early bone phenotypes 
of curved olecranon and splayed ischia. This indicates that Col1a1 is the causative 
mutation for these phenotypes. The combination of phenotypes is shown in Figure 5.12, 
and examples of the radiographs are shown in Figure 5.13.  
 
Figure 5.12.  Diagram showing the number of animals that exhibited each phenotype, or 
combination of phenotypes for wild-type and heterozygous animals at 2 months of age. 
All heterozygous (HET, Col1a1+/ T M4 4,  Sectm1a+ /+) animals exhibited at least one 






Figure 5.13.  Representative X-ray images of wild-type and heterozygous animals at 2 
months.  (A) Wild type (WT, Col1a1+/ +,  Sectm1a+/ +) animals exhibited no evidence of the 
curved olecranon or splayed ischia (B&C) heterozygous (HET, Col1a1+/ TM 4 4,  Sectm1a+/+) 
animals either exhibited the curved olecranon (orange arrow), or the splayed ischia (Blue 





All animals which were heterozygous for the Col1a1 mutation showed some 
phenotype regardless of sex (Table 5.1). 





Male - Col1a1+/TM44, Sectm1a+/+ 5 3 2 0 5 100 % 
Male - Col1a1+/+, Sectm1a+/+ 5 0 0 0 0 0% 
Female - Col1a1+/TM44, Sectm1a+/+ 5 5 2 0 5 100% 
Female - Col1a1+/+, Sectm1a+/+ 5 0 0 0 0 0% 
 
Table 5.1.  A table displaying the number of animals phenotyped in the 2-month cohort 
and the number of animals presenting with each phenotype. 100 % of heterozygotes 
(Col1a1+/ TM 4 4,  Sectm1a+/+) exhibited either the curved olecranon, the splayed ischia, or a 
combination of phenotypes. No phenotype was observed in the wild types (Col1a1+ / +,  
Sectm1a+/ +).  
In addition to the previously noted phenotypes of curved olecranon at the elbow and 
splayed ischia at the pelvis, in the heterozygotes (HET, Col1a1+/TM44, Sectm1a+/+), one 
heterozygote (HET, Col1a1+/TM44, Sectm1a+/+) appeared to have extra bone formation at 
the elbow rather than the curved olecranon seen in other heterozygous animals (Figure 
5.14).  It should be noted that this animal was included, in Figure 5.12 and Table 5.1 as 
having an olecranon phenotype, however as this was not the only phenotype in this 






Figure 5.14. X-ray images of wild-type and heterozygous animals at 2 months showing the 
olecranon phenotypes. (A) Wild type (WT, Col1a1+/+,  Sectm1a+ / +) exhibits no evidence of 
the curved olecranon, (B) a heterozygote (HET, Col1a1+ / T M4 4,  Sectm1a+ / +) exhibits the 
curved olecranon (orange arrow), (C) a heterozygote (HET, Col1a1+/ TM 4 4 ,  Sectm1a+/+) 
exhibits apparent abnormal bone growth at the olecranon (Purple arrow) (only seen in 
one animal).  
A small cohort of TM44 animals were aged to 18 months to investigate whether the 
TM44 animals exhibited late onset phenotypes. These animals were bred prior to the 
segregation of mutations, and therefore carry the Sectm1a mutation in addition to the 




to the early phenotype previously noted, a number of heterozygotes (HET, Col1a1+/TM44) 
were starting to show abnormal bone growth at the knee (5/8, 62.5% male 
heterozygotes and 5/6, 83.3% female heterozygotes), similar in appearance to the 
phenotype seen in MP-107.  Four heterozygotes were also observed to have a mild bone 
abnormality at the heel. No phenotype was observed in the wild types (Col1a1+/+) (Figure 
5.15). 
 
Figure 5.15.  Representative X-ray images of wild-type and heterozygous animals at 12 
months.  (A) Wild-type (WT, Col1a1+/+) and (B&C) heterozygous (HET, Col1a1+/ TM 4 4)  animals 
at 12 months of age. (A) Wild types (WT, Col1a1+ /+) display no evidence of the curved 
olecranon splayed ischia or abnormal bone growth at the knee. (B-C) Heterozygotes (HET,  
Col1a1+ /T M 44)  displays curved olecranon (not shown in this figure), abnormal bone growth 
at the knee (red arrow), splayed ischia (blue arrow), abnormal calcaneus (green arrow) or 




At the 18-month time point, two animals that did not display the abnormal bone growth 
at the knee had developed the phenotype. At 12-months, 100% of heterozygotes 
exhibited some form of phenotype, and at 18-months 100% of heterozygotes exhibited 
the knee phenotype.  No phenotype was observed in the wild types (Figure 5.16). 
 
Figure 5.16.  Representative X-ray images of wild-type and heterozygous animals at 18 
months.  (A) Wild-type (WT, Col1a1+/+) and (B&C) heterozygous (HET, Col1a1+/ TM 4 4)  animals 
at 12 months of age. (A) Wild types (WT, Col1a1+ /+) display no evidence of the curved 
olecranon splayed ischia or abnormal bone growth at the knee. (B-C) Heterozygotes (HET,  
Col1a1+ /T M 44)  displays curved olecranon (not shown in this figure), abnormal bone growth 
at the knee (red arrow), splayed ischia (blue arrow) or a combination of phenotypes. No 
heterozygous (HET, Col1a1+/ TM 4 4)  animals exhibited the abnormal calcaneus at 18 months 





Table 5.2 shows the number of animals displaying each phenotype in each cohort, and 
Figure 5.17 shows the actual combination of phenotypes that were observed. 
 







Col1a1+/TM44  8 2 3 5 3 8 100 % 
Col1a1+/+ 6 0 0 0 0 0 0% 
12 month 
Female 
Col1a1+/TM44  6 5 0 5 0 6 100% 
Col1a1+/+ 4 0 0 0 0 0 0% 
18-month 
Male 
Col1a1+/TM44  3 1* 1* 3* 0* 3 100 % 
Col1a1+/+ 4 0 0 0 0 0 0% 
18-month 
Female 
Col1a1+/TM44  5 4* 0 5 0 5 100% 
Col1a1+/+ 4 0 0 0 0 0 0% 
 
Table 5.2.  A table displaying the number of animals phenotyped in the 12- and 18-month 
cohorts and the number of animals presenting with each phenotype. 100% of 
heterozygotes (Col1a1+/ T M4 4)  exhibited either the curved olecranon, the splayed ischia, 
abnormal bone growth at the knee, the abnormal calcaneus, or a combination of 
phenotypes. No phenotype was observed in the wild types (Col1a1+ /+) *numbers reduced 





Figure 5.17.  Diagram showing the number of animals that exhibited each phenotype, or 
combination of phenotypes for wild-type and heterozygous animals at 12- and 18-months.  
(A) At 12-months all heterozygous (HET, Col1a1+ /T M4 4 )  exhibit at least one of the following 
three phenotypes, curved olecranon, splayed ischia or abnormal bone growth at the knee, 
either in isolation or in combination. Additionally,  four heterozygotes also exhibited an 
abnormal calcaneus; this phenotype was only ever observed in combination with another 
phenotype. No wild-type (WT, Col1a1+/+)  animals exhibited any phenotype. (B) At 18-
months all heterozygous (HET, Col1a1+ /T M 44)  exhibit at least one of the following three 
phenotypes, curved olecranon, splayed ischia or abnormal bone growth at the knee,  
either in isolation or in combination. No heterozygotes exhibited the abnormal calcaneus 
phenotype, as those animals were all culled for welfare reasons. No wild-type (WT, 
Col1a1+ /+) animals exhibited any phenotype. Reduced N numbers at 18 months were due 
to animals being culled for welfare reasons. 
The X-ray data shows that the TM44 heterozygotes exhibit similar phenotypes to MP-
107, with the addition of a phenotype affecting the calcaneus. These three cohorts show 






5.6.2. DEXA Analysis of TM44 Animals 
DEXA allows accurate analysis of bone composition. DEXA analysis was undertaken for 
the 2-month cohort of TM44 animals with segregated mutations and the 18-month 
cohort of TM44 animals bred at a previous backcross, before the segregation of 
mutations, and therefore contains both the Sectm1a and the Col1a1 mutation. 
The 2-month cohort showed that heterozygotes (HET, Col1a1+/TM44, Sectm1a+/+) had a 
significantly decreased BMC and BMD when compared to wild types (WT, Col1a1+/+, 
Sectm1a+/+). This significant difference was observed in both sexes (Figure 5.18) (BMC-
Male P=0.000009, Female P=0.00285, BMD- Male P=0.0240, Female P=0.00074). No 
significant differences were observed in any other parameter. The phenotypes observed 
are an indication that the line TM44 may be osteoporotic, and at a higher risk of bone 






Figure 5.18.  DEXA analysis of wild types and heterozygotes of both sexes at 2-months. (A) 
A significant reduction in bone mineral content was observed in the heterozygotes (HET, 
Col1a1+ /T M 44,  Sectm1a+/ +)  compared to wi ld types (WT, Col1a1+/+,  Sectm1a+/+) in both 
sexes. (B) A significant reduction in bone mineral density was observed in the 
heterozygotes (HET,  Col1a1+ /T M4 4,  Sectm1a+ /+)  compared to wild types (WT, Col1a1+/ +,  
Sectm1a+/ +) in both sexes. No significant difference between genotypes was observed in 
(C) Weight, (D) Percentage Fat or (E) Length.  (N = 5 Female HET, 5 Female WT, 5 Male 
HET, 5 Male WT, *P<0.05, **P<0.01, *** P<0.001, **** P<0.0001) 
DEXA analysis of the 18-month cohort showed that heterozygotes (HET, Col1a1+/TM44) 
had a significantly reduced percentage fat when compared to wild types (WT, Col1a1+/+) 
in females (P=0.025). No significant difference was observed in the BMD, BMC, body 
weight or body length between genotypes of either sex, and no significant difference 






Figure 5.19. DEXA analysis of wild types and heterozygotes of both sexes at 18-months. 
No signif icant difference was observed between genotypes in either sex in (A) bone 
mineral content,  (B) bone mineral density, (C) body weight or (E) body length. (D) No 
significant difference was observed in percentage fat between genotypes in males,  
however, females heterozygotes (HET, Col1a1+/ TM 4 4)  exhibited a reduced percentage fat 
when compared with wild types (WT, Col1a1+/+) (N = 5 Female HET, 4 Female WT, 3 Male 
HET, 4 Male WT T-Test *P<0.05).  
It is not known why the female heterozygotes show a reduction in percentage fat; 
however, this could be a result of the knee abnormalities making it more difficult for the 
female heterozygotes to over-eat, as food is stored in a hopper. The reduction in both 
BMC and BMD seen in the 2-month cohort is not replicated here.  This could be due to 
the 2-month cohort being a much later backcross, as this was required to segregate 
mutations, and therefore has a reduced proportion of the C57BL/6J genome, or it could 




5.6.3. Histological analysis of TM44 Knee Joints 
Histological analysis of 18-month old knee joints reveal that in addition to the abnormal 
bone formation observed by X-ray imaging, the heterozygotes (HET, Col1a1+/TM44) also 
show a profound loss of articular cartilage indicating an OA phenotype (Figure 5.20).  
 
Figure 5.20. Safranin O stained sections of knee joints from a wi ldtype and a heterozygote 
at 18 months.  (A-B) The wild-type (WT, Col1a1+/+) joint shows normal healthy cartilage 
at the articular surface (Blue arrow) and no evidence of osteophytes.  (C-D) The 
heterozygous (HET, Col1a1+ /T M4 4)  knee shows severe osteophyte formation (Yellow 
arrows), synovial inflammation and an absence of articular carti lage on the medial  
femoral condyle and medial t ibial plateau (Red arrow).  Medial and lateral  side denoted 
by M and L respectively.  
OARSI scoring of histological sections from heterozygous and wild-type knees indicates 
that there is a significantly elevated maximum OARSI score in the heterozygotes when 
compared with wild types (P=0.0357). This comparison was only carried out in male 







Figure 5.21.  Maximum OARSI scores of Safranin O stained histological section of knee 
joints from wild-type and heterozygous male animals at 18-months of age. Heterozygote 
(HET, Col1a2+/ 1 07) max OARSI scores were significantly higher than their wild type (WT, 
Col1a2+ /+) counterparts (Het- N=5, WT- N=3, Mann Whitney test *p<0.05).  
5.7. Collagen Content of TM44 Tendons 
Mutations in the collagen I genes could reasonably be assumed to cause changes in the 
folding and make-up of the collagen I heterotrimer. It is known that collagen I can exist 
as a homotrimer made up solely of α1 chains.  Analysis of radiolabelled collagen in MP-
107 tail tendons in Chapter 4 (Section 4.5) revealed that there was no difference in either 
the extracellular, or the intracellular collagen I between wild-type and heterozygous 
samples, indicating that the mutant COL1A2 was being produced and incorporated into 
the collagen fibrils.  
The radiolabelling assay was not available for the analysis of TM44 lines.  For this reason, 
to analyse the secretion of collagen I, Collagen was extracted from 4-month old tail 
tendons using a pepsin/acetic acid extraction, before being analysed using gel 
electrophoresis. Separating out the α1 and α2 bands on a gel before staining allows a 
comparison of the ratio of α1 and α2. The theory behind this is that as normal collagen 
I is a heterotrimer of two α1 chains and one α2 chain, the expected ratio would be 
approximately 2:1 (provided the bands are solely α1 and α2). If a mutation impairs the 
production of the heterotrimer, homotrimer may be produced instead, which would 
modify the ratio in the heterozygote. The collagen extracts from wild-type and 




samples were run on a 4-12% Tris-Bis gel, before staining with Brilliant Coomassie blue 
stain. (Figure 5.22).  
 
Figure 5.22. Coomassie stained collagen extracts from wild-type and heterozygous 
tendons for the l ines MP-107 and TM44. The ratio of α1: α2 is d isplayed beneath each 
lane. The analysis shows no visible difference in ratio of α1 to α2 between genotypes in 
either MP-107 or TM44, indicating the TM44 heterozygote is not producing homotrimer.  
Comparison of the ratio of α1 to α2 between wild type (WT, Col1a2+/+) and 
heterozygotes (HET, Col1a2+/107) are similar in MP-107. Indicating that this assay is a 
suitable alternative to the unavailable radiolabelling assay. No obvious difference was 
identified between ratio of α1 to α2 in wild types (WT, Col1a1+/+) and heterozygotes 
(HET, Col1a1+/TM44) in TM44, indicating that the heterozygote is not producing 
homotrimer. It should be noted that as the extract from the tendon will contain other 
proteins, these bands may contain similar sized proteins, which could account for the 







The line TM44 was originally incorporated into this project due to the similarities in the 
early onset phenotypes, consisting of splayed ischia and curved olecranon, between this 
line and MP-107.  The subsequent identification of a late onset knee phenotype 
consisting of abnormal bone growth, and cartilage loss at the articular surface mirrored 
the late phenotype seen in MP-107.  
The initial work of Dr Esapa in mapping the causative mutation to a region on 
Chromosome 6, and the identification of Col1a1 and Sectm1a as possible candidate 
genes, laid the groundwork for the eventual segregation of these mutations. The 
segregation of the Sectm1a and Col1a1 mutations occurred after many rounds of 
backcrossing, and therefore happened towards the end of the project.  As a result, it 
was not possible to age the animals heterozygous for the Col1a2 mutation and wild-type 
for the Sectm1a mutation (Col1a1+/TM44, Sectm1a+/+) in order to confirm that the late 
phenotype occurred in the absence of the Sectm1a mutation.  However, early 
phenotyping did confirm that the splayed ischia and curved olecranon do occur in the 
presence of the Col1a1 mutation alone. The segregation of the mutations and the 
presence of the early bone phenotypes indicate that the premature stop in Col1a1 is the 
causative mutation. 
Like the MP-107 line, the TM44 is found to be homozygous lethal, although the TM44 is 
lethal far earlier in development than MP-107. The homozygous embryos were found to 
be lethal between 12.5 and 14.5 dpc and showed evidence of hydrocephalus. 
Interestingly, parallels can be drawn between this lethal phenotype and the Mov-13−/− 
model of Type II OI, which is recorded as having arrested development between day 11 
and day 12 of gestation, and being lethal between days 13 and 14. The first observation 
of type I collagen in the embryo is around day 9, however day 11-12 is when high 







The three phenotypes observed by X-ray in heterozygotes of both lines, appear with 
greater frequency in the TM44 line, with 100% of heterozygotes (Col1a1+/TM44) exhibiting 
at least one of the phenotypes, while in the MP-107 line 20-40% of heterozygotes 
(Col1a2+/107) exhibited no phenotype. The histology of the knee joints of heterozygotes 
from the line TM44 (Col1a1+/TM44) is very similar to the histology of the knee joints of 
heterozygotes from the line MP-107 (Col1a2+/107), including the presence of large 
osteophytes and articular cartilage erosion. In addition to the phenotypes noted in the 
MP-107 line, X-ray imaging revealed that three male TM44 heterozygotes (Col1a1+/TM44) 
also displayed an abnormal calcaneus at 12 months. These animals were culled for 
welfare reasons due to impaired mobility. 
DEXA analysis indicates that the heterozygotes (Col1a1+/TM44) have osteopenia. The 
osteopenic phenotype shown by DEXA analysis in the TM44 heterozygotes 
(Col1a1+/TM44), was not replicated in the MP-107 heterozygotes (Col1a2+/107).  However 
the µCT analysis did indicate evidence of osteopenia in the heterozygotes (Col1a2+/107) 
[295]. That both lines show evidence of osteopenia is not surprising given the similarities 
in the bone phenotype. The fact that osteopenia was not detected by DEXA in MP-107, 
and only by µCT analysis indicates again that the phenotype in TM44 is more severe than 
in MP-107. 
The similarities in phenotypes between heterozygous (Col1a1+/TM44) TM44 animals and 
heterozygous (Col1a2+/107) MP-107 animals are numerous and are summarised in Figure 
5.23 along with images from wild-type (Col1a2+/+) MP-107 animals for reference.  Both 
lines display the same early phenotypes of curved olecranon, splayed ischia, the same 
late phenotypes including abnormal bone growth at the knee and loss of articular 





Figure 5.23.   A f igure comparing the observed phenotypes between the lines MP-107 and 
TM44. (A) MP-107 wild types (Col1a2+/+) show no abnormalit ies at the pelvis or olecranon 
at 3 months of age, and no evidence of abnormal bone growth or osteoarthritis at the 
knee at 18 months. (B) MP-107 heterozygotes (Col1a2+/ 10 7) and (C) TM44 heterozygotes 
(Col1a1+/ TM 4 4)  exhibit  the splayed ischia at the pelvis and the curved olecranon at the 
elbow at 3 months of age, in addition to the abnormal bone growth at the knee, and 
osteoarthritis at 18 months of age. 
Both lines contain mutations in collagen I alpha chains, the mutation in MP-107 is a 
splice variant in Col1a2 leading to the inclusion of an extra amino acid in the protein 
coding sequence, while the mutation in TM44 is a premature stop in Col1a1 which may 
be far more deleterious.  This is borne out in the phenotype data, with homozygous 
lethality at an earlier developmental time point in TM44 accompanied by a more severe 




more severe osteoporosis phenotype. Moreover, in MP-107, wild-type transcript is 
produced even in the homozygote (Col1a2107/107).  This may be mediating the damaging 
effects of the mutation, leading to lethality at a later time point and a less severe 
phenotype. We will return to a more detailed discussion of the genetic mechanisms of 




Chapter 6: Initial Characterisation of 





The ENU mutation in MP-107 is within the gene Col1a2, and leads to early onset 
phenotypes such as a curved olecranon and splayed ischia, and late phenotypes such as 
OA.  The mechanism by which the mutation leads to the phenotypes is not yet clear.  To 
help elucidate the mechanism, it is important to understand what happens in the 
absence of the gene that contains the mutation.  For this reason, the knockout of the 
Col1a2 gene (Col1a2-KO) was generated. Viability testing and phenotyping, such as X-
ray imaging and DEXA analysis, were carried out to investigate the phenotype of a null 
Col1a2 allele, and to determine if similar phenotypes were observed in the Col1a2-KO 
line and MP-107.  The aim of this chapter is to investigate if knocking out Col1a2 results 
in similar phenotypes to those observed in MP-107 and TM44, and to provide further 
information about the mechanisms by which the phenotypes occur. 
6.2. Creation of the Col1a2-KO Line 
A knockout of the Col1a2 gene (Col1a2-KO) was created by the gene editing team at 
MRC Harwell using CRISPR-Cas9 technology to delete critical exons in the gene Col1a2. 
A large region of 2087 nucleotides encompassing EXON 2 (ENSMUSE00001291037), 
Exon 3 (ENSMUSE00001247742) and Exon 4 (ENSMUSE00001305705) was deleted to 
induce a premature stop codon and a null allele.  
Briefly, Cas9 mRNA and sgRNAs (detailed in section 2.2.6) were diluted and mixed in a 
microinjection buffer to the working concentrations of 100 ng/μl and 50 ng/μl each 
respectively.  The sgRNAs in the buffer were then delivered by pronuclear injection into 
1-cell stage C57BL/6N embryos.  Injected embryos were re-implanted in CD1 pseudo-
pregnant females. Host females were allowed to litter and rear F0 progeny.   
An F0 animal was identified with the desired deletion, and an F1 cohort was then 
produced by crossing to C57BL/6N, producing 7 offspring, 5 heterozygotes (Col1a2+/-) 
and 2 wild types (Col1a2+/+).  The heterozygotes were then backcrossed to C57BL/6N to 
bulk up the colony before heterozygous animals were intercrossed to produce the 






6.3. Viability analysis of the Col1a2-KO Line 
Intercross matings between male heterozygotes (HET, Col1a2+/-) and female 
heterozygotes (HET, Col1a2+/-) were established to investigate the viability of the 
Col1a2-KO line.  Genotyping of the offspring of these intercross revealed that animals of 
all three genotypes wild types (WT, Col1a2+/+), heterozygotes (HET, Col1a2+/-) and 
homozygotes (HOM, Col1a2-/-) were present.  Statistical analysis indicates that there is 
no reduced viability and that all genotypes are represented in the expected ratios (χ2= 
0.51, 2df, P>0.7) (Figure 6. 1). 
 
Figure 6.1.   Proportions of animals of each genotype at weaning from intercross matings. 
Homozygotes (HOM, Col1a2 - / -) accounted for 22% of animals, heterozygotes (HET, 
Col1a2+ / -) accounted for 23% of animals and wild types (WT, Col1a2+/+) accounted for the 
remaining 55%. The number of animals of each genotype does not significant ly differ from 





6.4. Phenotyping of the Col1a2-KO Line 
The Col1a2-KO line is the first of the three lines investigated where the homozygous 
animals are viable into adulthood.  As such, intercross cohorts of animals including all 
three genotypes were bred for phenotyping. Due to an unusually high number of male 
animals that were culled for welfare purposes only female animals were included in this 
analysis, the reasons for these welfare concerns will be addressed later in this chapter. 
The phenotyping included X-ray imaging and DEXA analysis at an early time point (2 
months) and a late time point (12 months). 
6.4.1. X-ray Imaging of the Col1a2-KO line 
X-ray imaging at 2 months of age indicated the presence of mild bone abnormalities in 
heterozygotes (HET, Col1a2+/-) and homozygotes (HOM, Col1a2-/-). The heterozygotes 
(HET, Col1a2+/-) exhibited only a mild splayed ischia phenotype, and homozygotes (HOM, 
Col1a2-/-) exhibited mild splayed ischia and a curved olecranon phenotype. As seen 
previously in MP-107 and TM44, these phenotypes are variable. Not all heterozygotes 
or homozygotes exhibited phenotypes.  There was no evidence of abnormal bone 






Figure 6.2.  Representative X-ray images of female animals of al l  three genotypes at 2-
months of age. (A) Wild types (WT, Col1a2+ /+)  exhibited no evidence of the curved 
olecranon or splayed ischia (B) 40% of heterozygotes (HET,  Col1a2+/ -) exhibited a splayed 
ischia phenotype (Blue arrow), and (C) 60% of homozygotes (HOM, Col1a2 - / -) exhibited a 
splayed ischia phenotype (Blue arrow) with some animals also exhibit ing a curved 
olecranon phenotype (Orange arrow). No evidence of abnormal bone growth at the knee 
was detected in any genotype. 
X-ray imaging at 12 months of age indicated the presence of mild bone abnormalities in 
heterozygotes (HET, Col1a2+/-) and homozygotes (HOM, Col1a2-/-). The heterozygotes 




Col1a2-/-) exhibited splayed ischia and a curved olecranon phenotype. As seen previously 
in MP-107 and TM44, these phenotypes are variable. Not all heterozygote and 
homozygotes exhibited phenotypes.  There was no evidence of abnormal bone growth 
at the knee (Figure 6.3). 
 
 
Figure 6.3.  Representative X-ray images of female animals of al l three genotypes at 12-
months of age. (A) Wild types (WT, Col1a2+ /+)  exhibited no evidence of the curved 
olecranon or splayed ischia, (B) 60% of heterozygotes (HET, Col1a2+/ -) exhibited a splayed 
ischia phenotype (Blue arrow), and (C) 70% of homozygotes (HOM, Col1a2 - / -) exhibited a 
splayed ischia phenotype (Blue arrow) with some animals also exhibit ing a curved 
olecranon phenotype (Orange arrow). No evidence of abnormal bone growth at the knee 





No heterozygotes (HET, Col1a2+/-) exhibited the curved olecranon at all, and no 
homozygotes (HOM, Col1a2-/-) exhibited the curved olecranon in isolation, it only 
occurred in tandem with the splayed ischia phenotype (Table 6.1). This indicates that 
the heterozygotes exhibit a less severe phenotype than the homozygotes. 






Col1a2+/+ 7 0 0 0 0 0% 
Col1a2-/+ 5 2 0 0 2 40% 
Col1a2-/- 6 4 1 0 4 67% 
12-month 
 
Col1a2+/+ 3 0 0 0 0 0% 
Col1a2-/+ 5 3 0 0 3 60% 
Col1a2-/- 7 5 3 0 5 71% 
 
Table 6.1.  A table displaying the number of animals presenting with each phenotype in 
the 2- and 12-month female cohorts.  
 
6.4.2. DEXA Analysis of the Col1a2-KO line 
DEXA analysis was carried out on the same cohorts that were used for X-ray imaging, at 
2 and 12 months of age, to investigate whether the loss of one or more Col1a2 alleles 
caused changes in parameters such as BMC and BMD. Statistical analysis showed that 







Figure 6.4 DEXA analysis of al l three genotypes in the 2- and 12-month female cohorts.  
No significant differences were detected in either (A) bone mineral content (BMC) or (B) 
bone mineral  density (BMD) between wild types (WT, Col1a2+ /+),  heterozygotes (HET, 
Col1a2+ / -) and homozygotes (HOM, Col1a2 - / -) at 2- and 12-months of age. (2 month cohort-
WT-N=7,  HET-N=5,  Hom-N=6, 12 month cohort- WT-N=3,  HET-N=5,  Hom-N=7- Statistical 
test- one way ANOVA).  
 
6.5. Welfare Observations of the Col1a2-KO line 
It was noted that a number of male animals, older than 6 months of age, had swollen 
ankles and were culled for welfare reasons. In male homozygotes swollen ankles 
occurred with an incidence of 31% (5/16), in heterozygotes 13% (7/53) and in wild types 
3% (1/27).  Initially, the occurrence of swollen ankles was attributed to fighting. However 
due to the genotypes of the affected animals, two affected homozygotes and an 
unaffected wild types were X-ray imaged to try to identify a possible cause for the 
swollen ankles.  Both affected homozygotes imaged exhibited calcification of the 
Achilles tendon, while the unaffected wild types did not (Figure 6.5).  In 2020, a preprint 
paper [296] found similar swollen ankles in their Col1a2 null male animals, although they 





Figure 6.5. X-ray images from a male wild type and a male homozygote,  showing the 
calcified Achi lles tendon in the homozygote. Neither the (A) wild type (WT, Col1a2+ /+),  or 
the (B) homozygote (HOM, Col1a2 - / -) animals exhibited any overt phenotypes. High-
resolution X-ray imaging of the ankles of (C) a wild type (WT, Col1a2+ / +),  and (D) a 
homozygote (HOM, Col1a2 - / -) reveals that the homozygote with swollen ankles exhibited 
a calcified Achilles tendon (blue arrow). 
 
6.6. Collagen Content of Col1a2-KO Tendons 
As discussed in section 5.11, the radiolabelling assay was not available for the analysis 
of TM44 lines and this was the case for this line too. To confirm that this line produced 
homotrimer α1 (I), the collagens were extracted from tail tendon from all three 




The collagen extracts from wild-type and heterozygous tendons from both MP-107 and 
TM44, and all three genotypes in the line Col1a2-KO were diluted to 0.25mg/ml and 
samples were run on a 4-12% Bis-Tris gel, before staining with Brilliant Coomassie blue 
stain. (Figure 6.6).  
 
Figure 6.6. Coomassie stained  collagen extracts from all available genotypes for each of 
the lines, MP-107, TM44 and Col1a2-KO. The ratio of α1: α2 is displayed beneath each 
lane. The analysis shows no visible difference in ratio of α1 to α2 between genotypes in 
either MP-107 or TM44.  In the case of the Col1a2-KO differences were detectable 
between all three genotypes.  
The ratios of α1 to α2 in the MP-107 and TM44 have been discussed previously (Section 
5.7), and are included here to validate the Coomassie staining as an alternative for the 
unavailable radiolabelling assay. In both MP-107 and TM44, the wild-type and 
heterozygous ratios are comparable.  The ratios varied between the three genotypes in 
the Col1a2-KO line, as expected with a Col1a2 null allele. The heterozygote (HET, 
Col1a2+/-) exhibits a 37% increase in the ratio between the α1 to α2 band compared to 
the wild type (WT, Col1a2+/+). The homozygous (HOM, Col1a2-/-) collagen sample 
exhibited a 200-fold increase in the ratio between α1 and α2. These results in the 
Col1a2-KO line, are due to the null alleles of Col1a2, causing an increase in α1 production 
and homotrimer.  It should be noted that as the extract from the tendon will contain 
other proteins, these bands may contain similar sized proteins, which could account for 
the ratios being lower than the expected 2:1 for heterotrimers, and why a very subtle 
band is detected in the homozygous Col1a2-KO extract (HOM, Col1a2-/-) allowing for a 






The viability testing analysis outlined in this chapter shows that the Col1a2-KO 
homozygotes are viable, and that all genotypes are represented at the expected ratios.  
While the homozygotes Col1a2-KO (Col1a2-/-) are viable, homozygote MP-107 
(Col1a2107/107) and homozygote TM44 (Col1a1TM44/TM44) both have lethal phenotypes. 
The Mov-13 model is effectively a null Col1a1 allele, while the oim model is effectively a 
null Col1a2 allele. The Mov-13 homozygote is lethal, and the oim homozygote is viable 
[66, 76]. It is therefore not surprising that the Col1a2-KO homozygote is also viable as 
the null Col1a2 allele appears to have a less severe effect, presumably as homotrimers 
can be formed. The reduced severity of the Col1a2 null compared with the Col1a2 
mutant is very informative and we will return to a more detailed discussion of the 
genetic mechanisms of the respective mutations in Chapter 7. 
The early phenotypes observed by X-ray in heterozygous MP-107 (Col1a2+/107) and TM44 
(Col1a1+/TM44) animals, were also observed in the heterozygous Col1a2-KO (Col1a2+/-) 
animals at slightly lower frequency than either MP-107 or TM44. Homozygous Col1a2-
KO (Col1a2-/-) also exhibited the early bone phenotypes, with the frequency being higher 
than heterozygous MP-107 (Col1a2+/107), but still lower than the TM44 (Col1a1+/TM44) 
animals. No evidence of any abnormal bone growth at the knee was detected in either 
the heterozygous (Col1a2+/-) or homozygous (Col1a2-/-) Col1a2-KO animals at the later 
time point, although it should be noted that animals were only aged to 12 months due 
to time constraints. These results indicate that the bone phenotypes are less severe in 
the Col1a2-KO animals than in the MP-107 and TM44 lines. As is also seen in human 
patients, null COL1A2 alleles tend to result in less severe OI phenotypes, than mutations 
affecting the glycine repeating motif [46-48]. 
DEXA analysis of Col1a2-KO animals showed there were no significant differences 
between genotypes in BMD and bone mineral content at either, the early, or the late 
time point. This indicates that if any osteoporosis phenotype is present, it is less severe 
than the TM-44 heterozygotes (Col1a1+/TM44). No direct comparison can be drawn with 
the MP-107 heterozygotes (Col1a2+/107), as they showed no phenotype using DEXA, but 




The calcification of the Achilles tendons in some of the Col1a2-KO mice, appears to be 
another variable phenotype that is not present in all mice, and appears to be limited to 
male mice over the age of 2 months.  This may be due to the increased likelihood of 
fighting in adult male mice housed together.  The preprint paper by Lee et al. observed 
a similar ‘swollen ankle’ phenotype in their male Col1a2 null animals, however no cause 
was attributed to the swollen ankles [296]. No ‘ankle phenotype’ phenotype was 
observed in MP-107 mice, however 3 male heterozygous TM44 animals were found to 
have abnormalities at the calcaneus at 12 months of age by X-ray imaging (See section 
5.6.1, Figure 5.15 and Table 5.3). These animals were kept under observation and were 
culled before the 18-month time point due to impaired movement.  
The collagen analysis of tendons confirmed that in the homozygote, the collagen I in 
tendon was homotrimer, and both heterotrimer and homotrimer were present in the 
heterozygote tendons.   
The data presented in this chapter indicates that a single or double null Col1a2 allele 
results in a less severe OI phenotype than either a mutation affecting the glycine 




Chapter 7: Investigating the Genetics 
and Effects of Mutations in Col1a1 and 





The similarities and differences between the two ENU lines and the knockout line raises 
a number of mechanistic questions about the severity of the mutations in Col1a1 and 
Col1a2 alleles. Both MP-107 and TM44 heterozygous animals display very similar overt 
phenotypes such as the skeletal abnormalities and the late onset severe OA at the knee 
joint (See Chapter 5, Figure 5.19). Homozygotes of both lines were lethal embryonically 
or perinatally (See Chapter 3, Figure 3.21 and Chapter 5, Figure 5.8).  In contrast, the 
Col1a2 null homozygote was viable (See Chapter 6, Figure 6.1). The homozygotes 
exhibited a similar early phenotype including the splayed ischia and curved olecranon, 
but showed no evidence of abnormal bone growth at the knee at 12-months. The 
heterozygotes exhibited a milder early phenotype displaying the splayed ischia 
phenotype only (See Chapter 6, Figure 6.3). 
In addition, TM44 heterozygotes (Col1a1+/TM44) exhibit low BMD and low bone mineral 
content phenotypes at 2 months of age when compared to the wild-type animals, while 
MP-107 heterozygotes (Col1a2+/107) and Col1a2-KO heterozygotes (Col1a2+/-)  and 
homozygotes (Col1a2-/-) do not (See Chapter 3, Table 3.11; Chapter 5, Figure 5.19, and 
Chapter 6, Figure 6.4). 
Whilst all of these lines have mutations in genes coding for collagen I alpha chains, the 
nature of the mutations are very different, and the roles each of the alpha chains play 
are different, leading to questions about the mechanisms by which these mutations lead 
to the phenotypes we see. 
To observe how these genes interact and to throw light on the genetic mechanisms 
involved, the two ENU mutant lines, TM44 and MP-107, and the Col1a2 knockout line, 
were intercrossed in a compound cross experiment. After an initial viability assessment 
involving all animals at weaning (P21), a small cohort of male animals were X-ray imaged 
and DEXA scanned at 4 months of age. 
It should be noted that there is some variation in the backgrounds of these animals, and 
this should be taken into account when interpreting results. The MP-107 animals used 
in these crosses are congenic C3H/HeH. The TM44 animals are incipient congenic 




The Col1a2-KO line was created on the C57BL/6N genome. Ideally these crosses would 
be carried out with all lines on the same congenic background, however due to time 
constraints this was not possible. 
The crosses included in this chapter are  
 TM44 (Col1a1+/TM44) x MP-107 (Col1a2+/107) – Section 7.2 
 Col1a2-KO (Col1a2+/-) x MP-107 (Col1a2+/107) – Section 7.3 
 TM44 (Col1a1+/TM44) x Col1a2-KO (Col1a2+/-) – Section 7.4 
 
7.2. TM44 x MP-107 Compound Cross 
7.2.1. Viability Assessment of the TM44/MP-107 Compound Cross 
Intercross matings between heterozygous TM44 (Col1a1+/TM44) and heterozygous MP-
107 (Col1a2+/107) animals were used to produce a cohort of compound genotypes, which 
would in theory contain animals of the following genotypes- 
Wild type MP-107 / Wild type TM44 - Col1a2+/+, Col1a1+/+ 
Wild type MP-107 / Heterozygous TM44 - Col1a2+/+, Col1a1+/TM44 
Heterozygous MP-107 / Wild type TM44- Col1a2+/107, Col1a1+/+ 
Heterozygous MP-107 / Heterozygous TM44 -Col1a2+/107, Col1a1+/TM44    
The total number of pups was recorded at birth, and animals were genotyped at 
weaning, at approximately P21.  Of 88 pups born, 9 pups went missing between birth 
and weaning, and the remaining 79 pups were genotyped (Table 7.1).  It is likely that the 
9 missing animals had a lethal phenotype, and were ingested by the mother.  
Statistical analysis indicates that the ratios of genotypes differ from the expected 
Mendelian ratios (χ2= 7.86, 3df, P<0.05). The genotyping data revealed that the pups 
were present in the expected ratios for all the genotypes except for the Col1a2+/107, 
Col1a2+/TM44, which were present at around half the expected numbers (using total 




pups were Col1a2+/107, Col1a2+/TM44, as they went missing prior to genotyping, the ratios 




Col1a2+/107, Col1a1+/TM44 10 
Col1a2+/+, Col1a1+/TM44 20 
Col1a2+/107, Col1a1+/+ 27 
Col1a2+/+, Col1a1+/+ 22 
Unknown 9 
 
Table 7.1.  A table displaying the number of animals of each genotype from intercross 
matings between TM44 heterozygotes and MP-107 heterozygotes.  Nine animals went 
missing without genotyping and are therefore included in their own category.  
 
 
Figure 7.1.  Proportions of animals of each genotype produced from intercross matings 
between TM44 heterozygotes and MP-107 heterozygotes. Ten percent of animals born 





As noted in previous chapters, Col1a1+/TM44 and Col1a2+/107 animals are viable, so the 
reduced viability of the Col1a2+/107, Col1a1+/TM44 animals indicates that there is some 
interaction between the mutant genes. 
 
7.2.2.  X-ray Imaging of the TM44/MP-107 Compound Cross at 4-months 
X-ray imaging of animals in the MP-107xTM44 male cohort at 4 months of age revealed 
that the majority of animals with at least one mutant allele, Col1a2+/107 or Col1a1+/TM44, 
exhibited a similar early phenotype to the heterozygote MP-107 (Col1a2+/107) and 
heterozygote TM44 (Col1a1+/TM44), including splayed ischia at the pelvis, a curved 
olecranon or a combination of both phenotypes. The animals with both mutant alleles 
also exhibit a similar phenotype (Col1a2+/107, Col1a1+/TM44), however the incidence is 
increased with all double heterozygotes exhibiting a phenotype (Table 7.2 and Figure 
7.2).  A single Col1a2+/107, Col1a1+/TM44 animal also exhibited the abnormal calcaneus 
phenotype (Figure 7.3), similar to the phenotype observed in some TM44 heterozygotes 
(See Chapter 5, Figure 5.15). 







 4 4 1 1 4 100% 
Col1a2+/+,  Col1a1
+/TM44
 4 3 0 0 3 75% 
Col1a2+/107, Col1a1
+/+
 4 3 1 0 3 75% 
Col1a2+/+, Col1a1
+/+
 4 0 0 0 0 0% 
 
Table 7.2. A table showing the number of animals exhibiting each phenotype, for each 













































































































































































































































Figure 7.3.  Radiographs comparing the calcaneus of a compound wild type and a 
compound heterozygote result ing from intercross matings between TM44 heterozygotes 
and MP-107 heterozygotes at 4-months. (A) The calcaneus of the Col1a2+/ +,  Col1a1+/ +  
animals appears normal,  (B) the calcaneus of the Col1a2+/ 10 7,  Col1a1+/ T M4 4  animal appears 
curved, and to have abnormal bone growth, only one of the four Col1a2 +/ 10 7 ,  Col1a1+ / T M 44  
animals exhibited this phenotype. 
 
7.2.3. DEXA Analysis of the TM44/MP-107 Compound Cross at 4-months 
DEXA analysis of animals in the MP-107xTM44 male cohort revealed that there were no 
differences between genotypes in either BMD or BMC (Figure 7.4).  The phenotyping on 
each individual lines showed that the Col1a1+/TM44 animals exhibited a significantly 
reduced BMD and BMC when compared with Col1a1+/+ animals at the 2-month early 
time point, while the Col1a2+/107 animals showed no difference in reduced BMD and 
BMC when compared with to the Col1a2+/+ animals (See Chapter 3, Table 3.11 and 
Chapter 5, Figure 5.16).  
The Col1a1+/TM44, Col1a2+/+ animals would logically behave similarly to the Col1a1+/TM44 
from the individual TM44 line, as there should be no effect of the Col1a2 allele, however 
no significant difference was found.  It is likely that this loss of effect is due to the 
experiment being underpowered, as the individual original TM44 line only contained 
two genotypes, Col1a1+/TM44 and Col1a1+/+, and this compound cohort contains 4 
genotypes and therefore an ANOVA was used.  While there is a slight variation in 







Figure 7.4. DEXA analysis of all four compound genotypes resulting from intercross matings between 
TM44 heterozygotes and MP-107 heterozygotes at 4-month. Neither (A) Bone mineral density 
(BMD) nor (B) Bone mineral content (BMC) differed between genotypes (one-way ANOVA, 
N=4 for all genotypes).  
 
7.2.4. X-ray Imaging of the TM44/MP-107 Compound Cross at 12-months 
A limited number of animals (only 1 of each genotype) were aged to 12 months of age 
and X-ray imaged. While no conclusions can be drawn due to the limited numbers, the 
Col1a2+/107, Col1a1+/TM44 and Col1a2+/+, Col1a1+/TM44 animals both displayed a knee 
phenotype observable by X-ray imaging, while the Col1a2+/107, Col1a1+/+ and Col1a2+/+, 































































































































































































































































































As seen in the individual MP-107 line phenotyping (Chapter 3, Section 6), upwards 
of 20% of heterozygotes (Col1a2+/107) show no phenotype by X-ray, so the lack of 
phenotype in the single Col1a2+/107, Col1a1 +/+ animal is not surprising.  
7.3. MP-107 x Col1a2 KO Compound Cross 
7.3.1. Viability Assessment of the Col1a2-KO/MP-107 Compound Cross 
Intercross matings between heterozygous Col1a2-KO (Col1a2+/-) and heterozygous MP-
107 (Col1a2+/107) animals were used to produce a compound cohort, which would in 
theory contain animals of the following genotypes- 
Wild type MP-107 / Wild type Col1a2-KO - Col1a2+/+ 
Wild type MP-107 / Heterozygous Col1a2-KO - Col1a2+/- 
Heterozygous MP-107 / Wild type Col1a2-KO - Col1a2+/107 
Heterozygous MP-107 / Heterozygous Col1a2-KO - Col1a2-/107 
The total number of pups was recorded at birth, and animals were genotyped at 








Table 7.3.  A table displaying the number of animals of each genotype from intercross 







Figure 7.6 .  Proportions of animals of each genotype produced from intercross matings 
between Col1a2-KO heterozygotes and MP-107 heterozygotes.  
Statistical analysis indicates that the ratios of genotypes do not differ from the expected 
Mendelian ratios (χ2= 1.83, 3df, P>0.5), and that there are no lethal phenotypes 
observed in this cross. 
The homozygote MP-107 (Col1a2107/107) was non-viable, so the fact that the double 
heterozygote (Col1a2-/107) is viable is intriguing.  It suggests that the MP-107 mutation is 
a dominant negative mutation and indicates that the mode of action of the mutation is 





7.3.2. X-Ray Imaging of the Col1a2-KO/MP-107 Compound Cross at 4-Months 
X-ray imaging of animals in the MP-107/Col1a2-KO male cohort at 4 months of age 
revealed that only animals containing a mutant MP-107 allele (Col1a2+/107 or Col1a2 -
/107) exhibited any phenotype and then the incidence was only 25%. No evidence of 
splayed ischia at the pelvis was observed, and a curved olecranon was observed in each 
of the Col1a2+/107 and Col1a2-/107 animals (Table 7.4 and Figure 7.7).  It should be noted 
that this cohort only contained two Col1a2+/+ animals. No animals displayed the 
abnormal calcaneus. However, as this phenotype has only been observed in 
heterozygote TM44 animals (Col1a1+/TM44) or animals with a compound genotype 
containing Col1a1+/TM44, it would not be expected to appear in this compound cross. 





Col1a2-/107 4 0 1 0 1 25% 
Col1a2+/- 4 0 0 0 0 0% 
Col1a2+/107 4 0 1 0 1 25% 
Col1a2+/+ 2 0 0 0 0 0% 
 
Table 7.4. A table showing the number of animals exhibiting each phenotype, for each 
genotype in the phenotyping cohort resulting from the Col1a2-KO and MP-107 intercross.  
Both the heterozygote MP-107 (Col1a2+/107) and heterozygote Col1a2-KO (Col1a2+/-) 
animals from the individual lines showed a degree of variability in the phenotype. 
However, in this cross in both genotypes, where there should be no impact from the 
other allele: Col1a2+/107 and Col1a2+/- the incidences are much lower than seen in the 
individual line. Col1a2+/107 in the MP-107 line was 80% affected at early time points, but 
in this compound cross only 25% affected. Col1a2+/- in the Col1a2-KO line was 40% 
affected at early time points, but in this compound cross 0% affected. It is unlikely that 
this is due to the different genetic backgrounds of the progenitor lines, as both were 
congenic on their respective background and therefore a reduction in both compound 
heterozygotes (Col1a2+/107 and Col1a2+/-) would not be expected if the backgrounds 
were the cause. It is possible that the reduced percentage of affected animals is due to 
the small cohort size, with only 4 animals of each of these compound heterozygotes 




























































































































































































7.3.3. DEXA of the Col1a2-KO/MP-107 Compound Cross at 4-Months 
DEXA analysis of animals in the MP-107/Col1a2-KO male cohort at 4 months of age 
revealed that there were no significant differences in BMD or bone mineral content in 
any of the genotypes. (Figure 7.8).   It should be noted that this cohort only contained 
two Col1a2+/+ animals, and therefore the statistical testing should be interpreted with 
caution. The one-way ANOVA was repeated both with and without this genotype and in 
neither case were any differences detected. As there was no DEXA phenotype detected 
in either of the individual lines, it is not surprising that a phenotype is not detected here. 
However, as the cohort size here was similar to that used in (Section 7.2.3) and would 
therefore have the same limitation of power, a larger cohort would be required to rule 
out any additive effects of the two mutant alleles.   
 
Figure 7.8. DEXA analysis of all four compound genotypes resulting from intercross 
matings between TM44 heterozygotes and MP-107 heterozygotes at 4-month. Neither (A) 
Bone mineral density (BMD) nor (B) Bone mineral content (BMC) differed between 





7.4. TM44 x Col1a2 KO Compound Cross 
7.4.1. Viability Assessment of the TM44/Col1a2-KO Compound Cross 
Intercross matings between heterozygous TM44 (Col1a1+/TM44) and heterozygous 
Col1a2-KO (Col1a2+/-) animals were used to produce a compound cohort, which would 
in theory contain animals of the following genotypes- 
Wild type Col1a2-KO / Wild type TM44 - Col1a2+/+, Col1a1+/+ 
Heterozygous Col1a2-KO / Wild type TM44 - Col1a2+/-, Col1a1+/+ 
Wild type Col1a2-KO / Heterozygous TM44 - Col1a2+/+, Col1a1+/TM44 
Heterozygous Col1a2-KO / Heterozygous TM44 - Col1a2+/-, Col1a1+/TM44 
The total number of pups was recorded at birth, and animals were genotyped at 
weaning, at approximately P21 (Table 7.5 and Figure 7.9).   
 
Genotype Number 
Col1a2-/+, Col1a1+/TM44 11 
Col1a2+/+, Col1a1+/TM44 12 
Col1a2-/+, Col1a1+/+ 9 
Col1a2+/+, Col1a1+/+ 15 
 
Table 7.5.  A table displaying the number of animals of each genotype from intercross 







Figure 7.9.  Proportions of animals of each genotype produced from intercross matings 
between Col1a2-KO heterozygotes and TM44 heterozygotes.  
 
Statistical analysis indicates that the ratios of genotypes do not differ from the expected 
Mendelian ratios (χ2= 1.60, 3df, P>0.5), and that there is no lethal phenotype in this line. 
As noted earlier in this chapter the Col1a2+/107, Col1a1+/TM44    animals arising from the 
intercross between heterozygous TM44 (Col1a1+/TM44) and heterozygous MP-107 
(Col1a2+/107) animals exhibited some level of lethality.  In this line, the mutant Col1a2+/107 
allele is replaced by a null Col1a2+/- and this prevents the lethal phenotype.  Again, it 
suggests that the MP-107 mutation is a dominant negative mutation and indicates that 
the mode of action of the MP-107 mutation is via the presence of the mutant protein, 
not the lack of wild-type protein. 
7.4.2. X-ray Imaging of the TM44/Col1a2-KO Compound Cross at 4-Months 
X-ray imaging of animals in the Col1a2-KO/TM44 male cohort at 4 months of age 
revealed that all animals with a mutant TM44 Col1a1 allele (Col1a1+/TM44) exhibited a 
similar early phenotype to the heterozygote TM44 (Col1a1+/TM44), including splayed 
ischia at the pelvis, a curved olecranon, or a combination of both phenotypes, whether 




Additionally, one animal of each of these genotypes (Col1a2+/-, Col1a1+/TM44) and 
Col1a2+/+, Col1a1+/TM44) exhibited the abnormal calcaneus phenotype observed in the 
original TM44 line (See Chapter 5, Figure 5.15) and in the TM44/MP-107 compound 
cross (Figure 7.3) 
The animals with a null Col1a2 allele (Col1a2+/-), without the presence of a mutant 
Col1a1 allele (Col1a1+/TM44) exhibit no phenotype, a lower incidence to what was 
previously seen in the individual line (40%) and similar to the effect seen in the 
MP107/Col1a2-KO compound cross (See Section 7.3.2).  
As with the MP107/Col1a2-KO compound cross, the lines crossed here were on different 
genetic backgrounds, with TM44 being incipient congenic on C3H, and Col1a2-KO being 
congenic C57BL/6N. The addition of C57BL/6N genome to the animals with the TM44 
mutant allele (Col1a2-/+, Col1a1+/TM44 and Col1a2+/+, Col1a1+/TM44) has not reduced the 
percentage of affected animals.  
The animals with added C3H to their C57BL/6J genome (Col1a2+/-, Col1a1+/+and 
Col1a2+/+, Col1a1+/+) showed no phenotypes although only the Col1a2+/-, Col1a1+/+ 
animals would be expected to display a phenotype, and only 40%. While it is possible 
that the addition of C3H is responsible for the reduction in affected animals, it is equally 
possible that this is due to the small cohort size.  
 









 4 3 0 1 4 100 % 
Col1a2+/+, Col1a1
+/TM44





 4 0 0 0 0 0% 
Col1a2+/+, Col1a1
+/+
 4 0 0 0 0 0% 
 
Table 7.6. A table showing the number of animals exhibiting each phenotype, for each 

















































































































































































































7.4.3. DEXA Analysis of the TM44/Col1a2-KO Compound Cross at 4-Months 
DEXA analysis of animals in the TM-44/Col1a2-KO male cohort at 4 months of age 
revealed that there were no significant differences in BMD or bone mineral content in 
any of the genotypes. (Figure 7.11).   
 
 
Figure 7.11.  DEXA analysis of all  four compound genotypes resulting from intercross 
matings between TM44 heterozygotes and Col1a2-KO heterozygotes at 4-month. Neither 
(A) Bone mineral density (BMD) nor (B) Bone mineral content (BMC) differed between 
genotypes (One-way ANOVA N=4 for al l genotypes). 
As mentioned previously (See Section 7.2.3), it is possible that the statistical testing here 
may be underpowered to observe if there is a difference in this cohort. 
7.5. Discussion 
The compound cross experiment revealed interesting insights into the mutations and 
their modes of action. As noted in previous chapters, Col1a1 +/TM44 and Col1a2 +/107 




compound cross between the MP-107 and TM44 (Col1a2+/107, Col1a1+/TM44) indicates 
that there is some interaction between the mutant genes.  It also provides additional 
confirmation that the mutations are causative. 
The double heterozygotes from the compound cross between the Col1a2-KO and TM44 
(Col1a2+/-, Col1a1+/TM44) were viable. Thus, comparing the 2 double heterozygotes, 
(Col1a2+/107, Col1a1+/TM44 and Col1a2+/-, Col1a1+/TM44), the mutant Col1a2+/107 allele in 
(Col1a2+/107, Col1a1+/TM44), is replaced by a null Col1a2+/- in (Col1a2+/-, Col1a1+/TM44), and 
this restores the viable phenotype.  This reflects the nature of the mutation in MP-107, 
as its presence in tandem with the TM44 mutation is more deleterious than the presence 
of the TM44 mutant allele and a null Col1a2 allele.   
The compound cross experiment revealed that the Col1a2+/107, Col1a1+/TM44 animals 
were less viable than either Col1a2+/107 animals or Col1a1+/TM44 animals confirming 
epistasis between mutant genes. This experiment also revealed that the Col1a2 -/107 was 
less deleterious than Col1a2107/107, which indicates that the MP-107 mutation is likely a 
gain of function mutation, possibly acting as a dominant negative. The presence of a 
single mutant Col1a2 allele and a null allele was less deleterious than two copies of the 
mutant Col1a2 allele, which indicates that the severity of phenotype is related to the 
quantity of mutant protein, rather than the absence of wildtype protein. 
Due to the variable nature of the phenotypes, the small cohort sizes and the limitations 
of X-ray imaging, drawing conclusions from the X-ray imaging data of the compound 
crosses is difficult. Table 7.7 shows collated incidence of early phenotype across the 





  TM44 MP-107 Col1a2-KO 
  Col1a1
+/+ Col1a1+/TM44 Col1a2+/+ Col1a2+/107 Col1a2+/+ Col1a2+/- 
TM44 
Col1a1+/+ 0% 100% c 0% 75% 0% 0% 
Col1a1+/TM44 100% c N/A 75% 100% a 100% 100% 
MP-107 
Col1a2+/+ 0% 75% 0% 80% 0% b 0% 
Col1a2+/107 75% 100% a 80% N/A 25% 25% 
Col1a2-KO 
Col1a2+/+ 0% 100% 0%b 25% 0% 40% 
Col1a2+/- 0% 100% 0%g   25% 40% 67% 
 
Table 7.7.  A table displaying the incidence of early phenotype in the lines TM44, MP-107 
and Col1a2-KO, and the compound l ines.  The unshaded boxes indicate the data from the 
individual lines (with grey shading where the animals were non-viable). Green shading 
indicates the data from the MP-107 x TM44 cross, blue shading indicates the data from 
the Col1a2-KO x TM44 cross, and yellow shading indicates the data from the Col1a2-KO x 
TMP-107 cross.  a  indicates that the genotype had reduced viability,  b  indicates only 2 
animals were X-rayed. c  It should be noted that in the case of heterozygous TM44 
(Co1a1+/ TM 4 4) animals from original cohort, although 100% of the early cohort exhibited 
an early phenotype,  some of the 12-month old cohort did not exhibit any of the early  
phenotypes (ischia/olecranon/calcaneus) and therefore this 100% incidence is a snapshot 
and is not a true representation of all Co1a1+ /T M 44  animals.  
It is clear that the TM44 line has the highest incidence of phenotypes detectable by X-
ray in the individual lines, followed by MP-107 and then by Col1a2-KO, where even the 
homozygous animals had a lower incidence than the heterozygotes of the other two 
lines (Table 7.7, white boxes).  Any compound cross genotype which contained a single 
Col1a1 allele (Col1a1+/TM44) in any of the genotypes in the compound crosses causes the 
highest incidence within each compound cross, with a lower incidence of 75%. The 
compound cross of MP-107 and Col1a2-KO contains the lowest incidence of X-ray 
phenotypes, with animals containing an MP-107 mutant allele (Col1a2+/107) having an 
incidence of only 25%, much lower than the 80% seen in the individual line MP-107 
(80%). The animals with the Col1a2-KO allele in the absence of any other mutant allele 
(Col1a2-/+ and Col1a2-/+, Col1a1+/+) show incidence of 0%, compared with 40% for 
heterozygotes from the Col1a2-KO line (Col1a2-/+). It is possible to explain this variance 
due the inherent variances in the phenotypes in all three lines, and the limitations of 










8.1. Summary of Results 
To summarise these results, each line will be addressed individually before discussing 
how each of these lines provides information about the other and leads to general 
synthesis and conclusions. 
8.1.1. MP-107 
The majority of this thesis has focused on the line MP-107. The direction of the project 
changed over time, from identifying the causative gene behind the observed phenotype 
in the original cohort, to identifying a range of other phenotypes in a wide range of 
tissues and the mechanisms underlying the observed phenotypes. There were a number 
of complicating factors in this investigation including alternative splicing, resulting in 
variable levels of mutant transcript, and in the case of homozygous mutant, wild-type 
transcript in the absence of the wild-type genomic sequence; variable phenotypes 
between animals of the same genotype; and the possibility that some phenotypes could 
be secondary to one or more other phenotypes. 
Initial phenotyping of MP-107 revealed the presence of two early phenotypes, a curved 
olecranon at the elbow, and splayed ischia at the pelvis and a third late onset phenotype 
at the knee involving abnormal bone growth and cartilage erosion.  
8.1.1.1 Causative mutation in MP-107 
A T to A transversion was identified at position 4521226 of Chromosome 6. The effect 
of this splice region variant was the incorporation of three intronic bases into the exon 
as an extra amino acid, which disrupted the repeating glycine motif. A large proportion 
of osteogenesis imperfecta cases are caused by glycine substitutions, which also cause 
the repeating glycine motif to be disrupted [46-48].  
Further analysis of the cDNA using both PCR and qPCR revealed that even in the absence 
of wild-type genomic sequence, wild-type cDNA was produced indicating that the 
original splice acceptor site was used, in addition to the novel splice acceptor site, albeit 
at a far lower rate. From the data obtained, it appeared that the levels of mutant and 
wild-type transcript varied. Genotyping of affected and unaffected animals revealed 
that there was a degree of variability in the phenotypes, including heterozygotes, which 




phenotype could be linked with the level of mutant, or wild-type transcript, but this has 
not been shown here. However, expression of Col1a1 was shown to be downregulated 
in the homozygotes compared with both the wild types and heterozygotes. Col1a1 
expression has previously been found to be downregulated in chondrocytes of a mouse 
model of OI with a mutation in Col1a2 (G610C) [250]. 
8.1.1.2 Homozygous Lethal Phenotype of MP-107 
Homozygous animals were found to have a perinatal lethal phenotype. Homozygous 
embryos were viable at 18.5 dpc, however some homozygous pups were identified in 
‘respiratory distress’ at P0. Approximately a quarter of pups from intercross matings 
went missing shortly after birth.  It is likely that this was causing the gasping phenotype 
observed in some homozygotes, which in turn caused the death of the homozygotes. 
The disappearance is likely due to the mothers consuming the cadavers soon after 
death. An OI mouse model (Brtl),  with a mutation in Col1a1, has previously been 
reported to die shortly after birth from respiratory distress [250]. 
8.1.1.3 OI phenotypes of MP-107 
In addition to the mild bone abnormalities including curved olecranons and splayed 
ischia in the heterozygous animals, other bone phenotypes were detected, including a 
reduced BMD in female heterozygotes at 12 months of age. Due to the possible 
confounding effect of the mixed background, further phenotyping was carried out on 
incipient congenic cohorts, with a cleaner C3H/HeH background, particularly as 
C57BL/6J animals have been shown to have lower BMD than C3H/HeH or F1 hybrids 
[271]. The BMD phenotype was replicated in some cohorts, but not others and a lowered 
BMC phenotype was noted in two cohorts.  
Three-point bending of humeri showed a decrease in maximum flexural load and work 
to fracture in the heterozygous animals. Analysis of the trabecular bone of the epiphysis 
and metaphysis showed a number of differences between genotypes including in the 
bone volume fraction, trabecular number, trabecular separation and trabecular 
thickness. Taking all of these bone phenotypes together, in addition to the bone 
breakages identified in some heterozygous animals, by X-ray and µCT imaging, it appears 
that a mild type IV OI phenotype is present in the heterozygotes.  Additionally, the mild 




seen in an OI model, Brtl, which have been attributed to fractures [80]. The Brtl model 
has a glycine substitution in Col1a1and exhibits  variable phenotypes including similar 
ischia and olecranon phenotypes and some lethality. The lethal phenotype of the MP-
107 homozygotes, coupled with the evidence of bone breakage in utero, indicates a 
more severe OI phenotype than the type I/IV seen in heterozygotes, similar to type II OI 
in humans. The presence of an OI phenotype is perhaps not surprising given that 
approximately 90% of cases of OI in humans are due to mutations in either COL1A1 or 
COL1A2 [53], the vast majority of which affect the repeating glycine motif.   
8.1.1.4 EDS phenotypes of MP-107 
Mechanical testing of skin and tendons revealed that both tissues have altered visco-
elastic properties. There was no difference in the load at rupture in either tissue, 
however the skin appeared to be hyperextensible, likely due to the removal of the 
macroscopic crimp followed by straightening of molecular kinks in the gaps between 
Collagen molecules [36]. The radio labelling experiment indicated that there was no 
observable difference between the genotypes either intracellularly or extracellularly, 
indicating that the mutant protein is being secreted. Pepsin digestion and Coomassie 
staining of tendon fascicles also indicated that there was no difference in α1/ α2 ratio, 
indicating that the collagen I in the heterozygous tendons is heterotrimer. Tendon 
fascicles underwent DSC analysis, which revealed a difference in the dry entropy of the 
samples suggesting that the collagen molecules are less confined within the fibril 
structure [271, 297]. Together these results indicate that mutant α2 chains are being 
incorporated into the collagen fibrils.  The DSC data suggests that the mutation may be 
causing micro-unfolded regions within the molecule, making them less stable, and 
therefore requiring less energy to break apart the collagen I molecule [73]. It is therefore 
likely that the altered mechanical properties are a result of this micro-unfolding at the 
site of the repeating glycine motif disruption. This could explain why the initial elastic 
slope differs between genotypes, but the elastic slope does not (see section 4.2.3). 
Additionally, the TEM imaging of tendon revealed that the homozygous and 
heterozygous tendons had a reduced number of fibrils compared to wild-type tendons, 
which could also alter the mechanical properties. A reduction in the number of fibrils 




the amount of water that can be retained. This implies an EDS, or EDS like phenotype, 
as two common phenotypes shown by patients with EDS are hyperextensible skin, and 
ligament laxity leading to joint hypermobility [298].  
8.1.1.5 OA phenotypes of MP-107 
The heterozygous MP-107 (Col1a2+/107) animals showed ossification of the collateral 
ligaments and synovium, from as early as 4 months in the female animals and 9 months 
in the males by µCT, although it should be noted that no tissue from animals between 
these time points underwent µCT analysis. Significant differences were detected 
between the genotypes at the early time points due to the lack of any ossification in the 
wild types, however at 18 months there was evidence of some minor ossification in the 
wild types, which is not surprising as the incidence of ossified ligaments in human 
increase with age [299, 300]. Between 80% (female) and 100% (male) of heterozygotes 
exhibited severe ossification, and between 20% (female) and 50% (male) of wild types 
exhibited some mild ossification (see Chapter 3, Figure 3.38 for a comparison). As this 
analysis was based on the presence or absence of the ossification, rather than severity, 
no significant difference was detected at 18 months. A volumetric analysis of this 
ossified tissue, would likely remedy this [257]. Ossification and inflammation of the 
synovium was noted in histological sections of heterozygotes in the 12- and 18-month 
cohorts. 
OARSI scoring of histological sections of the knee revealed that in both males and 
female, the heterozygotes had significantly higher scores at 18 months than their wild 
type counterparts, confirming the OA phenotype. It is worth noting that the ligament 
and synovium changes in heterozygotes precede the cartilage damage.  Ramos-Mucci et 
al., reported increased volume of mineralised tissue in joint space, and increased 
ossification of the meniscus and collateral ligaments in animals with spontaneous and 
induced OA [257].  
The ossification of ligaments occurring before the cartilage damage in MP-107, does not 
necessarily indicate causation, but this would be worthy of further investigation. It has 
been suggested that pathological calcification of joint tissues is likely a disease initiator, 
for example there is a strong association between the presence of calcium crystals in 




tissues could disrupt normal mechanoadaptive joint responses and lead to increased 
levels of potentially pro-inflammatory crystals in the synovial fluid [301, 302]. 
OA was surgically induced using DMM surgery on a small cohort of animals. There was 
a large degree of variability in the levels of OA that were produced, meaning that no 
significant difference was detected. Due to the variability in phenotype observed in the 
heterozygotes, it is extremely likely that this experiment was underpowered. Animals 
were culled 6 weeks post-surgery; it is likely that a stronger effect would have been seen 
if there had been a longer period between the surgery and culling of the animals[278]. 
Analysis of µCT data in Chapter 3 demonstrated an increased incidence of abnormal 
bone growth in heterozygotes when compared to wild types at multiple time points, and 
this is similar to what is seen in the DMM surgical model of OA.  The histological analysis 
in Chapter 3 also indicated that the osteophyte formation in heterozygotes preceded 
cartilage changes, and that may also be the case with this DMM experiment. However, 
to further investigate this, a longer period of time between surgery and harvesting tissue 
should be used. 
Micro-indentation analysis of the femoral condyles revealed a significant increase in 
structural stiffness in the medial femoral condyle of the heterozygotes compared with 
the wild types. No difference was detected in the lateral femoral condyles or the tibial 
plateaux. It should be noted that while the indenter was applied to the cartilage, the 
subchondral bone will have an effect, and therefore this difference cannot be attributed 
to a single tissue. 
8.1.1.6 ER stress phenotypes in MP-107 
TEM imaging revealed the presence of dilated ER in homozygous and heterozygous 
tenocytes.  Cell lysates of MEFs harvested from 12.5 dpc embryos of all genotypes, were 
probed with BIP, a marker of ER stress, which indicated that homozygotes and 
heterozygotes had increased levels of ER stress compared to wild types. IHC was 
undertaken on 18-month knee sections, again using an Anti-BIP antibody, and DAB 
staining revealed evidence of ER stress in the chondrocytes of the heterozygous articular 
cartilage. Combined with the evidence that the mutant protein is secreted rather than 




collagen folding process. The G610C mouse of OI, which has a glycine substitution in 
Col1a2, exhibits ER stress in the chondrocytes and osteoblasts [250]. 
Chondrocytes are particularly sensitive to ER stress, due to their secretory role, and ER 
stress has been associated with OA [70]. BIP has also been reported to be upregulated 
in osteoarthritic tissue in both humans and mice [276, 303]. For this reason, the sections 
used for the IHC experiment were from a heterozygote that did not show signs of OA, 
to reduce the risk of ER stress being secondary to the OA itself. However, further 
experiments with additional samples are required to be able to draw conclusions. 
 
8.1.2. TM44 
6.1.1.1. Causative mutation in TM44 
Mapping of affected animals and unaffected controls identified a region on 
Chromosome 11; exome sequencing revealed two mutations, which were confirmed by 
Sanger sequencing. Subsequent segregation of mutations revealed the causative 
mutation as a nonsense mutation causing a premature stop codon in Exon 31 of the 
gene Col1a1.   
8.1.2.1 Bone Phenotypes of TM44 
Phenotyping of the line TM44 was not as extensive as MP-107. Nevertheless, initial 
phenotyping of TM44 revealed the presence of similar early phenotypes to those 
observed in MP-107, including a curved olecranon at the elbow, and splayed ischia at 
the pelvis, abnormal bone growth and cartilage erosion in the knee. Three animals also 
exhibited abnormal calcaneus.  The phenotypes observed were variable, as seen in MP-
107, however every heterozygote TM44 animals in the studied cohort displayed at least 
one of the bone phenotypes.  
DEXA analysis indicates that the heterozygotes (Col1a1+/TM44) have significantly lower 
BMD and BMC in both sexes at 2 months of age, indicating that the animals are 
osteopenic. The presence of similar phenotypes at the olecranon and pelvis, to those 
seen in models of OI (Brtl), OI/EDS overlap (Jrt) and MP-107, which have been attributed 
to bone breakage, coupled with this observed osteopenic phenotype indicates an OI 




(seal), 50% of homozygous animals exhibited swollen heels and footpads due to 
pathological fractures, which could explain the phenotype at the calcaneus of this line 
[304]. 
8.1.2.2 OA Phenotype of TM44 
100% of animals exhibited abnormal bone growth at the knee by 12 months, indicating 
an earlier onset disease, although OARSI scoring was only performed at 18 months, so 
it is not possible to confirm the large deposits of abnormal bone were coinciding with 
cartilage degradation at the earlier time point.  At 18 months 100% of the heterozygotes 
displayed evidence of OA, a higher proportion than observed in MP-107.  
8.1.2.3 Homozygous Lethal Phenotype of TM44 
 The homozygous embryos were found to be lethal between 12.5 and 14.5 dpc and 
showed evidence of hydrocephalus, similar to the Mov-13−/− model of Type II OI, which 
is recorded as having arrested development between day 11 and day 12 of gestation 
around the time when high transcription of Col1a1 occurs, and death shortly [294]. 
8.1.2.4 EDS or Col1 Related Overlap Phenotype of TM44 
Analysis of tendon collagen extracts reveals that the α1/ α1 ratio is similar between 
genotypes (and to MP-107) indicating that homotrimer is not formed, and the molecular 
weight of the α1 band is also similar, indicating that a truncated protein is not present. 
This indicated that the mutant protein is unlikely to be able to trimerise, and is likely 
removed by ERAD. Likely leading to a reduction of collagen I produced. Further work is 
required to establish if this is in fact the nature of the TM-44 mutation. 
There are examples of similar nonsense mutations in Exon 31 leading to OI (Type I/IV) in 
humans [305, 306] and to Col1-related overlap disorder [80, 115]. Due to the 
phenotyping analysis on TM44 being limited in scope, it is not possible to discern what 






8.1.3.1 Bone Phenotypes of Col1a2-KO 
As with TM44, phenotyping of the line Col1a2-KO was not as extensive as MP-107. 
However, initial phenotyping of Col1a2-KO revealed the presence of similar early 
phenotypes to those observed in MP-107 and TM44, including a curved olecranon at the 
elbow, and splayed ischia at the pelvis.   These phenotypes were present in both 
homozygous and heterozygous animals.  No difference in BMC or BMD was detected. 
Nevertheless, as shown for MP-107, this does not mean that the bones are not 
osteopenic, just that any difference is not detectable by whole body DEXA analysis. 
8.1.3.2 OA Phenotype of Col1a2-KO 
No heterozygotes or homozygotes were identified as having abnormal growth at the 
knee at 12 months. Animals were not aged further so it is not possible to say whether 
Col1a2-KO animals, either heterozygotes or homozygotes would have gone on to 
develop abnormal bone formation at the knee or an OA phenotype. 
8.1.3.3 EDS or Col1 Related Overlap Phenotype of Col1a2-KO 
The collagen analysis of tendons, confirmed that in the homozygote, the collagen I in 
tendon was homotrimer, and both heterotrimer and homotrimer were present in the 
heterozygote tendons.   
8.1.4. Genetics 
The viability of the Col1a2-KO homozygotes (Col1a2-/-) indicates that the absence of 
COL1A2 protein is less deleterious than the mutation seen in MP-107, where 
Col1a2107/107 animals were not viable. Moreover, the presence of a single mutant MP-
107 Col1a2 allele and a null allele in the double mutant (Col1a2-/107) was less deleterious 
than two copies of the mutant Col1a2 allele, which indicates that the severity of 
phenotype is related to the quantity of mutant protein, rather than the absence of wild-
type protein. 
In addition the compound cross experiment revealed that the  Col1a2+/107, Col1a1+/TM44 
animals were less viable than either Col1a2+/107 animals or Col1a1+/TM44 animals 
confirming epistasis between mutant genes. Overall, we can conclude from the 





8.2. Overall Conclusions 
All three lines show evidence of an OI phenotype. The more thorough phenotyping of 
MP-107 allows a more in-depth analysis of this model. The Col1a2-KO appears to have 
a mild type I/IV OI phenotype in both heterozygotes and homozygotes. The TM44 
heterozygotes also appear to have a type IV OI phenotype, with late onset OA, and the 
homozygotes appear to have a type II OI phenotype, it is important to note that this line 
did not undergo phenotyping which would reveal the presence of an EDS phenotype so 
this cannot be ruled out.  The MP-107 homozygotes, have an OI type II phenotype, and 
the heterozygotes have an OI, EDS and OA phenotype. Due to the presence of both OI 
and EDS phenotypes, it is likely that this line is a model for Col1-related overlap disorder. 
The cause of the OA phenotype in the MP-107 line and TM44 line is not entirely clear.  
There is more evidence for possible mechanisms in the MP-107 line, due to the variety 
of phenotyping procedures undertaken. 
As previously stated, OA is a disorder involving the whole joint, and many of the tissues 
that make up the joint are made up of collagen I. It is therefore highly likely that 
abnormal collagen I could alter the behaviour, and interactions of these tissues. 
A large proportion of ligament, tendon, joint capsule and meniscus are composed of 
collagen I fibres.  Mechanical testing of tendons provided evidence that in MP-107 
heterozygous fascicles, the hysteresis is reduced, making tissues less effective at 
absorbing energy. The collagen I tissues within the joint all play a stabilising role in the 
knee joint, to varying degrees.  Ossification of soft tissues is often a response to trauma, 
micro trauma or repetitive mechanical stress [307]. Therefore the ossification of the 
ligaments, which precedes the cartilage erosion, could be a sign that the joint is not 
behaving normally. Ossification in tendons and meniscus is known to occur in animals 
with OA, however it is not known which process precedes the other [257]. It is also 
known that modifying the heterotypic nature of tendons, such as targeted deletion of 
Collagen V, can result in EDS and early onset OA [104]. 
The EDS phenotypes seen in the skin and tendon may indicate that there is a level of 




predictor of developing OA [308-310]. Patients with EDS are at a far higher risk of 
complications of hypermobility which include symptomatic subluxation, dislocation, and 
tendon ruptures [298]. It is therefore possible the OA observed in the MP-107 line could 
be secondary to joint injury. Although there is little published evidence that inherited 
hypermobility predisposes to OA in humans, Sun et al. have shown that a mouse model 
of classic EDS, does exhibit OA [104]. 
The µCT of MP-107 heterozygotes revealed altered subchondral trabecular bone. The 
relationship between articular cartilage and subchondral bone is well established. 
Additionally, it has been shown in multiple cases that abnormal COL1A1 and COL1A2 can 
lead to altered mineralisation and affect osteoblast differentiation, which could modify 
the remodelling process that occurs in the subchondral bone 
The presence of markers for ER stress in the chondrocytes of heterozygotes, could 
indicate that the mutation may be having an effect on the chondrocytes which could 
then lead to apoptosis, or impede the ability of the chondrocytes to modulate 
homeostasis. Chondrocytes produce collagen I as a minor ECM collagen and it is 
therefore not surprising that a collagen processing delay may cause knock on affects in 
this tissue.  The Aga model of OI leads to osteoblast ER-stress mediated apoptosis [71]. 
A simple mechanical explanation for the development of OA could be that the breakage 
in the pelvis, could be leading to an abnormal gait, which in turn causes abnormal 
loading, and OA.  This is unlikely to be the cause due to the OA phenotype occurring in 
animals, which did not exhibit the splayed ischia phenotype, however gait analysis could 
be used to investigate if this is the case.   
The possible mechanisms listed above are all direct results of the collagen I mutations, 
however there are instances where mutations in collagen I lead to dysregulation of other 
genes, which could lead to altered cartilage or bone homeostasis; these possibilities will 
be discussed in the next section. 
8.3. Implications for the Study of Osteoarthritis 
One of the aims of this project was to elucidate the mechanism by which the mutations 
in either of the collagen I genes resulted in OA. The experiments have shown lots of 




phenotype observed in our mice. Some of these mechanisms have been discussed in the 
previous chapter. However, the interaction of the tissues within the joint has been 
shown to play a role in OA [161], and it is therefore possible  the changes observed could 
be leading indirectly to OA. For example, cross-talk of bone and cartilage at the 
osteochondral junction is known to occur, and therefore the OI phenotype and changes 
to the subchondral trabecular bone may influence the biomechanical response to joint 
loading indirectly [311]. 
Figure 8.1. shows many of the interactions between the joint tissues that can have an 
effect on the progression of OA.  
 
 
Figure 8.1.  A representation of an osteoarthrit ic knee, including the main contributing 
tissue and their interactions. Articular carti lage loss typifies OA but the exact balance of 
tissue involvement and interaction is dependent on both joint site and OA subtypes. 
Taken from Mimpen and Snelling, 2019 [312].   
OA is a disease of the joints, and involves all the tissues of the joint. Given so many of 
the components of a joint are tissues which contain collagen I, it is perhaps surprising 
that the genes COL1A1 and COL1A2 have not been found to be associated with OA, with 




was found between COL1A2 and hip OA [313]. This study is likely underpowered, 
however, due to the nature of a founder population, mutations are more likely to be 
replicated within the population. Loughlin et al., found a weak association between 
COL1A1 and OA, however upon correcting for multiple testing the result was not 
significant [314]. It is therefore possible that mutations in collagen I genes may be having 
an effect on a small subset of patients, making them more difficult to identify. 
It is feasible that the mutation in Col1a1 or Col1a2 is impairing a cartilage repair process 
within the osteoarthritic cartilage. Several different studies have shown that 
chondrocytes in OA cartilage express matrix genes that are expressed at very low levels, 
or not at all, in normal cartilage, including collagen I genes [315-318]. Styczynska-Soczka 
et al. suggest that the increased production of collagen type I during cartilage 
degeneration implies that there may be a change in the differentiation status of some 
chondrocytes towards a fibroblastic phenotype. They also suggest that a mechanically 
weak fibro-cartilaginous repair tissue is present in otherwise macroscopically non-
degenerate human cartilage, which then degenerates [319]. Miosge et al. found that the 
levels of collagen type I mRNA were increased as the degeneration worsened, 
supporting the conclusion that collagen type I gradually becomes one of the factors 
involved in the pathogenesis of OA [315]. Impairment of a repair process could certainly 
explain the severity of the late onset OA phenotype that the MP-107 animals develop.  
The line MP-107 was noted to exhibit signs of ER stress in tenocytes, fibroblasts and 
chondrocytes. This ER stress may lead to ER stress mediated apoptosis of these cells, 
which could result in altered cartilage homeostasis and degeneration [71]. Apoptosis is 
observed in OA, but it is not clear if it is the cause of irreversible cartilage degeneration 
or if it is initiated by it [320, 321]. Nevertheless, Uehara et al. demonstrated that ER 
stress induced apoptosis contributes to articular cartilage degradation using a Chop 
knockout [322]. 
The surgical induction of OA in the line MP-107 was inconclusive and would need to be 
repeated in an appropriately powered study. 
It appears that in the line MP-107 the ossification of the soft tissues including the 
synovium, ligaments and capsule precedes the destruction of the cartilage, however as 




histology it is not possible to say with certainty that it precedes the degradation of 
cartilage. While it may not be the case that the bone changes precede cartilage 
destruction in other models or in OA patients, it could prove a useful tool for 
investigating the downstream effects of this ossification including alterations to the 
synovial fluid, both from the release of crystallites, and the impairment of the type A 
and B cells in the synovium. 
Finally, Bianchi et al., showed that modification of Col1a1 can affect cytoskeletal 
organization, affecting osteoblast proliferation, collagen deposition, integrin and TGF-β 
signalling [81]. It would therefore be prudent to investigate if this is having an effect on 
the pathogenesis of OA as TGF-β levels have been found to be elevated in the synovial 
fluid of OA patients and TGF-β is thought to play a role in synovitis [323-326]. While the 
elevated TGF-β levels may be part of a pro-repair mechanism, other downstream effects 
of altering Col1a1 expression should be investigated.   
There are many ways in which a mouse model that develops late onset OA could be used 
to help elucidate the mechanisms that lead to OA, either due to the genetic component, 
or the mechanical or chemical pathways identified. For example, studies have shown 
that genetic predisposition to hip OA is often due to altered shape of the joint, leading 
to altered mechanical load [327, 328]. It is possible that a similar mechanism is 
happening here, and modelling the joint to investigate change associated with the 
genetic changes could elucidate mechanisms leading to OA.  
8.4. Implications for the Study of OI/ EDS 
Generally the mechanisms causing OI as a result of mutations in Collagen I genes are 
fairly well understood, and it is unlikely that the work discussed here will have much of 
an impact in the field of OI as a single disorder, additionally there are many mouse model 
of OI caused by mutations in Collagen I genes. 
 Classical EDS and vascular EDS  are very rarely caused by mutations in Collagen I genes, 
the more common types of EDS caused by mutations in Collagen I genes are 
arthrochalasia EDS and cardiac-valvular EDS.  There are no mouse models of EDS caused 




the understanding of how mutant collagen I affects the material and mechanical 
properties of collagen rich tissues, such as skin, tendons and ligaments. 
OI/EDS overlap, or Col-1 overlap disorder, appear to be almost exclusively caused by 
mutations in Collagen I genes, and therefore these mouse lines would be a useful 
resource to help understand the development of this disorder and why it appears to be 
distinct from the both OI and EDS.  
8.5. Future Work 
The work detailed here has not been able to elucidate the specific mechanism by which 
mutations in Col1a1 and Col1a2 lead to OA, only possible mechanisms.  Were time not 
limited, several avenues of investigation could have been undertaken. 
8.5.1 Further Study of Bone Phenotypes 
The bone phenotyping undertaken in this study was limited to mechanical testing and 
µCT imaging and analysis. However, the µCT work undertaken in this study did not 
investigate the structure of cortical bone. However, the mechanical testing of humeri 
indicated that there were differences in the mechanical properties in the cortical bone. 
Further µCT analysis of cortical bone provides information about why the MP-107 
heterozygote bones are weaker than the wild types. 
OI phenotypes can arise from abnormal osteoblast function. A wide variety of 
phenotyping tests were carried out by Jeong et al. on the G610C model of OI, including 
dynamic and static histomorphometry, which could indicate if the mutations had an 
effect on the bone remodelling, as well as the effect on all the cell types involved in the 
remodelling process [329]. Additionally, the effect of the mutation on steady state bone 
resorption in vivo could be determined by analysis of the serum level of the type I 
collagen α1 chain C-terminal telopeptide (CTX), a biomarker for osteoclast activity [304]. 
To investigate the quality of the osteoid which is subsequently mineralised, the 
hydroxyproline content could be measured in demineralised bone hydrolysate, to 
indicate the collagen content [304]. 
8.5.2 Further Study of Collagen Phenotypes 
DSC analysis revealed that the collagen molecules had a lower dry enthalpy, indicating 




microscopy could be used to investigate what the structural changes to the collagen 
molecules are, and how these impact the formation of the fibrils. 
The mechanical testing of tendons indicated that there was an increased initial 
extension for little force in the so-called ‘toe’ of the graph. It is believed that the toe of 
the extension is the straightening of the crimped fibres. Polarised light microscopy could 
be used to investigate if the abnormal collagen fibrils in MP-107 heterozygotes have an 
impact on the crimp waveform of fascicles, which might help explain the mechanical 
differences in these animals. 
TEM showed that the collagen fibrils in MP-107 heterozygous and homozygous tail 
tendons were less densely packed than in wild types. 3D TEM would allow imaging of 
the fibrils to understand how the less densely packed fibril bundles interact with each 
other. 
 
8.5.3 Further Study of OA Phenotype 
The calcification of ligaments in heterozygous mice was visible in µCT imaging from as 
early as 4 months of age. Ramos-Mucci et al. investigated the calcification of the 
ligaments and meniscus of STR/ort animals with OA, using a volumetric analysis of 
ossified tissue.  This technique could provide clear evidence as to the development of 
the phenotype observed in the MP-107 heterozygotes over time [257]. 
The presence of crystals in the synovial fluid as a result of the ossification of the soft 
tissues of the joint could be increasing the severity of disease and therefore assessing 
the crystals in synovial fluid prior to articular cartilage degradation could be informative. 
Recovering synovial fluid from the murine joint is difficult, however, Seifer et al. have 
published a method [330].  It should be noted that the presence of crystals in the 
synovial fluid of OA patients does not necessarily indicate that they are pathogenic 
[331]. A compound cross with the Toll like receptor 4 (TLR4) knock out could be 
informative in this regard.  
Although the OA phenotype was present in animals that did not show an abnormal 
pelvis, it is still possible that there was a mild pelvis abnormality that wasn’t identified, 




whether heterozygotes had a gait abnormality that might cause abnormal loading, 
leading to OA.  
Phenotyping of skin and tendons of MP-107 indicated that there were altered 
mechanical properties of these tissues, and indicated that the heterozygous animals 
may have some degree of joint laxity. Ex vivo joint laxity experimentation may indicate 
if this is the case, and using an in vivo non-invasive murine joint loading model such as 
described by Poulet et al., may indicate if this instability is leading to OA [225]. 
Analysis of the subchondral bone of MP-107 via µCT imaging and analysis did not show 
any difference between genotypes, due to the effect the Col1a2 mutation had on bones 
including trabecular bone alteration, mechanically weaker bone and increased fracture 
risk, it is surprising no difference was detected here. It is possible that the resolution of 
the imaging undertaken was insufficient, and therefore imaging using advanced higher 
resolution techniques such as synchrotron X-ray tomography may enable a better 
understanding of the bone changes within the joint [332]. 
To investigate if the OA phenotype is a result of alterations in the joint shape during 
development as a result of the mutations in Col1a1 or Col1a2, an inducible knock in of 
the mutations could be used to ensure the joint forms normally. Should the OA 
phenotype still appear, then it is likely that the phenotype is as a result of one of the 
mechanism discussed here, where as if no phenotype occurred this would indicate that 
the OA phenotype is caused due to changes during development, such as altered joint 
morphology. 
With the exception of the micro-indentation assay and histological analysis, changes to 
the articular cartilage were not investigated in these lines. Further µCT imaging using 
phosphotungstic acid as a contrast agent will allow visualisation and comparison of the 
cartilage in 3 dimensions [243, 333]. 
8.5.4 Further Study of Genetics 
The MP-107 mutation leads to the production of both wild-type and alternatively spliced 
mutant transcripts. It is unknown what effect variation in the levels of these transcripts 
between cells, or between animals might have on phenotype. It would be of 




heterozygous animals with varying phenotypes and to establish if there is a link between 
levels of mutant transcript expression and phenotype severity. 
While GWAS studies have not identified either COL1A1 or COL1A2 as being associated 
with OA, the knowledge that a mutation in either of these genes can lead to an OA 
phenotype, regardless of the mode of action, could make these genes a possible target 
for further study. OA clinics often have DNA biobanks for patients with OA, and a 
possible research angle could be screening these DNA samples for mutations in either 
of these genes.  
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Appendix 1 - Radiolabelling Gels 
 
 
Figure 9.1. S1 (f irst Salt extract),  S4 (fourth Salt extract) and N extracts (final detergent 
extract) run on Tris-Glycine gels and then exposed to a phosphor plate, show that there are 
similar levels of proα1,  proα2 pCα1, pCα2 in the N and S1 extracts of the wild type (WT, 
Col1a2+ /+)samples when compared to the heterozygous Col1a2+/ 10 7   samples,  indicating that  
the Collagens are being secreted normally. The S4 extract is included to show that the 
majority of the extracellular collagens had been extracted prior to the N extract ion 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix 3- Time Course Full Body X-rays 
2 Months X-ray 
 
Figure 9.2.  Representative X-ray images of wild type (WT, Col1a2+/ +) and heterozygous (HET,  
Col1a2+ /1 0 7)  animals at 2 months of age. At this t ime point the majority of heterozygous animals 
either showed a curved olecranon at one or both elbows (orange arrows), or splayed ischia at 




4 Months X-ray 
 
Figure 9.3.  Representative X-ray images of wild type (WT, Col1a2+/ +) and heterozygous (HET,  
Col1a2+ /1 0 7)  animals at 4 months of age. At this t ime point the majority of heterozygous animals 
either showed a curved olecranon at one or both elbows (orange arrows), or splayed ischia at 




6 Months X-ray 
 
Figure 9.4.  Representative X-ray images of wild type (WT, Col1a2+/ +) and heterozygous (HET,  
Col1a2+ /1 0 7)  animals at 6 months of age. At this t ime point the majority of heterozygous animals 
either showed a curved olecranon at one or both elbows (orange arrows), or splayed ischia at 




9 Months X-ray 
 
Figure 9.5.  Representative X-ray images of wild type (WT, Col1a2+ / +)  and heterozygous 
(HET, Col1a2+/ 1 0 7) animals at 9 months of age.  At this time point the majority  of 
heterozygous animals either showed splayed ischia at the pelvis (blue arrows), abnormal 
bone growth at the knee (red arrows), or a combination of both phenotypes, no animals 





12 Months X-ray 
Figure 9.6. Representative X-ray images of wild type (WT, Col1a2+ / +) and heterozygous 
(HET, Col1a2+/ 10 7) animals at 12 months of age. At this time point the majority of 
heterozygous animals either showed a curved olecranon at one or both elbows (orange 
arrows), splayed ischia at the pelvis,  abnormal bone growth at the knee (red arrows), or 





15 Months X-ray 
 
Figure 9.7.  Representative X-ray images of wild type (WT, Col1a2+ / +)  and heterozygous 
(HET, Col1a2+/ 10 7) animals at 15 months of age. At this time point the majority of 
heterozygous animals either showed a curved olecranon at one or both elbows (orange 
arrows), splayed ischia at the pelvis,  abnormal bone growth at the knee (red arrows), or 





18 Months X-ray 
 
Figure 9.8.  Representative X-ray images of wild type (WT, Col1a2+ / +)  and heterozygous 
(HET, Col1a2+/ 10 7) animals at 18 months of age. At this time point the majority of 
heterozygous animals either showed a curved olecranon at one or both elbows (orange 
arrows), splayed ischia at the pelvis(blue arrows), abnormal bone growth at the knee (red 





Figure 9.9.  Higher resolution X-ray images of the knees of a wild type (WT, Col1a2+ / +) and 
a heterozygous (HET, Col1a2+ /1 0 7) animal at 18 months of age. The heterozygous animals 




Appendix 4- High Magnification TEM Images 
 
Figure 9.10.  TEM images of embryonic tail tendon from wild-type embryos.  Red arrows 





Figure 9.11.  TEM images of embryonic tail tendon from heterozygous embryos.  Red 





Figure 9.12.  TEM images of embryonic tail tendon from homozygous embryos.  Red 





Appendix 5- Full Gels for ER Stress of MEFs 
 
 
Figure 9.13. Western blot showing levels of BIP in cell lysates from MP-107 MEFS. A and 






Appendix 6- Immunohistochemistry Analysis of ER Stress in Articular Cartilage 
 
Figure 9.14.  Immunohistochemical staining of wild-type and heterozygous knee sections 
using BIP antibody. (A) Negative control wild-type (WT, Col1a2+/+) section without 
primary ant ibody, (B) Wild-type (WT, Col1a2+/+) sect ion with primary antibody, (C) 
Heterozygous (HET,  Col1a2+/107) section with primary antibody. Dark brown staining is 
only visible in the chondrocytes of the heterozygous section (black arrows),  indicating 
increased levels of ER stress in the heterozygote chondrocytes. It should be noted that 
only one 18-month heterozygous animal showed no evidence of joint damage, and was 
therefore used for IHC, and therefore no statist ical testing was carried out.   
